CA2512813A1 - Use of substituted 2-phenylbenzimidazoles as phamaceutical compositions - Google Patents

Use of substituted 2-phenylbenzimidazoles as phamaceutical compositions Download PDF

Info

Publication number
CA2512813A1
CA2512813A1 CA002512813A CA2512813A CA2512813A1 CA 2512813 A1 CA2512813 A1 CA 2512813A1 CA 002512813 A CA002512813 A CA 002512813A CA 2512813 A CA2512813 A CA 2512813A CA 2512813 A1 CA2512813 A1 CA 2512813A1
Authority
CA
Canada
Prior art keywords
alkyl
phenyl
denotes
group
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002512813A
Other languages
French (fr)
Inventor
Ruediger Streicher
Juergen Mack
Rainer Walter
Ingo Konetzki
Thomas Trieselmann
Volkhard Austel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2512813A1 publication Critical patent/CA2512813A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The invention relates to the use of a substituted 2-phenylbenzimidazole of formula (I), where R1, R2, R3, R4, R5 and m have the meanings given in the claims, for the production of a medicament for the treatment or prevention of diseases in which glucagon receptors are implicated and novel compounds of formula (I), where R1 is a group of formula (II).

Description

1/1446-ff Boehringer Ingelheim International GmbH

83045fft Use of substituted 2-phenylbenzimidazoles as pharmaceutical compositions Description The present invention relates to the use of substituted 2-phenylbenzimidazoles for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors, as well as new substituted 2-phenylbenzimidazoles in which the substituent of the nitrogen atom in the 1- position of the benzimidazole group is a dehydroabietyl group.
Diabetes is a complex disease characterised by hyperglycaemia caused by a lack of insulin production or insufficient insulin activity. The metabolic complications of diabetes - hyperglycaemia and ketosis - are linked to the relative or absolute increase in the ratio of glucagon to insulin. Consequently, glucagon is a hyperglycaemic factor which brings about the rise in the blood sugar.
Therefore, suitable antagonists which block the glucagon receptor are agents for treating diabetes, by inhibiting the production of glucose in the liver and reducing the glucose levels in the patient.
Various publications disclose peptidic and non-peptidic glucagon receptor antagonists (McCormick et al., Curr. Pharm. Des. 7, 1451 (2001) a summary). In, particular, the inhibition of the glucagon-stimulated glucose production in humans by Bay 27-has been reported (Petersen et al., Diabetologia 44, 2018 (2001 )).
The aim of the present invention was to indicate new non-peptidic active substances which are suitable as highly effective glucagon receptor antagonists for the treatment of diabetes.
2-Phenylbenzimidazoles are already known. Thus, for example, International Patent Application WO 02/04425 proposes substituted benzimidazoles which may be substituted by phenyl, inter alia, in the 2- position, as viral polymerase inhibitors, 1/1446-ff Boehringer Ingelheim International GmbH

particularly for the treatment or prevention of HCV infections. There is no reference of any kind to the possibility of using such compounds as glucagon receptor antagonists.
Surprisingly it has now been found that certain substituted 2-phenylbenzimidazoles are highly effective glucagon receptor antagonists.
The present invention thus relates to the use of a substituted 2-phenylbenzimidazole of formula I
R4~m _ s R3 ~ s (I) ~Rs R' wherein Rl denotes optionally substituted C1-C6 alkyl, C6-Clo aryl or C3-Cg cycloalkyl, the substituents being selected from the group consisting of halogen, C6-Cio aryl, C3-Cg cycloalkyl groups and a group of formula wherein Ril, Ri2 and R13 each independently of one another denote hydrogen or halogen or C1-C6 alkyl, CI-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy;
R2 denotes hydrogen, C1-C6 alkyl, C3-C7-cycloalkyl, C2-C6 alkenyl, C6-Clo aryl-C1-C6 alkyl, C6-Coo aryl-C2-C6 alkenyl, carboxy or cyano; or in the 4-, 5- or 6- position of the benzimidazole denotes optionally substituted C6-Clo aryl, to which a C6-Clo-aryl or a 5- or 6-membered heteroaryl may be fused, or an optionally substituted, optionally benzo- or cyclohexano-fused 5-or 6-membered heteroaryl group, wherein 1/1446-ff Boehringer Ingelheim International GmbH
the substituents are selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 alkylthio, CI-C6 alkylsulphinyl, C1-C6 alkylsulphonyl, Cl-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkanoyl, C6-Clo aryl, C6-Clo haloaryl, C6-Cio aryloxy, C6-Clo aryl-C1-C6 alkyl, C6-Clo aryl-C1-C6 alkoxy, C3-C8 cycloalkyl, amino-C1-C6 alkyl, C1-C6 alkylamino-C1-C6 alkyl, di-(C1-C6 alkyl)-amino-CI-C6 alkyl, 5- to 7-membered cycloalkyleneimino-C1-C6 alkyl, morpholino-C1-C6 alkyl, piperazino-C1-C6 alkyl, C1-C6 alkoxy-C~-C6 alkyl, di-(C~-C6 alkoxy)-C1-C6 alkyl, cyano-C1-C6 alkyl, hydroxy-C1-C6 alkyl, dihydroxy-C1-C6 alkyl, amino, C1-C6 alkylamino, di-(C1-C6 alkyl)-amino, C1-C6 alkanoylamino, C1-C6 alkylsulphonylamino, aminocarbonyl, C~-C6 alkylaminocarbonyl, di-(C1-C6 alkyl)-aminocarbonyl, carboxy-CI-C6 alkyl, carboxy-C1-C6 alkoxy, carboxy, cyano, formyl, hydroxy, nitro;
or denotes a carboxamide group of formula-CO-NR2lRzz in the 5- or 6- position of the benzimidazole, while Rzl and R22 each independently of one another denote hydrogen, C1-C6 alkyl, C2-Cg alkenyl, C4-C12 alkadienyl, C1-C6 haloalkyl, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkylthio-C1-C6 alkyl, C6-Clo aryl, C3-Cg cycloalkyl, CS-C8 cycloalkenyl, C3-C8 cycloalkyl-C1-C6 alkyl, C3-C8 cycloalkyloxy-C1-C6 alkyl, C3-C8 cycloalkanoyl-C1-C6 alkyl, CS-Cg cycloalkenyl-C1-C6 alkyl, adamantyl-C1-C6 alkyl, amino-C1-C6 alkyl, C1-C6 alkylamino-C1-C6 alkyl, di-(C1-C6 alkyl)-amino-C1-C6 alkyl, C1-C6 alkoxycarbonylamino-CI-C6 alkyl, cyano-C1-C6 alkyl, hydroxy-C1-C6 alkyl; or one of the groups R21 and R22 denotes hydrogen or C1-C6 alkyl, and the other denotes C6-Clo aryl-C1-C6 alkyl, wherein C6-Clo aryl may carry a benzo-fused aromatic 6-membered ring or one or more substituents, while the substituents are selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, Cl-C6-haloalkoxy, C6-Clo aryl, thiadiazolyl, C6-Cio aryloxy, hydroxy-C6-Clo aryloxy, C1-C6 alkoxycarbonyl, C1-C6 I/1446-ff Boehringer Ingelheim International GmbH
alkoxycarbonyl-C1-C6 alkyl, aminocarbonyl, aminosulphonyl, carboxy, amino, hydroxy, cyano and wherein C1-C6 alkyl may carry a hydroxy group; or one of the groups R2' and R22 denotes hydrogen or C1-C6 alkyl, and the other denotes a group of formula -(CHZ)~-X-Het wherein n denotes 0 or an integer from 1 to 6, X denotes CO or a single bond and if n is other than 0 may also denote O, S or NH, and Het denotes an optionally substituted S- or 6-membered heterocyclic group which may be substituted by nitro or di-(C1-C6 alkoxy-C6-Clo aryl and wherein a CH2 group may be replaced by a carbonyl group, and -(CHZ)"- may be substituted by C1-C6-alkyl if n is other than 0;
or RZ1 and Rz2 in each case form, with the enclosed nitrogen atom, an optionally substituted, optionally benzo- or cyclohexano-fused 5- to 7-membered heterocyclic ring wherein one or two CH2 groups may be replaced by O, S or NR23, wherein R23 denotes hydrogen, C~-C6 alkyl, adamantyl-CI-C6 alkyl, C6-Cio aryl-CI-C6-alkyl, C6-Cio aryl, Cl-C6 alkoxy-CI-C6 aryl, or di-(C1-C6 alkoxy)-C1-C6 aryl and the optionally benzo-condensed ring may carry one or two C1-C6 alkoxy groups, R3 denotes a group of formula A-(E)rY-(E)rZ_ wherein A denotes a tetrazolyl, amido, methylamido, amidino or hydroxyamidino group or a group of formula--COOR31, wherein R3' denotes hydrogen or C1-C6 alkyl; and E denotes a C1-C6 alkylenediyl or C2-C6 alkenylenediyl group optionally mono- or polysubstituted by halogen or hydroxy or a C2-C6 alkynylenediyl group; and I/1446-ff Boehringer Ingelheim International GmbH
-$-Y denotes O, S, CO-NH, CO-N(CH3), NH-CO, N(CH3)-CO, NH, N(CH3) or a single bond; and Z denotes O, S, NH, N(CH3) or a single bond; and r denotes 0 or 1; or denotes a 4-7-membered cycloalkyleneimino or 4 to 7-membered cycloalkyleneiminocarbonyl group, which is substituted by the abovementioned group A;
R4 in each case independently of one another denotes halogen, cyano, nitro, C1-C6 alkyl, Cl-C6 alkoxy, Cl-C6 alkylthio, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkanoyl, C6-Clo aryl, C6-Clo aryloxy, C6-Clo aryl-CI-C6 alkyl, C6-Clo aryl-C1-C6 alkoxy, C3-C8 cycloalkyl, amino-C1-C6 alkyl, Cl-C6 alkylamino-C1-C6 alkyl, di-(C1-C6 alkyl)-amino-C1-C6 alkyl, amino, Cl-C6 alkanoylamino or C1-C6 haloalkanoylamino or when m = 2 denotes a fused-on aromatic 6-membered ring ;
Rs denotes a hydrogen atom, halogen, hydroxy or C,-C6 alkoxy; and m denotes 0 or is an integer from 1 to 4;
for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors.
The invention further relates to substituted 2-phenylbenzimidazoles of formula IA
R4) s R3 ~ - s ( IA ) N ~Rs Zu Ris wherein Rll, R'2 and RI3 each independently of one another denote hydrogen or halogen or C1-C6 alkyl, C1-C6 alkoxy, Cl-C6 haloalkyl or Cl-C6 haloalkoxy;
RZ denotes hydrogen, C1-C6 alkyl, C3-C7-cycloalkyl, CZ-C6 alkenyl, C6-C1o aryl-CI-C6 alkyl, C6-Clo aryl-CZ-C6 alkenyl, carboxy or cyano; or 1/1446-ff Boehringer Ingelheim International GmbH

in the 4-, 5- or 6- position of the benzimidazole denotes optionally substituted C6-CIO aryl, to which a C6-CIO-aryl or a 5- or 6-membered heteroaryl may be fused, or an optionally substituted, optionally benzo- or cyclohexano-fused 5-or 6-membered heteroaryl group, while the substituents are selected from the group consisting of halogen, CI-C6 alkyl, Cz-C6 alkenyl, CI-C6 alkoxy, CI-C6 alkylthio, CI-C6 alkylsulphinyl, CI-C6 alkylsulphonyl, CI-C6 haloalkyl, CI-C6 haloalkoxy, CI-C6 alkanoyl, C6-CIO aryl, C6-CIO haloaryl, C6-CIo aryloxy, C6-CIO aryl-CI-C6 alkyl, C6-CIO aryl-CI-C6 alkoxy, C3-Cg cycloalkyl, amino-CI-C6 alkyl, CI-C6 alkylamino-CI-C6 alkyl, di-(CI-C6 alkyl)-amino-CI-C6 alkyl, 5-7-membered cycloalkyleneimino-CI-C6 alkyl, morpholino-CI-C6 alkyl, piperazino-CI-C6 alkyl, CI-C6 alkoxy-CI-C6 alkyl, di-(CI-C6 alkoxy)-CI-C6 alkyl, cyano-CI-C6 alkyl, hydroxy-CI-C6 alkyl, dihydroxy-CI-C6 alkyl, amino, CI-C6 alkylamino, di-(CI-C6 alkyl~amino, CI-C6 alkanoylamino, CI-C6 alkylsulphonylamino, aminocarbonyl, CI-C6 alkylaminocarbonyl, di-(CI-C6 alkyl)-aminocarbonyl, carboxy-CI-C6 alkyl, carboxy-CI-C6 alkoxy, carboxy, cyano, formyl, hydroxy, nitro, or denotes a carboxamide group of formula-CO-NRzIRzz in the 5- or 6- position of the benzimidazole, while Rz1 and Rzz each independently of one another denote hydrogen, CI-C6 alkyl, Cz-Cg alkenyl, C4-CIZ alkadienyl, CI-C6 haloalkyl, CI-C6 alkoxy-CI-C6 alkyl, CI-C6 alkylthio-CI-C6 alkyl, C6-CIO aryl, C3-Cg cycloalkyl, CS-Cg cycloalkenyl, C3-C8 cycloalkyl-CI-C6 alkyl, C3-C8 cycloalkyloxy-CI-C6 alkyl, C3-Cg cycloalkanoyl-CI-C6 alkyl, CS-C8 cycloalkenyl-CI-C6 alkyl, adamantyl-CI-C6 alkyl, amino-CI-C6 alkyl, CI-C6 alkylamino-CI-C6 alkyl, di-(C,-C6 alkyl)-amino-CI-C6 alkyl, CI-C6 alkoxycarbonylamino-C~-C6 alkyl, cyano-CI-C6 alkyl, hydroxy-CI-C6 alkyl; or one of the groups Rz1 and Rzz denotes hydrogen or CI-C6 alkyl, and the other denotes C6-CIO aryl-CI-C6 alkyl, wherein ' I/1446-ff Boehringer Ingelheim International GmbH
C6-Clo aryl may carry a benzo-fused aromatic 6-membered ring or one or more substituents, the substituents being selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, Cl-C6-haloalkoxy, C6-Clo aryl, thiadiazolyl, C6-Clo aryloxy, hydroxy-C6-Clo aryloxy, C1-C6 alkoxycarbonyl, C1-C6 alkoxycarbonyl-C1-C6 alkyl, aminocarbonyl, aminosulphonyl, carboxy, amino, hydroxy, cyano and C1-C6 alkyl may carry a hydroxy group; or one of the groups RZ1 and R22 denotes hydrogen or C1-C6 alkyl, and the other denotes a group of formula -(CHZ)~ X-Het wherein n denotes 0 or an integer from 1 to 6, X denotes CO or a single bond and if n is other than 0 may also denote O, S or NH, and Het denotes an optionally substituted 5- or 6-membered heterocyclic group which may be substituted by vitro or di-(C,-C6 alkoxy-C6-Clo aryl and wherein a CH2 group may be replaced by a carbonyl group, and -(CH2)n may be substituted by C1-C6-alkyl if n is other than 0;
or R21 and R22 in each case form, with the enclosed nitrogen atom, an optionally substituted, optionally benzo- or cyclohexano-fused 5-7-membered heterocyclic ring, wherein one or two CHZ groups may be replaced by O, S or NR23, wherein R23 denotes hydrogen, C1-C6 alkyl, adamantyl-C1-C6 alkyl, C6-Clo aryl-C1-C6-alkyl, C6-CIO aryl, C1-C6 alkoxy-C1-C6 aryl or di-(C1-C6 alkoxy)-CI-C6 aryl and the optionally benzo-condensed ring may carry one or two C1-C6 alkoxy groups, R3 denotes a group of formula A-(E)rY-(E)r-Z_ wherein 1/1446-ff Boehringer Ingelheim International GmbH
_g_ A denotes a tetrazolyl, amido, methylamido, amidino or hydroxyamidino group or a group of formula-COOR31, wherein R31 denotes hydrogen or C1-C6 alkyl; and E denotes a C1-C6 alkylenediyl or C2-C6 alkenylenediyl group optionally mono- or polysubstituted by halogen or hydroxy or a C2-C6 alkynylenediyl group; and Y denotes O, S, CO-NH, CO-N(CH3), NH-CO, N(CH3)-CO, NH, N(CH3) or a single bond; and Z denotes O, S, NH, N(CH3) or a single bond; and r denotes 0 or 1; or denotes a 4- to 7-membered cycloalkyleneimino or 4- to 7-membered cycloalkyleneiminocarbonyl group which is substituted by the abovementioned group A;
R4 in each case independently of one another represents halogen, cyano, nitro, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, Cl-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkanoyl, C6-Clo aryl, C6-Clo aryloxy, C6-Clo aryl-C1-C6 alkyl, C6-Cio aryl-C1-C6 alkoxy, C3-Cg cycloalkyl, amino-C1-C6 alkyl, CI-C6 alkylamino-C1-C6 alkyl, di-(C1-C6 alkyl)-amino-C1-C6 alkyl, amino, C1-C6 alkanoylamino or C~-C6 haloalkanoylamino or where m = 2 denotes a fused-on aromatic 6-membered ring;
RS denotes a hydrogen atom, halogen, hydroxy or C1-C6 alkoxy; and m denotes 0 or is an integer from 1 to 4.
The alkyl groups used (including those which are part of other groups, especially alkoxy) unless otherwise specified are branched or unbranched alkyl groups with 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, more preferably with 1 to 6 carbon atoms, particularly with 1 to 4 carbon atoms. The following are mentioned by way of example: methyl, ethyl, propyl, butyl, pentyl, hexyl etc. Unless otherwise specified, the above terms propyl, butyl, pentyl or hexyl include all the possible isomeric forms.
For example, the term propyl includes the two isomeric groups n-propyl and iso-propyl, the term butyl includes n-butyl, iso-butyl, sec. butyl and tert.-butyl, the term pentyl includes iso-pentyl, neopentyl etc. In some cases common abbreviations such 1/1446-ff Boehringer Ingelheim International GmbH

as Me for methyl, Et for ethyl etc may be used to denote the abovementioned alkyl groups.
Examples of haloalkyl groups (including those which are part of other groups, particularly haloalkoxy) unless otherwise specified include branched and unbranched haloalkyl groups with 1 to 12 carbon atoms, preferably 1 to 6 carbon atoms, particularly preferably with 1 to 3 carbon atoms, which are substituted by at least one halogen atom, particularly a fluorine atom. Fluorinated groups of formula -(CH2)p-(CF2)q-Y
are preferred wherein p denotes 0 or an integer from 1 to 4, q denotes an integer from 1 to 4, and Y denotes hydrogen or fluorine.
The following may be mentioned by way of example: trifluoromethyl, trifluoromethoxy, difluoromethoxy, perfluoroethyl, perfluoropropyl, 2,2,2-trifluoroethyl, 2,2,2-trifluoroethoxy, 1,1,1-trifluoroprop-2-yl, etc..
Suitable alkenyl groups (including those which are part of other groups) are branched and unbranched alkenyl groups with 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms, particularly 2 to 4 carbon atoms, provided that they have at least one double bond, for example the aforementioned alkyl groups provided that they have at least one double bond, such as for example vinyl (provided that no unstable enamines or enolethers are formed), propenyl, iso-propenyl, butenyl, pentenyl, hexenyl.
Suitable alkadienyl groups (including those which are part of other groups) are alkadienyl groups with 4 to 12 carbon atoms, preferably 4 to 8 carbon atoms, particularly 4 to 6 carbon atoms, provided that they have at least two double bonds, for example butadienyl, pentadienyl and hexadienyl.
Suitable cycloalkyl groups (including those which are part of other groups) are cycloaliphatic groups with 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms, 1/1446-ff Boehringer Ingelheim International GmbH

particularly 4 to 6 carbon atoms, such as for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
The term halogen generally denotes fluorine, chlorine, bromine or iodine.
Suitable aryl groups (including those which are part of other groups, particularly aryloxy or aryl-alkyl) are, unless otherwise specified, aromatic groups with 6 to 10 carbon atoms, preferably 6 carbon atoms. The following are mentioned by way of example: phenyl or naphthyl, which may be substituted by 1 to 5 substituents, preferably 1 to 2 substituents selected from among halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, CI-C6 haloalkyl, C1-C6 haloalkoxy, CI-C6 alkanoyl, C6-CIO
aryl, C6-Clo aryloxy, C6-Clo aryl-C1-C6 alkyl, C6-Clo aryl-C1-C6 alkoxy, C3-Cg cycloalkyl, amino-C1-C6 alkyl, Cl-C6 alkylamino-C1-C6 alkyl, di-(CI-C6 alkyl)-amino-C1-C6 alkyl, piperidyl-C1-C6 alkyl, morpholino-C1-C6 alkyl, CI-C6 alkoxy-Cl-C6 alkyl, di-(C1-C6 alkoxy)-C1-C6 alkyl, cyano-C1-C6 alkyl, hydroxy-CI-C6 alkyl, dihydroxy-C1-C6 alkyl, amino, C1-C6 alkylamino, di-(C1-C6 alkyl)-amino, C1-C6 alkanoylamino, C1-C6 alkylsulphonylamino, aminocarbonyl, C1-C6 alkylaminocarbonyl, di-(CI-C6 alkyl)-aminocarbonyl, carboxy-C1-C6 alkyl, carboxy-C1-C6 alkoxy, carboxy, cyano, formyl, hydroxy and nitro.
The term "5- or 6-membered heterocyclic group containing nitrogen, oxygen and/or sulphur " as used in connection with the group R2, generally denotes an aromatic or saturated group with 5 or 6 ring atoms, at least one ring atom being a heteroatom selected from among N, O and S, which may optionally be fused to another ring system.
The term "5- to 7-membered heterocyclic ring" as used for the group formed by and R22 together with the enclosed nitrogen atom, generally denotes a saturated nitrogen-containing group with 5 to 6 ring atoms which may optionally comprise one or more heteroatoms selected from among N, O and S.
Examples of particularly preferred 5- or 6-membered, saturated or unsaturated heterocycles which may contain nitrogen, oxygen or sulphur as heteroatoms, unless I/1446-ff Boehringer Ingelheim International GmbH

otherwise stated in the definitions, may include, for example, furan, tetrahydrofuran, tetrahydrofuranone, y-butyrolactone, a-pyran, y-pyran, dioxolane, tetrahydropyran, dioxane, thiophene, dihydrothiophene, thiolane, dithiolane, pyrrole, pyrroline, pyrrolidine, pyrazole, pyrazoline, pyrazolidine, imidazole, imidazoline, imidazolidine, triazole, tetrazole, pyridine, piperidine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, tetrazine, morpholine, thiomorpholine, diazepam oxazole, isoxazole, oxazine, thiazole, isothiazole, thiadiazole, oxadiazole and pyrazolidine, while the heterocyclic group may be substituted as in the definitions.
Compounds of general formula I may have acid groups, mainly carboxyl groups, and/or basic groups such as e.g. amino functions. Compounds of general formula I
may therefore be present as internal salts, as salts with pharmaceutically acceptable inorganic acids such as hydrochloric acid, sulphuric acid, phosphoric acid, sulphonic acid or organic acids (such as for example malefic acid, fumaric acid, citric acid, tartaric acid or acetic acid) or as salts with pharmaceutically acceptable bases such as alkali or alkaline earth metal hydroxides or carbonates, zinc or ammonium hydroxides or organic amines such as e.g. diethylamine, triethylamine, triethanolamine etc.
The compounds according to the invention may occur as racemates or mixtures of diastereomers but may also be obtained as pure enantiomers or diastereomers, i.e. in the (R) or (S) form. Compounds of formula IA wherein the group Rl is derived from (+)-dehydroabietylamine and thus has the same absolute configuration as dehydroabietylamine are preferred.
Preferred substituted 2-phenylbenzimidazoles of formula IA are those wherein Ru, Rlz and Ri3 each independently of one another denote hydrogen or C1-C6 alkyl;
Rz denotes hydrogen, C1-C6 alkyl, C3-C7-cycloalkyl, Cz-C6-alkenyl, phenyl-C1-alkyl, phenyl-Cz-C6 alkenyl, carboxy or cyano; or in the 4, 5 or 6 position of the benzimidazole denotes optionally substituted phenyl, naphthyl, quinolinyl, isoquinolinyl or a 5- or 6-membered heteroaryl group selected from the group consisting of imidazolyl, pyrazolyl, furanyl, tetrahydrofuranyl, thiophenyl, thiazolyl, pyridyl, pyrimidyl, pyrazinyl, wherein 1/1446-ff Boehringer Ingelheim International GmbH

the substituents are selected from the group consisting of fluorine, chlorine, bromine, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy, Cl-C6 alkylthio, C1-C6 alkylsulphinyl, C1-C6 alkylsulphonyl, CI-C6 haloalkyl, C1-C6 haloalkoxy, Cl-C6 alkanoyl, phenyl, halophenyl, phenoxy, phenyl-C1-C6 alkyl, phenyl-C1-C6 alkoxy, CS-C6 cycloalkyl, amino-C1-C6 alkyl, Cl-C6 alkylamino-C1-C6 alkyl, di-(C1-C6 alkyl)-amino-Cl-C6 alkyl, piperidyl-C1-C6 alkyl, morpholino-C1-C6 alkyl, Cl-C6 alkoxy-C1-C6 alkyl, di-(C1-C6 alkoxy)-C1-C6 alkyl, cyano-C1-C6 alkyl, hydroxy-C1-C6 alkyl, dihydroxy-C1-C6 alkyl, amino, C1-C6 alkylamino, di-(C1-C6 alkyl)-amino, C1-C6 alkanoylamino, C1-C6 alkylsulphonylamino, aminocarbonyl" C~-C6 alkylaminocarbonyl, di-(C1-C6 alkyl)-aminocarbonyl, carboxy-C1-C6 alkyl, carboxy-C1-C6 alkoxy, carboxy, cyano, formyl, hydroxy and vitro; or denotes a carboxamide group of formula-CO-NR21Ra2 in the 5 or 6 position of the benzimidazole, wherein R21 denotes hydrogen, C1-C6 alkyl, C2-C8 alkenyl, C4-C12 alkadienyl, C1-C6 haloalkyl, C1-C6 alkoxy-C1-C6 alkyl, CI-C6 alkylthio-C1-C6 alkyl, phenyl, CS-C6 cycloalkyl, CS-C6 cycloalkenyl, C5-Cg cycloalkyl-C1-C6 alkyl, C3-Cg cycloalkoxy-C1-C6 alkyl, C3-C8 cycloalkanoyl-C~-C3 alkyl, CS-C8 cycloalkenyl-C1-C3 alkyl, adamantyl-C1-C2 alkyl, amino-C~-C6 alkyl, C1-C6 alkylamino-C1-C6 alkyl, di-(C1-C6 alkyl)-amino-C1-C6 alkyl, C1-C6 alkoxycarbonylamino-C1-C6 alkyl, cyano-C1-C6 alkyl, hydroxy-C1-C6 alkyl or denotes phenyl-C1-C6 alkyl, wherein phenyl may carry a fused-on benzene ring or one or more substituents, the substituents being selected from the group consisting of fluorine, chlorine, bromine, C1-C6 alkyl, C1-C6 alkoxy, C1-C6-haloalkoxy, phenyl, thiadiazolyl, phenyloxy, hydroxy-phenyloxy, C1-C6 alkoxycarbonyl, C1-C6 alkoxycarbonyl-CI-C6 alkyl, aminocarbonyl, aminosulphonyl, carboxy, amino, hydroxy, cyano and C1-C6 alkyl may carry a hydroxy group; and R22 denotes hydrogen or C1-C3 alkyl, or 1/1446-ff Boehringer Ingelheim International GmbH

one of the groups RZ1 and R22 denotes hydrogen or CI-C3 alkyl, and the other denotes a group of formula -(CH2)n-X-Het wherein n denotes an integer from 1 to 4, X denotes CO, O, S, NH or a single bond, and Het denotes an optionally substituted 5- or 6-membered heterocyclic group selected from among imidazolyl, pyrrolidinyl, pyrrolidonyl, morpholino, furanyl, thienyl, pyridyl and pyrimidyl, while the above-mentioned heterocyclic group may be substituted by vitro or di-(C1-C6 alkoxy)-phenyl; or R21 and RZZ in each case form, with the enclosed nitrogen atom, a tetrahydrobenzoazepino, morpholino, piperidyl, benzopiperidyl or cyclohexanopiperidyl group, or a piperazyl group optionally substituted by Cl-C6 alkyl, adamantyl-C1-C2 alkyl, phenyl-C1-CZ alkyl, phenyl, C1-C6 alkoxyphenyl or di-(CI-C6 alkoxy)-phenyl, R3 denotes a group of formula A_(E)r y-(E)r Z_ wherein A denotes a 1H-tetrazol-5-yl group or a group of formula-COOR3y wherein R31 denotes hydrogen or C~-C6 alkyl; and E denotes a Cl-C4 alkylenediyl or an ethenylenediyl group optionally mono- or polysubstituted by halogen or hydroxy or a butynyldiyl group; and Y denotes O, S, CO-NH, CO-N(CH3), NH-CO, N(CH3)-CO, NH, N(CH3) or a single bond; and Z denotes O, S, NH, N(CH3) or a single bond; and r denotes 1; or denotes pyrrolidinyl, piperidinyl, pyrrolidinylcarbonyl or piperidinylcarbonyl, each of which is substituted by the abovementioned group A;
R4 in each case independently of one denotes another fluorine, chlorine, bromine, cyano, vitro, CI-C3 alkyl, Cl-C3 haloalkyl, C~-C3 alkoxy, C1-C3-haloalkoxy, 1/1446-ff Boehringer Ingelheim International GmbH

amino, C1-C3 alkanoylamino, Cl-C3 haloalkanoylamino or, where m = 2, a fused-on benzene ring;
RS denotes a hydrogen atom; and m is 0 or an integer from 1 to 2.
Also preferred are substituted 2-phenylbenzimidazoles of formula IA wherein Rll and Ri2 denote methyl, and R13 denotes isopropyl.
Particularly preferred are substituted 2-phenylbenzimidazoles of formula IA
wherein R2 denotes hydrogen, C1-C6 alkyl, C3-C7-cycloalkyl, C2-C6 alkenyl, phenyl-C1-alkyl, phenyl-C2-C6 alkenyl, carboxy or cyano; or denotes optionally substituted phenyl, naphthyl, quinolinyl, isoquinolinyl, imidazolyl, furanyl, thiophenyl, thiazolyl, tetrahydrofuranyl, pyridyl, pyrimidinyl, pyrazinyl in the 4, 5 or 6 position of the benzimidazole, wherein the substituents are selected from the group consisting of fluorine, chlorine, bromine, C1-C3 alkyl, trifluoromethyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C6 alkylsulphinyl, C1-C6 alkylsulphonyl, trifluoromethoxy, difluoromethoxy, Cl-C3 alkanoyl, phenyl, chlorophenyl, phenoxy, phenyl-C1-C2 alkyl, phenyl-C1-CZ alkoxy, cyclohexyl, amino-C1-C3 alkyl, C1-C3 alkylamino-C1-C3 alkyl, di-(C1-C3 alkyl)-amino-C1-C3 alkyl, piperidyl-C1-C3 alkyl, morpholino-C1-C3 alkyl, C1-C3 alkoxy-C1-C3 alkyl, di-(C1-C3 alkoxy)-C1-C3 alkyl, cyano-C1-C3 alkyl, hydroxy-C1-C3 alkyl, dihydroxy-C1-C3 alkyl, amino, C1-C3 alkylamino, di-(C1-C3 alkyl)-amino, C1-C3 alkanoylamino, C1-C3 alkylsulphonylamino, aminocarbonyl, CI-C6 alkylaminocarbonyl, carboxy-C1-C3 alkyl, carboxy-C1-C3 alkoxy, carboxy, cyano, formyl, hydroxy and nitro; or denotes a carboxamide group of formula-CO-NR2lRzz in the 5- or 6- position of the benzimidazole, wherein R21 denotes hydrogen, C1-C3 alkyl, C2-C6 alkenyl, C6-CIZ alkadienyl, 2,2,2-trifluoroethyl, C1-C3 alkoxy-C~-C3 alkyl, Cl-C3 alkylthio-Cl-C3 alkyl, phenyl, cyclohexyl, cyclohexenyl, cyclohexyl-C1-C3 alkyl, 1/1446-ff Boehringer Ingelheim International GmbH
-1$-cyclohexyloxy-C1-C3 alkyl, cyclohexanoyl-C1-C3 alkyl, cyclohexenyl-C1-C3 alkyl, adamantyl-C1-C2 alkyl, amino-C1-C3 alkyl, CI-C3 alkylamino-C1-C3 alkyl, di-(C1-C3 alkyl)-amino-C1-C3 alkyl, C1-C3 alkoxycarbonylamino-CI-C3 alkyl, cyano-C1-C3 alkyl, hydroxy-C1-C3 alkyl; or denotes phenyl-C1-C6 alkyl, wherein phenyl may carry a fused-on benzene ring or one or more substituents, the substituents being selected from the group consisting of fluorine, chlorine, bromine, C1-C4 alkyl, Cl-C3 alkoxy, trifluoromethoxy, phenyl, thiadiazolyl, phenyloxy, hydroxy-phenyloxy, CI-C3 alkoxycarbonyl, C1-C3 alkoxycarbonyl-CI-C6 alkyl, aminocarbonyl, aminosulphonyl, amino, hydroxy, cyano and C1-C3 alkyl may carry a hydroxy group; or denotes a group of formula - (CH2)~-X-Het wherein n denotes an integer from 1 to 4, X denotes CO, O, S, NH or a single bond, and Het denotes imidazolyl, pyrrolidinyl, pyrrolidonyl, morpholino, furanyl, thienyl and pyridyl, which may be substituted by nitro or dimethoxyphenyl, and R22 denotes hydrogen or methyl, or R21 and R22 in each case form, with the enclosed nitrogen atom, a tetrahydrobenzoazepino, morpholino, piperidyl, benzopiperidyl or cyclohexanopiperidyl group, or a piperazyl group optionally substituted by CI-C3 alkyl, adamantyl-C1-CZ alkyl, phenyl-C~-CZ alkyl, phenyl, methoxyphenyl or dimethoxyphenyl, R3 denotes a group of formula A-(E)~ Y-(E)r Z-wherein A denotes a 1 H-tetrazol-5-yl group or a group of formula -COOR31, wherein R31 denotes hydrogen or C1-C3 alkyl; and 1/1446-ff Boehringer Ingelheim International GmbH

E denotes a C1-C4 alkylenediyl or an ethenylenediyl group optionally mono- or polysubstituted by fluorine, chlorine, bromine or hydroxy;
and Y denotes O, S, CO-NH, CO-N(CH3), NH-CO, N(CH3)-CO, NH, N(CH3) or a single bond; and Z denotes O or a single bond; and r denotes 0 or 1; or denotes a 4- to 7-membered cycloalkyleneimino or 4- to 7-membered cycloalkyleneimino-carbonyl group which is substituted by the abovementioned group A;
R4 in each case independently of one another denotes fluorine, chlorine, bromine, vitro, C1-C3 alkyl, Cl-C3 haloalkyl, C1-C3 alkoxy, C1-C3-haloalkoxy, amino, acetylamino or trifluoroacetylamino;
RS denotes a hydrogen atom; and m is 0 or an integer from 1 to 2.
Compounds of formula IA are preferred wherein R2 is in the 4-, 5- or 6-position, particularly in the 5- position of the benzimidazole structure. The remaining 5- or 6-position of the benzimidazole structure is preferably substituted by the substituent R5.
Particularly preferred compounds are those wherein the 5- position of the benzimidazole structure is substituted by R2 and the 6- position of the benzimidazole structure is substituted by R5.
Most particularly preferred are the substituted 2-phenylbenzimidazoles of formula 1/1446-ff Boehringer Ingelheim International GmbH

R) m \ RZ
R3 v /
N
I
H ~CH ( IA1 ) H3C~CH /
I

wherein RZ, R3, R4 and m have the meanings given hereinbefore and hereinafter.
Also preferred are those substituted 2-phenylbenzimidazoles of formulae I, IA
and IAI, wherein the group R3 is in the meta or para position relative to the benzimidazole group.
The invention also relates to the substituted 2-phenylbenzimidazoles of formulae IA
and IA1 as pharmaceutical compositions as well as pharmaceutical preparations containing at least one substituted 2-phenylbenzimidazole of formulae IA or IAl and a pharmacologically acceptable carrier.
Preferred are pharmaceutical preparations containing at least one substituted phenylbenzimidazole of formula IA or IA 1 as well as an active substance selected from among:
acarbose, beraprost, bexarotene, captopril, denileukin, diftitox, etanercept, farglitazar, fidarestat, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, glucagon, ilomastat, imidapril, insulin, lanreotide, linogliride, lisinopril, metformin, mexiletine, miglitol, minalrestat, mitiglinide, moxonidine, nafagrel, nateglinide, octreotide, orlistat, oxcarbazepine, pegvisomant, pioglitazone, ponalrestat, pramlintide, ramipril, repaglinide, rosiglitazone, sirolimus, sorbinil, tolrestat, troglitazone, voglibose, zenarestat and zopolrestat.

1/1446-ff Boehringer Ingelheim International GmbH

The invention further relates to the use of a substituted 2-phenylbenzimidazole of formulae IA or IA1 for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors, particularly for the treatment or prevention of diabetes mellitus.
The substituted 2-phenylbenzimidazole derivatives of formula (I) may be synthesised by various methods. Possible approaches based on and using conventional chemical synthesis methods are illustrated by way of example hereinafter. Diagram 1 shows a possible method of synthesising the basic 2-phenylbenzimidazole component of the compounds according to the invention.
X \ RS i DHA-NH \ RS ii ON I / 2 I ~ 2 s R OZN R
( 1 ) X: F, C1, Br (2) (R4)m DHA
\ R iii DHA-NH \ RS
R N ~ Rz H N

(IA) (DHA bedeutet eine Dehydroabietylgruppe) (DHA denotes a dehydroabietyl group) (3) Diagram l:
Starting from the 2-halo-nitrobenzenes (1) , first of all aminolysis may be carried out with dehydroabietylamine to obtain the 2-abietylamino-nitrobenzenes (2) according to Diagram 1 (Step i). The aminolysis of the compounds (1) with the primary dehydroabietylamine DHA-NH2 is carried out in suitable organic solvents such as for example dimethylsulphoxide, N,N-dimethylformamide, N-methylpyrrolidone, acetone or optionally also in water or alcohols at ambient temperature or in a temperature range from 30-80°C, preferably 40-50°C.

1/1446-ff Boehringer Ingelheim International GmbH

The 2-dehydroabietylamino-nitrobenzene derivatives (2) which may be obtained by the procedure described above may be reductively converted into the 2-dehydroabietylaminoanilines (3) (Step ii, Diagram 1). The reduction of the nitro group to obtain the compounds (3) is carried out for example by catalytic hydrogenation in organic solvents such as for example methanol, ethanol, isopropanol, tetrahydrofuran, optionally also mixed with dimethylformamide, ethyl acetate, dioxane or acetic acid, at elevated hydrogen pressure or at normal pressure at temperatures between 0-50 °C, preferably at 20-40 °C. Suitable catalysts are common hydrogenation catalysts. Palladium and Raney nickel are preferred. According to the invention Raney nickel is preferably used. An alternative method of reducing the nitro compounds (3) envisages using reducing agents such as Na2S204 or SnCl2. This reaction is carried out in protic, water-miscible organic solvents such as short-chained alcohols (methanol, ethanol, isopropanol) or in a mixture of the abovementioned solvents with water, optionally with acetic acid, dimethylformamide or ethyl acetate.
The reaction is usually carried out at elevated temperature, preferably at the reflux temperature of the solvent or mixture of solvents used. After all the starting compounds (3) have reacted the mixture is worked up in the usual way. The compounds (4) may be purified for example by crystallisation from non-polar organic solvents such as diethyl ether, petroleum ether, optionally mixed with ethyl acetate.
The reaction of the compounds (3) with benzaldehyde derivatives in the presence of dehydrating conditions produces the 1-dehydroabietyl-2-phenyl-benzimidazoles (IA).
The reaction is optionally carried out in a solvent or mixture of solvents such as acetic acid, methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane. Suitable dehydrating agents include for example isobutyl chloroformate, tetraethyl orthocarbonate, trimethyl orthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, phosphorus oxychloride, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, ethyl 1,2-dihydro-2-ethoxy-quinoline-1-carboxylate (EEDQ), i-propyl 1,2-dihydro-2-i-propyloxy-quinoline-1-carboxylate (IIDQ), N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N,N'-dicyclohexylcarbodiimide/1-hydroxy-benzotriazole, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate, 2-(1H-benzotriazol-1-yl)-1,1,3,3-1/1446-ff Boehringer Ingelheim International GmbH

tetramethyluronium-tetrafluoroborate/ 1-hydroxy-benzotriazole, N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride. It may optionally be helpful to add a base such as pyridine, 4-dimethylaminopyridine, N-methyl-morpholine or triethylamine. The reaction is usually carried out at temperatures between 0 and 150°C, preferably at temperatures between 20 and 120°C.
Of course, it is also possible, by proceeding according to Diagram 1, to prepare compounds of formula IA wherein one or more of the groups RI to RS have a particular meaning and are then chemically converted into another group. For example a compound of formula IA wherein R2 denotes a benzyl group may be prepared, then the benzyl group can be cleaved hydrogenolytically at the stage of the compound of formula (3), so as to obtain a compound of formula IA wherein R2 denotes COOH. This carboxylic acid group can then be converted into an amide, for example.
Diagram 2 describes the preparation of the starting product of formula (1) wherein RZ
denotes an optionally substituted phenyl group and X denotes fluorine:
(R.)~
OZN ~ Br (HO)ZB ~ OZ R
F
Diagram 2 R' in Diagram 2 preferably denotes hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, di(C1-C6 alkyl)amine, C2-C6 alkanoyl, C2-C6 alkanoylamino, carboxamide or a group of formula -CO-NH-CHZ-aryl, while the aryl group may be substituted by one or two CI-C6 alkoxy groups, and n denotes 0, 1 or 2.
The cross-coupling with the phenylborane may be carried out in the presence of a homogeneous palladium catalyst such as for example tetrakis-(triphenylphosphine)-palladium(0) or palladium diacetate, a suitable phosphine ligand and a base 1/1446-ff Boehringer Ingelheim International GmbH

such as for example sodium carbonate by methods known from the literature [e.g. J.
Med. Chem. 42 (1999) 5120-5130].
Some methods of preparing the compounds according to the invention will now be described in more detail by way of example. The examples of synthesis that follow serve to provide a more detailed explanation without restricting the subject matter of the invention thereto.
Abbreviations used:
9-BBN: 9-borabicyclo[3.3.1 ]nonane BINAP: 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl CDI: N,N'-carbonyldiimidazole dehydroabietyl: 7-isopropyl-1,4a-dimethyl-1,2,3, 4,4a,9,10,10a-octahydro-phenanthren-1-ylmethyl:

H3C~
DMAP: 4-N,N-dimethylaminopyridine DMF: N,N-dimethylformamide DMS O dimethylsulphoxide EDC: N'-(3-dimethylaminopropyl)-N-ethylcarbodiimide HOBt: 1-hydroxy-1 H-benzotriazole TBTU: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium-tetrafluoroborate THF tetrahydrofuran I/1446-ff Boehringer Ingelheim International GmbH

Preparation of the starting compounds:
Example I
2-nitro-4 phenyl-fluorobenzene Analogously to methods known from the literature [J. Med. Chem. 42 (1999) 5120-5130] 1.54 g (7.0 mmol) 5-bromo-2-fluoro-nitrobenzene are dissolved in 7.5 ml dioxane under argon and combined with 0.91 g (7.5 mmol) benzeneboric acid and 0.34 g (0.3 mmol) tetrakis-(triphenylphosphine)-palladium(0). The mixture is heated to 80°C and 7.5 ml of 2M aqueous sodium carbonate solution are added.
Then the mixture is refluxed for 15 hours. After cooling water and ethyl acetate are added. The reaction solution is extracted with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, filtered through Celite and evaporated to dryness. The residue is chromatographed on silica gel (n-hexane/ethyl acetate/ethanol = 100:5:5).
Yield: 1.4 g (6.4 mmol, 92 % of theory) Cl2HgFN02 (217.20) Mass spectrum: M+ = 217 The following compounds were prepared analogously to Example I:
(1) 2-nitro-4-(3-fluorophenyl)-fluorobenzene C12H7FZN02 (235.19) Rf value: 0.55 (silica gel; hexane/ethyl acetate/ethanol = 100:5:5) (2) 2-nitro-4-(3,4-difluorophenyl)-fluorobenzene C12H6F3N02 (253.18) Rf value: 0.50 (silica gel; hexane/ethyl acetate/ethanol = 100:5:5) (3) 2-nitro-4-(3,5-difluorophenyl)-fluorobenzene C12H6F3N02 (253.18) Rf value: 0.35 (silica gel; hexane/ethyl acetate/ethanol = 100:5:5) 1/1446-ff Boehringer Ingelheim International GmbH

(4) 2-vitro-4-(4-isopropylphenyl)-fluorobenzene C15H14FN02 (259.28) Mass spectrum: (M+NH4)+ = 277 (5) 2-vitro-4-(2-methylphenyl)-fluorobenzene Ci3HioFNOz (231.23) Mass spectrum: M+ = 231 (6) 2-vitro-4-(2,4-difluorophenyl)-fluorobenzene C12H6F3NO2 (253.18) Rf value: 0.60 (silica gel; hexane/ethyl acetate/ethanol = 100:5:5) (7) 2-vitro-4-(2-fluorophenyl)-fluorobenzene C12H7F2N02 (235.19) Mass spectrum: M+=235 (8) 2-vitro-4-(4-fluorophenyl)-fluorobenzene C12H7FZN02 (235.19) Rf value: 0.60 (silica gel; hexane/ethyl acetate/ethanol = 100:5 :5) (9) 2-vitro-4-(3-methylphenyl)-fluorobenzene C13H1oFN02 (231.23) Rf value: 0.60 (silica gel; hexane/ethyl acetate/ethanol = 100:5:5) ( 10) 2-vitro-4-(2-acetylphenyl)-fluorobenzene CiaHioFN03 (259.24) Mass spectrum: M+ = 259 1/1446-ff Boehringer Ingelheim International GmbH

Example II
2-nitro-4- 4-dimethylamino-phenyl)-fluorobenzene 220 mg ( 1 mmol) 5-bromo-2-fluoro-nitrobenzene, 0.5 ml (3.6 mmol) triethylamine, 8.98 mg (0.04 mmol) palladium(II)acetate and 24 mg (0.08 mmol) 2-(di-tert-butylphosphino)-biphenyl are added to a solution of 165 mg (1 mmol) 4-dimethylamino-benzeneboric acid in 5 ml DMF. The mixture is stirred for 60 hours at ambient temperature and then the reaction solution is filtered through basic Alox. The filtrate is freed from solvent in vacuo. The residue is chromatographed through silica gel (cyclohexane/ethyl acetate = 9:1 -> 5:1 ).
Yield: 159 mg (0.61 mmol, 61 % of theory) C14H13FN2~2 (260.27) Mass spectrum: (M+H)+ = 261 The following compounds were prepared analogously to Example II:
(1) 2-nitro-4-(3-acetylamino-phenyl)-fluorobenzene C14H11~2~3 (274.25) Rf value: 0.43 (silica gel; dichloromethane/methanol = 15:1 ) (2) 2-nitro-4-(3-acetylphenyl)-fluorobenzene CiaHIOFNO3 (259.24) Mass spectrum: M+ = 259 (3) 2-nitro-5-(4-chlorophenyl)-fluorobenzene C12H7C1FN02 (251.65) (crude product further reacted without purification) . 1/1446-ff Boehringer Ingelheim International GmbH

Example III
4~- 3-aminocarbonyl-phenyl)-2-vitro-fluorobenzene a. 3-(2,4-dimethoxyphenvlmethylaminocarbon~rl)-benzeneboric acid 10.5 ml (69.8 mmol) 2,4-dimethoxybenzylamine, 24.6 g (76.7 mmol) TBTU and 11.6 ml (83.7 mmol) triethylamine are added to a solution of 11.6 g (69.8 mmol) 3-carboxybenzeneboric acid in 200 ml DMF. The mixture is stirred for 2 hours at ambient temperature. Then the solvent is eliminated in vacuo and the residue is chromatographed on silica gel (dichloromethane/methanol = 9:1 ).
Yield: 13.5 g (43 mmol, 61 % of theory) C16H1gBN05 (315.14) Mass spectrum: (M+H)+ = 316 b. 4-(3-(2,4-dimethoxyphenylmethylaminocarbon~)-phenyl]-2-vitro-fluorobenzene Prepared analogously to Example II by reacting 3-(2,4-dimethoxyphenylmethyl-aminocarbonyl)-benzeneboric acid with 5-bromo-2-fluoro-nitrobenzene.
Yield: 38 % of theory CzzHi9FNzOs (410.41) Rf value: 0.45 (cyclohexane/ethyl acetate = 1:1 ) c. 4-(3-aminocarbonyl-phenyl)-2-vitro-fluorobenzene 6.75 g (16.4 mmol) 4-[3-(2,4-dimethoxyphenylmethylaminocarbonyl)-phenyl]-2-nitro-fluorobenzene are dissolved in 35 ml dichloromethane and combined with 35 ml trifluoroacetic acid. The mixture is stirred for 15 hours at ambient temperature. The solvent is eliminated in vacuo. The residue is taken up in dichloromethane and insoluble matter is filtered off. The filtrate is washed successively with saturated sodium hydrogen carbonate solution, 1 M hydrochloric acid and saturated saline solution. The product is dried over sodium sulphate and the solvent is eliminated in vacuo.
Yield: 3.65 g ( 14 mmol, 85 % of theory) C13H9FN203 (260.23) Mass spectrum: (M+H)+ = 261 I/1446-ff Boehringer Ingelheim International GmbH

Example IV
1-dehvdroabietvlamino-4-(2-methvlnhenvll-2-nitrobenzene a. 4-bromo-1-dehydroabietylamino-2-nitrobenzene 9.14 g (32 mmol) (+)-dehydroabietylamine are dissolved in 192 ml DMF and combined with 7.74 g (35.2 mmol) 4-bromo-1-fluoro-2-nitrobenzene and 13.5 g (98 mmol) potassium carbonate. The mixture is stirred for 3 hours at ambient temperature.
The solid is filtered off and the filtrate is evaporated to dryness. The residue is dissolved in warm acetone. The product is precipitated out by the addition of water and suction filtered.
Yield: 13.7 g (28 mmol, 88 % of theory) C26H33BrN2O2 (485.47) Mass spectrum: (M+H)+ = 484, (M+HCOO)- = 531, 529 b. 1-dehydroabietylamino-4-(2-meth~phenyl)-2-nitrobenzene Prepared analogously to Example I by reacting 4-bromo-1-dehydroabietylamino-2-nitrobenzene with 2-methylbenzeneboric acid.
Yield: 87 % of theory C33H40N202 (496.70) Mass spectrum: (M+H)+ = 497 The following compounds were prepared analogously to Example IV:
( 1 ) 1-dehydroabietylamino-4-(4-chlorophenyl)-2-nitrobenzene CszH37C1N20z (517.12) Mass spectrum: (M+Na)+ = 541, 539 (2) 1-dehydroabietylamino-4-(2-chlorophenyl)-2-nitrobenzene C32H37C1N2O2 (517.12) Mass spectrum: (M+Na)+ = 541, 539 1/1446-ff Boehringer Ingelheim International GmbH

(3) 1-dehydroabietylamino-4-(pyridin-4-yl)-2-nitrobenzene C31H37N3~2 (483.66) Mass spectrum: M+ = 483 (4) 1-dehydroabietylamino-4-(pyridin-3-yl)-2-nitrobenzene C31H37N3~2 (483.66) Mass spectrum: (M+H)+ = 484 (5) 1-dehydroabietylamino-4-(3-chlorophenyl)-2-nitrobenzene C3zH37C1N2O2 (517.12) Mass spectrum: M+ = 518, 516 (6) 1-dehydroabietylamino-4-(3-furanyl)-2-nitrobenzene C30H36N2~3 (472.63) Mass spectrum: (M+H)+ = 473 (7) 1-dehydroabietylamino-4-(4-trifluoromethoxy-phenyl)-2-nitrobenzene C33H37F3N203 (566.67) Mass spectrum: (M+H)+ = 567 (8) 1-dehydroabietylamino-4-[4-(4-chlorophenyl)-phenyl)]-2-nitrobenzene C3gH41C1N2O2 (593.22) Mass spectrum: (M+H)+ = 595, 593 (9) 1-dehydroabietylamino-4-(4-methoxyphenyl)-2-nitrobenzene C33H40N2~3 (512.70) Mass spectrum: (M+Na)+ = 535 (10) 1-dehydroabietylamino-4-(3-trifluoromethoxy-phenyl)-2-nitrobenzene C33H37F3N2~3 (566.67) Mass spectrum: (M+Na)+ = 589 (11) 1-dehydroabietylamino-4-(2-thiophenyl)-2-nitrobenzene 1/1446-ff Boehringer Ingelheim International GmbH

C30H36N2~2S (488.70) Mass spectrum: (M+H)+ = 489 (12) 1-dehydroabietylamino-4-(2-methoxyphenyl)-2-nitrobenzene C33H40N2~3 (512.70) Mass spectrum: (M+H)+ = 513 (13) 1-dehydroabietylamino-4-(3-methoxyphenyl)-2-nitrobenzene C33H40N2~3 (512.70) Mass spectrum: (M+H)+ = 513 (14) 1-dehydroabietylamino-4-(2-trifluoromethoxy-phenyl)-2-nitrobenzene C33H37F3N2~3 (566.67) Mass spectrum: (M+H)+ = 567 (15) 1-dehydroabietylamino-4-(2-phenylethenyl)-2-nitrobenzene C34H40N2~2 (508.71) Mass spectrum: (M+H)+ = 509 (16) 1-dehydroabietylamino-4-(furan-3-yl)-2-nitrobenzene C30H36N2~3 (472.63) Mass spectrum: (M+H)+ = 473 Example V
1-dehydroabietylamino-4-(2-morpholinomethyl-phenyl)-2-nitrobenzene a. 2-morpholinomethyl-benzeneboric acid 500 mg (3.2 mmol) 2-formylbenzeneboric acid and 282 ~l (3.2 mmol) morpholine are dissolved in 30 ml THF. The reaction solution is adjusted to pH 5 with glacial acetic acid. At ambient temperature 722 mg (3.2 mmol) sodium triacetoxyborohydride are added and the mixture is stirred for 4 hours at ambient temperature. Then another 282 ul (3.2 mmol) of morpholine and 320 mg (1.4 mmol) of sodium I/1446-ff Boehringer Ingelheim International GmbH

triacetoxyborohydride are added. The mixture is stirred for 16 hours at ambient temperature. Then the solvent is distilled off and the residue is combined with water.
It is extracted with dichloromethane. The combined extracts are washed with saturated sodium chloride solution and dried over magnesium sulphate. Then the solvent is eliminated in vacuo.
Yield: 320 mg (1.4 mmol, 45 % of theory) C1,H16BN03 (221.07) Mass spectrum: (M+H)+ = 222 Rf value: 0.39 (silica gel, dichloromethane/methanol = 9:1 ) b. 1-dehydroabietylamino-4-(2-mor~holinomethyl-phenyl)-2-nitrobenzene Prepared analogously to Example I by reacting 4-bromo-1-dehydroabietylamino-2-nitrobenzene with 2-morpholinomethyl-benzeneboric acid.
Yield: 64 % of theory C37H47N3~3 (581.$0) Mass spectrum: (M+H)+ = 582 The following compounds were prepared analogously to Example V:
(1) 1-dehydroabietylamino-4-(3-morpholinomethyl-phenyl)-2-nitrobenzene C37Ha7N303 (5$1.80) Mass spectrum: (M+H)+ = 582 (2) 1-dehydroabietylamino-4-(4-morpholinomethyl-phenyl)-2-nitrobenzene C37H47N303 (581.80) Mass spectrum: (M+H)+ = 582 I/1446-ff Boehringer Ingelheim International GmbH

Example VI
1-dehydroabietylamino-4-(4-methvlsulphonvlamino-phenyl)-2-nitrobenzene a. 4-methylsulphonylamino-benzeneboric acid A solution of 0.93 ml (12 mmol) methanesulphonic acid chloride in 10 ml dichloromethane is slowly added dropwise at 0°C to a solution of 1.0 g (4.6 mmol) 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-aniline in 10 ml of pyridine.
The mixture is left to come up slowly to ambient temperature and then the solvent is eliminated in vacuo. The residue is taken up in dichloromethane and washed with water. Then it is evaporated to dryness.
Yield: 1.8 g (4.6 mmol, 99 % of theory) C13H2oBN04S (297.18) Mass spectrum: (M+NH4)+ = 315 Rf value: 0.69 (silica gel, petroleum ether/ethyl acetate = 1:1 ) b. 1-dehydroabietylamino-4-(4-methylsulphonylamino~henyl)-2-nitrobenzene Prepared analogously to Example I by reacting 4-bromo-1-dehydroabietylamino-2-nitrobenzene with 4-methylsulphonylamino-benzeneboric acid.
Yield: 46 % of theory C33H41N304s (575.78) Mass spectrum: (M+H)+ = 576 Rf value: 0.7 (silica gel, petroleum ether/ethyl acetate = 1:1 ) The following compounds were prepared analogously to Example VI:
(1) 1-dehydroabietylamino-4-(3-methylsulphonylamino-phenyl)-2-nitrobenzene C33H41N3~4s (575.78) Mass spectrum: (M+H)+ = 576 (2) 1-dehydroabietylamino-4-(2-methylsulphonylamino-phenyl)-2-nitrobenzene C33HaiN30as (575.78) Mass spectrum: (M+Na)+ = 598 1/1446-ff Boehringer Ingelheim International GmbH

Rf value: 0.11 (silica gel, cyclohexane/dichloromethane = 2:1 ) Example VII
1-dehydroabietylamino-4-(pyridin-2-yl)-2-nitrobenzene 1.0 g (2.1 mmol) 4-bromo-1-dehydroabietylamino-2-nitrobenzene, 262 mg (6.2 mmol) anhydrous lithium chloride and 112 mg (0.1 mmol) tetrakis-(triphenylphosphine)-palladium(0) are dissolved in 50 ml dioxane under a nitrogen atmosphere. 773 mg (2.1 mmol) of 2-(tri-n-butylstannyl)-pyridine are added and the mixture is refluxed for 48 hours. Then the precipitate is removed by suction filtering and the filtrate is evaporated to dryness. The residue is dissolved in 20 ml petroleum ether/ethyl acetate (1:1) and chromatographed on silica gel (petroleum ether/ethyl acetate = 84:16 -> 80:20).
Yield: 504 mg (1.0 mmol, 51 % of theory) C31H37N3~2 (483.66) Mass spectrum: (M+H)+ = 484 Rf value: 0.27 (silica gel, petroleum ether/ethyl acetate = 5:1 ) Example VIII
1-dehydroabietylamino-4-(4-aminocarbonyl-phenyl)-2-nitrobenzene a. 1-dehydroabietylamino-4-(4,4,5,5-tetrameth~l-jl 3 2]dioxaborolan-2 .~)-2-nitrobenzene g (10 mmol) 4-bromo-1-dehydroabietylamino-2-nitrobenzene are added to a solution of 253 mg (0.31 mmol) [l,1'-bis-(diphenylphosphino)-ferrocene]-palladium(II)-chloride-dichloromethane complex (1:1), 3.0 g (31 mmol) potassium acetate and 2.9 g (11 mmol) of bis-(pinacolato)-diboron in 60 ml DMSO. The mixture is refluxed for 60 hours. Then the reaction solution is poured onto 1 litre of water. The precipitate is suction filtered and dried in vacuo. The crude product is chromatographed on silica gel (petroleum ether/ethyl acetate = 4:1).
Yield: 2.34 g (4.4 mmol, 43 % of theory) C32H45BN2O4 (532.54) 1/1446-ff Boehringer Ingelheim International GmbH

Mass spectrum: (M+H)+ = 533, 532 Rfvalue: 0.62 (silica gel, petroleum ether/ethyl acetate = 9:1) b. 1-dehydroabietylamino-4-(4-aminocarbon~phenyl)-2-nitrobenzene 500 mg (0.94 mmol) 1-dehydroabietylamino-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2-nitrobenzene and 235 mg (l.l mmol) 4-bromobenzoic acid amide are dissolved in 10 ml dioxane and combined with 2 ml of 2 M
aqueous sodium carbonate solution. 80 mg (0.07 mmol) of tetrakis-(triphenylphosphine)-palladium(0) are added and the mixture is stirred for 72 h at ambient temperature.
Then the solvent is eliminated in vacuo and the residue is taken up in dichloromethane. It is washed twice with water, dried over magnesium sulphate and evaporated to dryness. The residue is filtered through silica gel (dichloromethane/ethyl acetate/petroleum ether = 1:2:2) and crystallised from dichloromethane/petroleum ether.
Yield: 402 mg (0.77 mmol, 81 % of theory) C33H39N3~3 (525.70) Mass spectrum: (M+H)+ = 526 Rf value: 0.49 (silica gel, petroleum ether/ethyl acetate = 1:3) The following compounds were prepared analogously to Example VIII:
( 1 ) 1-dehydroabietylamino-4-(5-chlorothiophen-2-yl)-2-nitrobenzene C3oH3sC1N202S (523.14) Mass spectrum: (M+H)+ = 525, 523 Rf value: 0.49 (silica gel, petroleum ether/ethyl acetate = 9:1 ) (2) 1-dehydroabietylamino-4-(thiazol-2-yl)-2-nitrobenzene C29H35N3~2S (489.69) Mass spectrum: (M+H)+ = 490 Rf value: 0.19 (silica gel, petroleum ether/ethyl acetate = 9:1 ) (3) 1-dehydroabietylamino-4-(5-methylthiophen-2-yl)-2-nitrobenzene C31H38N2~2S (502.73) 1/1446-ff Boehringer Ingelheim International GmbH

Mass spectrum: (M+H)+ = 503 Rf value: 0.67 (silica gel, petroleum ether/ethyl acetate = 9:1 ) (4) 1-dehydroabietylamino-4-(pyrazin-2-yl)-2-nitrobenzene C30H36N4~2 (484.65) Mass spectrum: (M+H)+ = 485 Rfvalue: 0.68 (silica gel, petroleum ether/ethyl acetate = 1:1) (5) 1-dehydroabietylamino-4-(pyrimidin-2-yl)-2-nitrobenzene C30H36N4~2 (484.65) Mass spectrum: (M+H)+ = 485 Rf value: 0.28 (silica gel, petroleum ether/ethyl acetate = 4:1) (6) 1-dehydroabietylamino-2-nitrobenzene Obtained as the hydro-deborination product when reacting 1-dehydroabietylamino-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2-nitrobenzene with 4-bromo-3,5-dimethylisoxazole.
C26H34N2~2 (406.57) Mass spectrum: (M+H)+ = 407 Rf value: 0.44 (silica gel, petroleum ether/ethyl acetate = 9:1 ) (7) 1-dehydroabietylamino-4-(2-methylpropen-1-yl)-2-nitrobenzene C30H40N2~2 (460.67) Rf value: 0.68 (silica gel, petroleum ether/ethyl acetate = 9:1 ) Exam In a IX
1-dehydroabietylamino-4-( 1 H-imidazol-2-yl)-2-nitrobenzene a. 1-dehydroabietylamino-4-formyl-2-nitrobenzene 3 g (17.7 mmol) 4-fluoro-3-nitrobenzaldehyde, 5 g (17.7 mmol) dehydroabietylamine and 11 g (80 mmol) potassium carbonate are dissolved in 20 ml DMF and stirred for 16 hours at ambient temperature . Then the insoluble matter is filtered off and the 1/1446-ff Boehringer Ingelheim International GmbH

solvent is eliminated in vacuo. The residue is triturated with ether and methanol, suction filtered and dried.
Yield: 3.5 g (8 mmol, 46 % of theory) C27H34N2~3 (434.58) Mass spectrum: (M+H)+ = 435 Rf value: 0.35 (silica gel, petroleum ether/ethyl acetate = 5:1) b. 1-dehydroabietylamino-4-(~l H-imidazol-2-~)-2-nitrobenzene 1 g (2.3 mmol) 1-dehydroabietylamino-4-formyl-2-nitrobenzene, 335 mg (2.3 mmol) glyoxal and 3 ml saturated aqueous ammonia solution are heated to 100°C
in 25 ml of ethanol for 1 hour in the bomb tube. Then the solvent is eliminated in vacuo and the residue is chromatographed on silica gel (petroleum ether/ethyl acetate =
67:33 ->
0:100).
Yield: 145 mg (0.3 mmol, 13 % of theory) C29H36N4~2 (472.64) Mass spectrum: (M+H)+ = 473 Rf value: 0.14 (silica gel, petroleum ether/ethyl acetate = 5 :1 ) The following compounds were prepared analogously to Example IX:
(1) 1-dehydroabietylamino-4-methoxycarbonyl-2-nitrobenzene C28H36N204 (464.61 ) Mass spectrum: (M+H)+ = 465 Rf value: 0.7 (silica gel, cyclohexane/ethyl acetate = 2:1 ) (2) 1-dehydroabietylamino-4-methylaminocarbonyl-2-nitrobenzene C37H43N3~4 (593.7) Mass spectrum: (M+H)+ = 594 (3) 1-dehydroabietylamino-4-methyl-2-nitrobenzene C27H36N2~2 (420.60) Rf value: 0.64 (silica gel, cyclohexane/ethyl acetate = 5:1 ) 1/1446-ff Boehringer Ingelheim International GmbH

Example X
1-dehydroabietylamino-4-isoprowl-2-nitrobenzene 0.5 g (1.6 mmol) 4-isopropyl-2-nitrophenyl trifluoromethanesulphonate and 0.46 g (1.6 mmol) (+)-dehydroabietylamine are dissolved in 20 ml DMF and heated to 40°C
for 16 hours. Then the solvent is eliminated in vacuo and the residue dissolved in dichloromethane. It is washed with water and the solvent is eliminated in vacuo. The residue is triturated with water, and the precipitate is suction filtered and dried in the vacuum drying cupboard at 50°C . The residue is then chromatographed on silica gel (petroleum ether/ethyl acetate = 100:0 -> 95:5).
Yield: 270 mg (0.6 mmol, 38 % of theory) C29H40N2~2 (448.65) Mass spectrum: (M+H)+ = 449 Rf value: 0.8 (silica gel, petroleum ether/ethyl acetate = 5:1 ) The following compounds were prepared analogously to Example X:
( 1 ) 1-dehydroabietylamino-4-cyclohexyl-2-nitrobenzene C32H44N2~2 (488.72) Mass spectrum: (M+H)+ = 489 Rf value: 0.74 (silica gel, petroleum ether/ethyl acetate = 5:1 ) (2) 1-dehydroabietylamino-4-tert-butyl-2-nitrobenzene C30H42N2~2 (462.68) Mass spectrum: (M+H)+ = 463 Rfvalue: 0.8 (silica gel, petroleum ether/ethyl acetate = 5:1) (3) 1-dehydroabietylamino-4-cyclopentyl-2-nitrobenzene C31H42N2~2 (474.69) Mass spectrum: (M+H)+ = 475 Rf value: 0.81 (silica gel, petroleum ether/ethyl acetate = 5:1 ) (4) 1-dehydroabietylamino-3-methyl-2-nitrobenzene 1/1446-ff Boehringer Ingelheim International GmbH

C27H36N2~2 (420.60) Mass spectrum: (M+H)+ = 421 Rf value: 0.73 (silica gel, petroleum ether/ethyl acetate = 5:1 ) (5) 1-dehydroabietylamino-3-phenyl-2-nitrobenzene C32H38N2~2 (482.67) Mass spectrum: (M+H)+ = 483 Rf value: 0.72 (silica gel, petroleum ether/ethyl acetate = 4:1 ) Example XI
~4-carboxypiperidino)-benzaldehyde a. 4-(4-ethoxcarbonyl-piperidino)-benzonitrile 15.7 g (0.1 mol) ethyl piperidine-4-carboxylate and 6.1 g (0.05 mol) 4-fluorobenzonitrile are dissolved in 100 ml acetonitrile and refluxed for 176 hours.
Then the acetonitrile is eliminated in vacuo. The residue is taken up in ether and washed with water. After drying over magnesium sulphate the solvent is eliminated in vacuo. The residue is chromatographed on silica gel (ethyl acetate/cyclohexane =
4:1).
Yield: 12.7 g (98 % of theory) CisHisNz~2 (258.31) Calc.: C 69.74 H 7.02 N 10.85 Found: 69.52 7.12 10.67 b. 4-(4-carboxypiperidino,)-benzonitrile 1 g (3.8 mmol) 4-(4-ethoxycarbonyl-piperidino)-benzonitrile are dissolved in 20 ml THF and combined with 9.7 ml 1 N sodium hydroxide solution. The mixture is stirred for 16 hours at ambient temperature and then 9.7 ml 1 N hydrochloric acid are added.
Then the solvent is eliminated in vacuo. The residue is stirred in water.
Yield: 0.83 g (3.6 mmol, 92 % of theory) C13H14N202 (230.27) Mass spectrum: (M+H)+ = 231 I/1446-ff Boehringer Ingelheim International GmbH

Rf value: 0.31 (silica gel, dichloromethane/methanol = 9:1 ) d. 4-(4-carboxypiperidino)-benzaldehyde In a pressure vessel 830 mg (3.6 mmol) 4-(4-carboxypiperidino)-benzonitrile are dissolved in 5 ml formic acid and combined with 1 g Raney nickel. The mixture is shaken for 12 hours at 100°C. Then the catalyst is removed by suction filtering and the filtrate is evaporated to dryness. The residue is stirred with water and suction filtered.
Yield: 360 mg (1.6 mmol, 39 % of theory) Cl3HISN~3 (233.27) Mass spectrum: (M-H)- = 232 Rfvalue: 0.25 (silica gel, dichloromethane/methanol = 19:1) The following compound was obtained analogously to Example XI:
3-carboxycarbonylamino-benzaldehyde C9H~N04 (193.16) Mass spectrum: (M-H)- = 192 Example XII
3-(1H tetrazol-5-ylmethylaminocarbonylmethyl)-benzaldeh ~~de 0.5 g (3 mmol) 3-formylphenylacetic acid are dissolved in 5 ml DMF. 0.49 g (3.7 mmol) HOBt and 0.64 g (3.4 mmol) EDC-hydrochloride are added and the mixture is stirred for one hour at ambient temperature. Then 0.36 g (3.7 mmol) 5-aminomethyl-1H-tetrazole are added. The mixture is stirred for 24 [hours] at ambient temperature.
Then the reaction mixture is poured into 100 ml ice water. The aqueous phase is extracted with ether. The combined organic phases are washed with saturated sodium chloride solution and dried over sodium sulphate. Then the solvent is eliminated in vacuo. The residue is chromatographed on silica gel (dichloromethane/methanol/
acetic acid = 9:1:0.1 ).
Yield: 0.22 g (0.59 mmol, 19 % of theory) CuHnNsOz (245.24) 1/1446-ff Boehringer Ingelheim International GmbH

Mass spectrum: M+ = 245 Rf value: 0.28 (silica gel, dichloromethane/methanol/acetic acid = 19:1:0.1 ) The following compounds were prepared analogously to Example XII:
( 1 ) 3-( 1 H tetrazol-5-ylmethylaminocarbonyl)-benzaldehyde CloH9NsO2 (231.22) Mass spectrum: (M+H)+ = 232 (2) 4-(1H tetrazol-5-ylmethylaminocarbonylmethoxy)-benzaldehyde CllHuNsO3 (261.24) Mass spectrum: (M-H)- = 260 (3) 3-(3-ethoxycarbonylpropylaminocarbonyl)-benzaldehyde C14H1~N04 (263.30) Mass spectrum: (M+H)+ = 264 Rf value: 0.25 (silica gel, petroleum ether/ethyl acetate = 1:1 ) (4) 3-(1H tetrazol-5-ylmethylaminocarbonylmethoxy)-benzaldehyde CuHIINsO3 (261.24) Mass spectrum: (M+H)+ = 262 (5) 3-(2-carboxyethylaminocarbonyl)-benzaldehyde C11H1,N04 (221.21) Mass spectrum: (M+H)+ = 222 (6) 4-(1H tetrazol-5-ylmethylaminocarbonylmethyl)-benzaldehyde C1,H11NsO2 (245.24) Mass spectrum: (M+H)+ = 246 1/1446-ff Boehringer Ingelheim International GmbH

Example XIII
3-(carboxvmethvlaminocarbonvlmethoxvl-benzaldehvde a. 3-(tert-butyloxycarbonylmethylaminocarbonylmethoxy)-benzaldehyde 1.6 g (9.1 mmol) 3-formylphenoxyacetic acid, 2.9 g (9.1 mmol) TBTU and 0.9 g (9.2 mmol) triethylamine are dissolved in 10 ml DMF. The mixture is stirred for 30 minutes at ambient temperature and then 1 g (7.6 mmol) glycine-tent-butylester is added. After 76 hours' stirring at ambient temperature the reaction mixture is evaporated to dryness. The residue is chromatographed on silica gel (petroleum etherlethyl acetate = 1:1).
Yield: 1 g (3.4 mmol, 45 % of theory) CisHI9NOs (293.32) Mass spectrum: (M-H)- = 292 Rf value: 0.43 (silica gel, petroleum ether/ethyl acetate = 1:1 ) b. 3-(carboxymethylaminocarbonylmethox~)-benzaldehyde 0.5 g (1.7 mmol) 3-(tent-butyloxycarbonylmethylaminocarbonylmethoxy)-benzaldehyde are dissolved in 15 ml dichloromethane and combined with 15 ml trifluoroacetic acid. The mixture is stirred for 1.5 hours at ambient temperature and then the solvent is eliminated in vacuo.
Yield: 0.4 g (1.68 mmol, 98 % of theory) ClIHuNOs (237.21) Mass spectrum: (M+H)+=238 Example XIV
4-(3-carboxypropyloxy)-3-fluorobenzaldehyde a. 4-(3-ethoxycarbonyl-propyloxy)-3-fluorobenzaldehyde 2.5 g (12.8 mmol) ethyl 4-bromobutyrate and 1.6 g (11.7 mmol) potassium carbonate are added to a solution of 1.5 g (10.7 mmol) 3-fluoro-4-hydroxybenzaldehyde in ml DMF. It is heated for 76 hours to 50°C. Then it is cooled to ambient temperature I/1446-ff Boehringer Ingelheim International GmbH

and saturated sodium hydrogen carbonate solution is added. The reaction mixture is extracted with ethyl acetate, the combined organic extracts are washed with water and dried over sodium sulphate. Then the solvent is eliminated in vacuo.
Yield: 2 g (7.9 mmol, 74 % of theory) C13H1sF04 (254.26) Mass spectrum: (M+H)+ = 255 Rf value: 0.58 (silica gel, petroleum ether/ethyl acetate = 3:2) b. 4-(3-carboxypropyloxy)-3-fluorobenzaldehyde Prepared analogously to Example XIb by saponifying 4-(3-ethoxycarbonyl-propyloxy)-3-fluorobenzaldehyde with sodium hydroxide solution in ethanol.
Yield: 74 % of theory CuHIIFOa (226.21) Mass spectrum: (M+H)+ = 227 The following compounds were prepared analogously to Example XIV:
(1) 4-(3-carboxypropyloxy)-2-chlorobenzaldehyde CnHuC104 (242.66) Mass spectrum: (M+H)+ = 245, 243 Rf value: 0.59 (silica gel, petroleum ether/ethyl acetate = 2:1 ) (2) 5-(3-ethyloxycarbonyl-propyloxy)-2-methoxybenzaldehyde Cl4HIgOs (266.30) Mass spectrum: (M+H)+ = 267 (3) 3-(3-ethyloxycarbonyl-propyloxy)-2-methoxybenzaldehyde C14H180s (266.30) Mass spectrum: (M+H)+ = 267 (4) 3-(3-tert-butyloxycarbonyl-propyloxy)-benzaldehyde CisHao~4 (264.32) Mass spectrum: (M+H)+ = 265 1/1446-ff Boehringer Ingelheim International GmbH

Rf value: 0.62 (silica gel, petroleum ether/ethyl acetate = 4:1 ) Example XV
3-(N-carboxymethyl-methylamino)-benzaldehyde-hydrochloride a. 3-(N-tert-butoxycarbonyl-methylamino)-benzaldehyde 12.8 g (65.7 mmol) tert-butyl bromoacetate and 17.2 ml (98.7 mmol) triethylamine are added to a solution of 11 g (65.7 mmol) 3-dimethoxymethyl-aniline in 200 ml DMF. The mixture is stirred for 76 hours at ambient temperature. Then the solvent is eliminated in vacuo. The residue is taken up in ethyl acetate and washed with water, 10% sodium hydrogen carbonate solution and saturated saline solution. Then the organic phase is dried over sodium sulphate and evaporated to dryness. 13.9 g product mixture are obtained (dimethylacetal/aldehyde = 27:73). 4 g of this mixture are dissolved in 100 ml DMF. 4.2 ml (24.1 mmol) N-ethyl-diisopropylamine and 1 ml (16.1 mmol) methyl iodide are added and the mixture is heated for 24 hours to 60°C.
Then 1 ml (16.1 mmol) methyl iodide is added three times at 24 hour intervals.
Then the solvent is eliminated in vacuo. The residue is taken up in ethyl acetate and washed with water, 10% sodium hydrogen carbonate solution and saturated saline solution.
After drying over sodium sulphate the solvent is eliminated in vacuo. The residue is chromatographed on silica gel (cyclohexane/ethyl acetate = 5:1).
Yield: 2.2 g (8.9 mmol, 56 % of theory) C 14H 19N~3 (249.31 ) Mass spectrum: (M+Na)+ = 272 Rf value: 0.16 (silica gel, cyclohexane/ethyl acetate = 5:1 ) b. 3-(N-carboxymethyl-methylamino)-benzaldehyde-hydrochloride 2.2 g (8.9 mmol) 3-(N-tert-butoxycarbonyl-methylamino)-benzaldehyde are dissolved in 100 ml acetic acid and combined with 10 ml of conc. hydrochloric acid. The mixture is stirred for 4 hours at ambient temperature. Then the solvent is eliminated in vacuo and the residue is taken up in ether. The precipitate is suction filtered.
Yield: 1.4 g (6 mmol, 70 % of theory) C,oH11N03 x HCl (229.66) 1/1446-ff Boehringer Ingelheim International GmbH

Rf value: 0.25 (silica gel, dichloromethane/methanol/NH40H = 4:1:0.25) Example XVI
3-(4-carboxypiperidino)-benzaldehyde a. 2-[3-(4-ethyloxycarbonyl~iperidino)-phenyl]-1,3-dioxolane 0.6 ml (3.8 mmol) 2-(3-bromophenyl)-1,3-dioxolane, 0.72 ml (4.6 mmol) ethyl piperidine-4-carboxylate and 1.7 g (5.2 mmol) sodium-tert-butoxide are added to a solution of 18 mg (0.03 mmol) BINAP and 8.7 mg (0.009 mmol) tris-(dibenzylideneacetone)-dipalladium(0) in 8 ml of toluene under a nitrogen atmosphere. The mixture is heated for 7 hours to 80°C. Then it is cooled, the reaction mixture is combined with 20% citric acid and extracted with dichloromethane.
The extracts are dried over magnesium sulphate and evaporated to dryness. The residue is chromatographed on silica gel (petroleum ester/ethyl acetate = 77:23 ->
70:30).
Yield: 270 mg (23% of theory) C17H23N04 (305.38) Mass spectrum: (M+H)+ = 306 b. 2-[3-(4-carboxypiperidino~phenyl]-1,3-dioxolane Prepared analogously to Example XIb by saponifying 2-[3-(4-ethyloxycarbonyl-piperidino)-phenyl]-1,3-dioxolane with sodium hydroxide solution in THF/methanol CisHisN04 (277.32) Rfvalue: 0.33 (silica gel, dichloromethane/methanol = 95:5) ~4-carboxypiperidino)-benzaldehyde 227 mg (0.82 mmol) 2-[3-(4-carboxypiperidino)-phenyl]-1,3-dioxolan are dissolved in 6 ml of methanol and combined with 3 ml 1 N hydrochloric acid. The reaction solution is stirred for 15 hours at ambient temperature. Then 3 ml 1 N sodium hydroxide solution are added. The solvent is evaporated down to half the volume.
Toluene is added, the organic phase is separated off, dried over magnesium sulphate and the solvent is eliminated in vacuo. To saponify the methyl ester obtained as a by-product the residue is dissolved in 5 ml THF and 0.5 ml of methanol, combined with 2 1/1446-ff Boehringer Ingelheim International GmbH

ml 1 N sodium hydroxide solution and stirred for 15 hours at ambient temperature.
Then 2 ml 1 N hydrochloric acid are added. After the solvent has been eliminated in vacuo the residue is stirred with acetone, dried over magnesium sulphate and freed from solvent.
C13H15N~3 (233.27) Mass spectrum: (M+H)+ = 234 The following compound was prepared analogously to Example XVI:
(1) 2-[3-(3-carboxypyrrolidin-1-yl)-phenyl]-1,3-dioxolane C~4H1~N04 (263.30) Mass spectrum: (M+H)+ = 264 Rf value: 0.44 (silica gel, petroleum ether/ethyl acetate = 5:1 ) Example XVII
3-(3-ethoxycarbonylpropyl)-benzaldehyde 6.3 g (55 mmol) ethyl vinylacetate are dissolved in 30 ml THF under a protective gas atmosphere. While cooling with ice 240 ml (120 mmol) of a 0.5 M solution of 9-BBN
in THF are added dropwise. Then the reaction solution is left to warm up to ambient temperature and stirred for 1.5 hours. 100 ml DMF are added and 40 ml (120 mmol) of a 3 M aqueous K3P04 solution are added dropwise. Then 6.6 ml (55 mmol) 3-bromobenzaldehyde and 2.2 g (3 mmol) [l,1'-bis-(diphenylphosphino)-ferrocene]-palladium(II)-dichloride are added. The mixture is stirred for 16 hours at ambient temperature. Then the solvent is eliminated in vacuo. The residue is chromatographed on silica gel (petroleum ether/ethyl acetate = 100:0 -> 65:35).
Yield: 5.7 g (47% of theory) C13H16~3 (220.27) Mass spectrum: (M+H)+ = 221 1/1446-ff Boehringer Ingelheim International GmbH

Example XVIII
3-(2-tent-butvloxvcarbonvlethvlcarbonvlamino)-benzaldehvde a. 3-(2-tert-butyloxycarbonylethylcarbonylamino)-benzaldehyde-dimeth lad 1 g (6.1 mmol) CDI are added to a solution of 1 g (5.7 mmol) 3-aminobenzaldehyde-dimethylacetyl in 20 ml THF. The mixture is stirred for 1 hour at 40°C.
Then 0.98 g (5.9 mmol) tert-butyl succinate are added. The mixture is stirred for 16 hours at ambient temperature. Then the solvent is eliminated in vacuo. The residue is taken up in ethyl acetate and washed with water, 1 N hydrochloric acid, 1 N sodium hydroxide solution and saturated saline solution. The organic phase is dried over magnesium sulphate and evaporated to dryness. The residue is chromatographed on silica gel (dichloromethane/methanol = 100:0 -> 95:5).
Yield 1.55 g (83% of theory) CI~HZSNOs (323.39) Mass spectrum: (M+H)+ = 324 Rf value: 0.75 (silica gel, dichloromethane/methanol = 98:2) b. 3-(2-tert-butyloxycarbonylethylcarbonylamino)-benzaldehyde Prepared analogously to Example XVIc from 3-(2-tert-butyloxycarbonylethylcarbonylamino)-benza.ldehyde-dimethylacetal CisHi9N04 (277.32) Mass spectrum: (M+H)+ = 278 Rf value: 0.5 (silica gel, petroleum ether/ethyl acetate = 2:1 ) Example XIX
~4-ethyloxvcarbonvlbut-1-vnvl)-benzaldehvde Under a protective gas atmosphere 1.3 g (6.9 mmol) ethyl 4-pentynoate, 280 mg (0.4 mmol) bis-(triphenylphosphine)-palladium(II)-dichloride and 57 mg (0.3 mmol) copper(I)-iodide are added to a solution of 1.6 g (6.9 mmol) 3-iodobenzaldehyde in 50 ml diisopropylamine. The mixture is heated for 1.5 hours to 40°C. Then the solvent is 1/1446-ff Boehringer Ingelheim International GmbH

eliminated in vacuo. The residue is chromatographed on silica gel (petroleum ether/ethyl acetate = 5:1 ).
Yield: 1.7 g (80% of theory) ClaHla03 (230.27) Rfvalue: 0.58 (silica gel, petroleum ether/ethyl acetate = 5:1) Preparation of the end products:
Example 1 2-(3-carboxymethoxy-phenyl)-5-(2-cyclohexylethylaminocarbonyl)-1-dehydroabietyl-benzimidazole a. 4-fluoro-3-nitrobenzoic acid-2-(cyclohex-1-end)-ethylamide 25 g (135 mmol) 3-fluoro-3-nitrobenzoic acid are refluxed for 2 hours in 100 ml of thionyl chloride. Then excess thionyl chloride is eliminated in vacuo. 27 g (133 mmol) crude product are obtained. 8.77 g (70 mmol) 2-(cyclohex-1-enyl)-ethylamine and 11 ml (80 mmol) triethylamine dissolved in 100 ml dichloromethane are added dropwise to a solution of 14 g (70 mmol) crude product in 300 ml dichloromethane over a period of 20 min. The mixture is stirred for 3 hours at ambient temperature.
Then the reaction solution is washed successively with water, dilute potassium carbonate solution and dilute hydrochloric acid and dried over sodium sulphate. After the solvent has been eliminated in vacuo the residue is chromatographed over silica gel (cyclohexane/ethyl acetate = 4:1 -> 2:1 ).
Yield: 14.6 g (50 mmol, 72 % of theory) C15H17~203 (292.3) Mass spectrum: (M+H)+ = 293 1/1446-ff Boehringer Ingelheim International GmbH

Rf value: 0.24 (silica gel, dichloromethane/methanol = 50:1 ) b. 3-amino-4-dehydroabietylamino-benzoic acid-2-cyclohexylethyl-amide 877 mg (3 mmol) 4-fluoro-3-nitro-benzoic acid-2-(cyclohex-1-enyl)-ethylamide are dissolved in 60 ml DMF and combined with 902 mg (3 mmol) (+)-dehydroabietylamine and 600 mg (4.3 mmol) potassium carbonate. The mixture is stirred for 15 hours at ambient temperature. The mixture is filtered through basic Alox. 1.77 g (3.2 mmol) crude product are obtained. 558 mg (1 mmol) crude product are dissolved in 20 ml of methanol and 10 ml THF and combined with 1.1 ml 1 N
hydrochloric acid and 200 mg palladium/charcoal (10 %). The reaction solution is hydrogenated for 4 hours at 3 bar hydrogen pressure. Then the catalyst is filtered off and the solvent is eliminated in vacuo.
Yield: 504 mg (0.89 mmol, 89 % of theory) c. 2-(3-carboxymethoxy-phenyl)-5-(2-cyclohexylethylaminocarbon,~~lL
dehydroabietyl-benzimidazole 504 mg (0.89 mmol) 3-amino-4-dehydroabietylamino-benzoic acid-2-cyclohexylethyl-amide are dissolved in 20 ml DMF and combined with 160 mg (0.89 mmol) 3-formylphenoxy-acetic acid. The mixture is stirred for 15 hours at ambient temperature. Then the solvent is eliminated in vacuo and the residue is chromatographed on silica gel (dichloromethane/methanol/NH40H = 9:1:0.1 ->
1:1:0.1).
Yield: 400 mg (0.58 mmol, 65 % of theory) CaaHssN304 (689.95) Mass spectrum: (M+H)+ = 690 Rf value: 0.69 (silica gel, dichloromethane/methanol/NH40H = 4:1:0.25) The compounds of Examples 1.1 to 1.14 listed in Table I are prepared analogously to Example 1:

(/1446-ff Boehringer Ingelheim International GmbH

Table I
ExampleRa Rb R.~ hysical data 4-(3-carboxypropyloxy)-2-cyclohexyl-1.1 H (M+H)+ = 752 2-methoxy-phenyl ethylaminocarbonyl 4-(3-carboxypropyloxy)-2-cyclohexyl-1.2 H (M+H)+ = 782 2,6-dimethoxy-phenylethylaminocarbonyl 3-carboxymethyloxy-dimethylamino- m.p.195C

1.3 H (decomp.) phenyl carbonyl +

(M+H) = 608 3-carboxymethyloxy-m. . 197C
1.4 piperidinocarbonylH P

phenyl (M+H)+ = 648 3-carboxymethyloxy-m. . 198C
1.5 morpholinocarbonylH p phenyl (M+H)+ = 650 3-carboxymethyloxy-4-methylpiperazino-H m.p.232C
1.6 phenyl carbonyl (M+H)+ = 663 4-(3-carboxypropyloxy)-4-methylpiperazino-1.7 H (M+H)+ = 721 2-methoxy-phenyl carbonyl 4-( 1-4-(3-carboxypropyloxy)-l .g adamantylmethyl)-H (M-H)- =854 2-methoxy-phenyl piperazinocarbonyl 3-carboxymethyloxy-2-phenylethylamino-1.9 phenyl carbonyl H (M+H)+ = 548 4-(3-carboxypropyloxy)-2-phenylethylamino-1.10 H (M+H)+ = 742 2-methoxy-phenyl carbonyl 3-carboxymethylamino-1.11 phenyl cyclohexylethylaminoH (M+H)+ = 689 -carbonyl 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb R~ hysical data 4-(1-3-carboxymethylamino- H

1.12 adamantylmethyl)- (M+H)+ = 796 phenyl piperazinocarbonyl 3-carboxymethyloxy-2-(3,4-1.13 phenyl dimethoxyphenyl)-H (M-H)- = 742 ethylaminocarbonyl 2-cyclohexyl-3-carboxymethyloxy-1.14 phenyl H ethylamino-(M-H)- = 688 carbonyl Example 2 5-(Benzylaminocarbonyl)-2-(3-carboxymethyloxy-phenyl)-1-dehydroabietyl-benzimidazole a. Benzyl 4-fluoro-3-nitrobenzoate 13.9 g (75 mmol) 4-fluoro-3-nitrobenzoic acid are dissolved in 100 ml THF.
17.4 ml (100 mml) N-ethyl-diisopropylamine are added and 12.82 g (75 mmol) benzylbromide are added dropwise. The mixture is stirred for 15 hours at ambient temperature. Then 200 ml of ethyl acetate are added. The reaction solution is washed with water. The organic phase is extracted with 50 ml 1N hydrochloric acid and washed again with saturated sodium chloride solution, then dried with sodium sulphate and evaporated down. The residue is chromatographed on silica gel (cyclohexane/ethyl acetate = 4:1 ). The product is dissolved in dichloromethane and filtered through basic aluminium oxide. Then the solvent is eliminated in vacuo.
Yield: 15.4 g (56 mmol, 75 % of theory) C,4H1oFN04 (275.24) I/1446-ff Boehringer Ingelheim International GmbH

Mass spectrum: M+ = 275 Rf value: 0.61 (silica gel, cyclohexane/ethyl acetate = 2:1 ) b. Benz l~ydroabietylamino-3-vitro-benzoate 571 mg (2 mmol) (+)-dehydroabietylamine are dissolved in 20 ml DMF. 400 mg (2.9 mmol) potassium carbonate and a solution of 550 mg (2 mmol) benzyl 4-fluoro-3-nitrobenzoate in 20 ml DMF are added. After 15 hours' stirring a further 24 mg (0.084 mmol) (+)-dehydroabietylamine are added, and the mixture is stirred for a further hour. The reaction solution is filtered through basic Alox, washed three times more with 15 ml DMF and evaporated to dryness.
Yield: 1.09 g (2 mmol, 100 % of theory) C3aHaoN2Oa (54'0.71 ) Mass spectrum: (M+Na)+ = 563 c. 3-Amino-4-dehydroabietylamino-benzoic acid-hydrochloride 1.09 g (2 mmol) benzyl 4-dehydroabietylamino-3-vitro-benzoate are dissolved in 40 ml of methanol and 20 ml THF and combined with 2 ml 1 N hydrochloric acid and 200 mg palladium/charcoal (10 %). The reaction solution is hydrogenated for 2 hours at 3 bar hydrogen pressure and ambient temperature. Then the catalyst is removed by suction filtering and the filtrate concentrated by rotary evaporation with some water.
Yield: 0.95 g (2 mmol, 100 % of theory) C27H36N202 (420.60) Mass spectrum: (M+H)+ = 421 Rfvalue: 0.37 (silica gel, dichloromethane/methanol/NH40H = 4:1:0.1) d. 2-(3-tert-Butoxycarbonylmethyloxy~hen~)-4-dehydroabietyl-benzimidazole-5-carboxylic acid 0.93 g (2 mmol) 3-amino-4-dehydroabietylamino-benzoic acid are dissolved in 40 ml DMF and combined with 0.48 g (2 mmol) 3-tent-butoxycarbonylmethyloxy-benzaldehyde. After 15 hours' stirring at ambient temperature the solvent is concentrated by evaporation and the residue chromatographed over silica gel (dichloromethane/methanol/NH40H=85:15:1.5 -> 75:25:2.5).
Yield: 0.75 g (l .l 8 mmol, 58 % of theory) 1/1446-ff Boehringer Ingelheim International GmbH

C4oH4sNaOs (636.84) Mass spectrum: (M+H)+ = 637 Rf value: 0.40 (silica gel, dichloromethane/methanol/NH40H = 4:1:0.25) e. S-(Benzylaminocarbonyl)-2-~3-carboxymethyloxy-phenyl)-1-dehydroabietyl-benzimidazole 21.6 mg (0.034 mmol) 2-(3-tert-butoxycarbonylmethyloxy-phenyl)-4-dehydroabietyl-benzimidazole-5-carboxylic acid are added to a solution of 0.3 ml benzylamine solution (O.1M in DMSO), 11 mg (0.034 mmol) TBTU and 5 ~.1 (0.034 mmol) triethylamine in 0.2 ml DMF and shaken for 3 days at ambient temperature. Then the mixture is filtered through basic Alox and evaporated to dryness. The residue is taken up with 0.25 ml TFA/dichloromethane/water (50:45:5), shaken, left to stand for hour and concentrated by evaporation.
Yield: 21 mg (0.031 mmol, 100 % of theory) C43Ha7N30a (669.87) Mass spectrum: (M+H)+ = 670 Rf value: 0.14 (dichloromethane/methanol/NH40H = 9:1:0.1) The compounds of Examples 2.1 to 2.80 listed in Table I are prepared analogously to Example 2:

1/1446-ff Boehringer Ingelheim International GmbH

Table II

HO~
ExampleRa physical data 2.1 2-( 1 H-imidazol-4-yl)-ethylamino(M+H)+ = 674 2.2 4-(3,4-dimethoxyphenyl)-piperazino(M+H)+ = 785 2.3 3-phenylpropylamino (M+H)+ = 698 2.4 4-(4-methoxyphenyl)-piperazinyl(M+H)+ = 755 7,8-dimethoxy-1,2,4,5-tetrahydro-2.5 (M+H)+ = 770 benzo[d]azepin-3-yl 2.6 2-(3-methoxyphenyl)-ethylamino(M+H)+ = 714 2.7 3-(4-amino-3,5-dichlorophenyl)-propylamino(M+H)+ = 781 2.8 2-phenylethylamino (M+H)+ = 684 2.9 2-(4-methoxyphenyl)-ethylamino(M+H)+ = 714 2.10 3-(4-methoxyphenyl)-propylamino(M+H)+ = 728 2.11 3-(imidazol-1-yl)-proylamino (M+H)+ = 688 2.12 N-methyl-N-(2-phenylethyl)-amino(M+H)+ = 698 2.13 3,4,5-trimethoxybenzylamino (M+H)+ = 760 2.14 2-(4-amino-3,5-dibromophenyl)-ethylamino(M+H)+ = 857 2.15 2-(pyridin-4-yl)-ethylamino (M+H)+ = 685 2.16 4-trifluoromethoxybenzyl-amino(M+H)+ = 754 2.17 4-benzylpiperazino (M-H)- = 737 2.18 4-([1,2,3]thiadiazol-4-yl)-benzylamino(M+H)+=754 2.19 2-(4-nitropyridin-2-ylamino)-ethylamino(M+H)+ = 745 2.20 3-(cyclohexyloxy)-propylamino (M+H)+ = 718 2.21 adamantan-1-ylmethylamino (M+H)+=728 1/1446-ff Boehringer Ingelheim International GmbH

physical ExampleRa data 3-[2-(2,4-dimethoxyphenyl)-1 2.22 H-imidazol-4- (M+H)+ = 824 yl]-propylamino 2.23 2-methylpropylamino (M+H)+ = 636 2.24 2-ethylsulphanyl-ethyl (M+H)+ = 668 2.25 2-(4-tert-butylphenyl)-ethylamino(M+H)+ = 740 2.26 2-dimethylamino-ethylamino (M+H)+ = 651 2.27 2-hydroxyethylamino (M+H)+ = 624 2.28 butylamino (M+H)+ = 636 2.29 2,2-dimethylpropylamino (M+H)+ = 650 2.30 2-(1-napthyl)-ethylamino (M+H)+ = 734 2.31 2-(4-cyanophenyl)-ethylamino (M+H)+ = 709 2.32 2-carboxyethylamino (M+H)+ = 652 2.33 2-morpholinocarbonyl-ethylamino(M+H)+ = 721 2.34 2-(4-methyloxycarbonyl-phenyl)-ethylamino(M+H)+ = 742 2.35 2-(4-bromophenyl)-ethylamino (M+H)+ = 764, 2.36 2-methoxyethylamino (M+H)+ = 638 2.37 allylamino (M+H)+ = 620 2.3 2-cyanoethylamino (M+H)+ = 633 2.39 2-methoxycarbonyl-ethylamino (M+H)+ = 666 2.40 3-(2-oxo-pyrrolidin-1-yl)-propylamino(M+H)+ = 705 2.41 3,3-dimethylbutylamino (M+H)+ = 664 2.42 2-methylsulphanyl-ethyl (M+H)+ = 654 2.43 2-(4-phenylphenyl)-ethylamino (M+H)+ = 760 2.44 4-methylcyclohexyl-amino (M+H)+ = 676 2.45 cyclohexylmethylamino (M+H)+ = 676 2.46 3-methylbutylamino (M+H)+ = 650 2.47 3-methoxypropylamino (M+H)+ = 652 2.48 2-(4-aminocarbonyl-phenyl)-ethylamino(M+H)+ = 727 2.49 3-hydroxybutylamino (M+H)+ = 652 2.50 2-hydroxy-2-phenyl-ethylamino (M+H)+ = 700 1/1446-ff Boehringer Ingelheim International GmbH

physical ExampleRa data 2.51 propylamino (M+H)+ = 622 2.52 2-(thiophen-2-yl)-ethylamino (M+H)+ = 690 2.53 2-(imidazol-1-yl-)-ethylamino (M+H)+= 674 2.54 furan-2-ylcarbonyl-methylamino (M+H)+ = 688 2.55 2-(4-aminosulphonyl-phenyl)-ethylamino(M+H)+ = 763 2.56 3-hydroxypropylamino (M+H)+ = 638 2.57 cyanomethylamino (M+Na)+ =

2-(4-methoxycarbonyl-methyl-phenyl)-2.58 (M+H)+ = 756 ethylamino 2.59 2-(tert-butoxycarbonylamino)-ethylamino(M+H)+ = 724 2.60 4-cyclohexylbutylamino (M+H)+ = 719 2.61 3-methoxycarbonyl-propylamino (M+H)+ = 680 2.62 pentylamino (M+H)+ = 650 2.63 2-isopropoxy-ethylamino (M+H)+ = 666 2.64 4-(pyridin-4-yl)-butylamino (M+H)+ = 713 2.65 1-cyclohexylcarbonyl-ethylamino (M+H)+= 718 2.66 2-(N-methylpyrrolidin-2-yl)-ethylamino(M+H)+ = 691 2.67 2-(pyridin-3-yl)-ethylamino (M+H)+ = 685 2.68 4-(pyridin-3-yl)-butylamino (M+H)+ = 713 2.69 2-(cyclohexen-1-yl)-ethylamino (M+H)+ = 688 2.70 2-(4-chlorophenyl)-ethylamino (M+H)+ = 718 2.71 4-(adamantan-1-ylmethyl)-piperazino(M+H)+ = 797 2.72 2-(pyridin-2-yl)-ethylamino (M+H)+ = 685 2.73 1-methyl-2-(pyridin-2-yloxy)-ethylamino(M-H)- = 713 2.74 2-(3-hydroxyphenyl)-ethylamino (M+H)+ = 780, 2.75 (E)-3,7-dimethylocta-2,6-dienylamino(M+H)+ = 716 2.76 3,4-dihydro-1H-isoquinolin-2-yl (M+H)+=696 2.77 octahydroisoquinolin-2-yl (M+H)+ = 702 2.78 2-(4-hydroxyphenyl)-ethylamino (M+H)+ = 700 2.79 2-(4-hydroxy-3-methoxyphenyl)-ethylamino(M+H)+ = 730 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa physical data 2-[4-(4-hydroxyphenoxy)-phenyl]-2.80 (M+H)+ = 792 ethylamino Example 3 2-(3-carboxymethyloxy-phenyl)-1-dehydroabietyl-5-(2-nitrophenyl)-benzimidazole Chiral a. 4-Bromo-1-dehydroabietylamino-2-nitrobenzene 7.04 g ( 32 mmol) 4-bromo-1-fluoro-2-nitrobenzene are dissolved in 200 ml DMF
and combined with 13.3 g (96 mmol) potassium carbonate and 9.14 g (32 mmol) (+)-dehydroabietylamine. The mixture is stirred for 3 hours at ambient temperature. Then the solid is separated off by suction filtering and the filtrate is evaporated to dryness.
The orange residue is dissolved in 450 ml acetone and combined with 150 ml of water. The product precipitates out, is suction filtered and dried in vacuo.
Yield: 12 g (25 mmol, 78 % of theory) melting point: 149-150°C
C26H33BrN2O2 (485.47) Mass spectrum: [M+H]+ = 487, 485 b. 2-Amino-4-bromo-1-dehydroabietylamino-benzene 3.5 g (7.2 mmol) 4-bromo-1-dehydroabietylamino-2-nitrobenzene are dissolved in 100 ml of ethyl acetate and 20 ml THF and combined with 1 g Raney nickel. The mixture is hydrogenated for 8 hours at ambient temperature under a hydrogen atmosphere of 3 bar. Then the catalyst is filtered off and the filtrate is freed from solvent in vacuo.
Yield 3.2 g (7 mmol, 97 % of theory) C26H35BrN2 (455.49) 1/1446-ff Boehringer Ingelheim International GmbH

Mass spectrum: [M+H]+ = 457, 455 c. 2-(3-tert-Butoxycarbonylmethyloxy-phenyl)-5-bromo-1-dehydroabietyl-benzimidazole Prepared analogously to Example 1 c from 2-amino-4-bromo-1-dehydroabietylamino-benzene and tert-butyl 3-formylphenoxyacetate.
Yield: 40 % of theory C39H47BrN2O3 (671.73) Mass spectrum: [M+H]+ = 673, 671 d. 2-(3-tent-Butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-5-(2-nitrophenyl)-benzimidazole 0.67 g (1 mmol) 2-(3-tert-butoxycarbonyl-methyloxy-phenyl)-5-bromo-1-dehydroabietyl-benzimidazole are dissolved in 5 ml dioxane under a nitrogen atmosphere. 0.3 g (1.8 mmol) 3-nitrophenylboric acid, 0.05 g (0.043 mmol) tetrakis-(triphenylphosphine)-palladium(0) and 1 ml 2 M aqueous sodium carbonate solution are added and the mixture is refluxed for 15 hours. Then the reaction solution is combined with aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The combined organic phases are evaporated down. The residue is chromatographed on silica gel (petroleum ether/ethyl acetate = 3:1 -> 1:1).
Yield: 0.37 g (0.52 mmol, 52 % of theory) melting point: 126-128°C
C45HS1N3~5 (713.92) Mass spectrum: [M+H]+ = 714 e. 2-(3 -Carboxymethyloxy-phenyl)-1-dehydroabietyl-5-(2-nitrophenyl)-benzimidazole 0.34 g (0.476 mmol) 2-(3-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-(2-nitrophenyl)-benzimidazole are dissolved in 6 ml dichloromethane. 6 ml trifluoroacetic acid and 0.04 ml of water are added and the mixture is stirred for 1 hour at ambient temperature. Then the solution is evaporated down and the residue is chromatographed on silica gel (petroleum ether/ethyl acetate/acetic acid =
3:1:0.08 ->
ethyl acetate/methanol/acetic acid = 2:1:0.06).

1/1446-ff Boehringer Ingelheim International GmbH

Yield: 0.29 g (0.44 mmol, 93 % of theory) melting point: 258-262°C
C41H43N3~5 (657.82) Mass spectrum: [M-H]- = 656 The compounds of Examples 3.1 to 3.37 listed in Tables IIIa and IIIb are prepared analogously to Example 3:
Table IIIa ~ Re / I
~N
R
Rb physical ExampleRa data m.p. 168-172C

3.1 2-nitrophenyl dehydroabietyl (M+H)+ = 658 m.p. 172-176C

3.2 4-nitrophenyl dehydroabietyl (M+H)+ = 658 m.p. 220-226C

3.3 4-fluorophenyldehydroabietyl (M-H)- = 629 m.p. 108C

3.4 3-fluorophenyldehydroabietyl (M+H)+ = 631 m.p. 233C
3.5 3,5-difluorophenyldehydroabietyl ~,1+ = 648 m.p. 133-141 3.6 3,4-difluorophenyldehydroabietylC

(M-H)- = 647 m.p. 129-156C
3.7 4-chlorophenyldehydroabietyl (M+H)+ = 649, m.p. 202C
3.8 3-cyanophenyl dehydroabietyl (M+H)+ = 638 3.9 4-cyanophenyl dehydroabietyl(M-H)- = 636 3.10 2-methoxyphenyldehydroabietylm.p.200-203C

1/1446-ff Boehringer Ingelheim International GmbH

physical ExampleRa data (M+H)+ = 643 m.p. 120C

3.11 3-methoxyphenyldehydroabietyl (M+H)+ = 643 m.p. 227-233C

3.12 4-methoxyphenyldehydroabietyl (M+H)+ = 643 m.p. 138-142C

3.13 3-benzyloxyphenyldehydroabietyl (M+H)+ = 719 2-trifluoromethoxy- m.p. 172-175 C

3.14 dehydroabietyl phenyl (M+H)+ = 697 2-methylsulphanyl- m.p. 154-160C

3.15 dehydroabietyl phenyl (M+H)+ = 659 3.16 3-methylphenyl dehydroabietyl(M+H)+ = 627 m.p. 146-150C

3.17 2-methylphenyl dehydroabietyl (M-H)- = 625 4-trifluoromethyl- m.p. 157-163C

3.18 dehydroabietyl phenyl (M-H)- = 679 3.19 2-acetylphenyl dehydroabietyl(M+H)+ = 655 m.p. 146-149C

3.20 3-acetylphenyl dehydroabietyl (M+H)+ = 655 m.p. 176-180C

3.21 4-acetylphenyl dehydroabietyl (M+H)+ = 655 m.p. 201-205C

3.22 3-carboxyphenyldehydroabietyl M+ = 656 m.p. 294-296C

3.23 4-carboxyphenyldehydroabietyl (M-H)- = 655 3.24 3-formylphenyl dehydroabietyl(M+H)+ = 641 3.25 4-formylphenyl dehydroabietyl(M+H)+ = 641 3.26 thiophen-3-yl dehydroabietyl(M+H)+ = 619 m.p. 252-256C

3.27 pyridin-3-yl dehydroabietyl (M-H)- = 612 1/1446-ff Boehringer Ingelheim International GmbH

3.28 quinolin-8-yl dehydroabietyl(M+H)+ = 664 3-aminocarbonyl-3.29 dehydroabietyl(M+H)+ = 656 phenyl 4-cyclohexyl-m.p.187C

3.30 4-acetylphenyl phenyl (M-H)- = 543 4-tert-butyl-m.p.246C

3.31 4-acetylphenyl phenyl (M-H)- = 517 2-(4-tert-butyl-m.p.230C

3.32 4-acetylphenyl phenyl)-ethyl(M-H)- = 545 m.p. >200C

3.33 4-pyridyl dehydroabietyl decomp.

Table IIIb Exam R hysical data le m.p. 185C

3.34 3-cyanophenyl (M+H)+ = 696 3.35 4-acetylphenyl (M+H)+ = 713 m.p. 257C

3.36 3-Actetylaminophenyl (M+H)+ = 728 3 .3 4-cyanophenyl (M+H)+ = 696 1/1446-ff Boehringer Ingelheim International GmbH

Example 4 2-(3-Carboxymethyloxy-phenyl)-1-dehydroabietyl-5-(3-hydroxyphenyl)-benzimidazole Chlrai 0.3 g (0.42 mmol) 2-(3-carboxymethyloxy-phenyl)-1-dehydroabietyl-5-(3-benzyloxy-phenyl)-benzimidazole (see Example 3.13) are dissolved in 30 ml of ethanol and 3 ml acetic acid and combined with 0.2 g palladium/charcoal. The mixture is hydrogenated for 27 hours at ambient temperature under a hydrogen pressure of 3.5 bar. Then the catalyst is filtered off and the solvent is distilled off. The residue is chromatographed on silica gel (ethyl acetate/petroleum ether/acetic acid = 1:1:0.02 -> ethyl acetate/methanol/acetic acid = 5:1:0.06).
Yield: 0.11 g (0.18 mmol, 42 % of theory) melting point: 238-242°C
CaIH~N20a (628.82) Mass spectrum: [M+H]+ = 629 Example 5 2-(3-Carboxymethyloxy-phenyl)-1-dehydroabietyl-5-(2-methylsulphonylphenyl)-benzimidazole Chiral O
50 mg (0.076 mmol) 2-(3-carboxymethyloxy-phenyl)-1-dehydroabietyl-5-(2-methylsulphanylphenyl)-benzimidazole (see Example 3.15) are dissolved in 2 ml dichloromethane and at 0°C combined with 33 mg (0.19 mmol) 3-chloroperbenzoic acid (77 %). Then the mixture is stirred for 48 hours at ambient temperature.
It is diluted with dichloromethane and the reaction solution is washed with 1 M
aqueous 1/1446-ff Boehringer Ingelheim International GmbH

sodium hydrogen sulphite solution. The organic phases are dried and evaporated down. The residue is chromatographed over silica gel (dichloromethane/methanol/NH40H = 9:1:0.1 -> 4:1:0.1 ).
Yield: 19 mg (0.03 mmol, 36 % of theory) C42H46N2~Ss (690.91) Mass spectrum: [M+H]+ = 691 Example 6 2-(3-Carboxymethyloxy-phenyl)-1-dehydroabietyl-5-(2-aminophenyl)-benzimidazole Chiral Prepared analogously to Example 3.b by catalytic hydrogenation of 2-(3-carboxymethoxy-phenyl)-1-dehydroabietyl-5-(2-nitrophenyl)-benzimidazole (Example 3.1 ) on Raney nickel in ethyl acetate.
Yield: 55 % of theory Melting point: 186-190°C
CaW4sN303 (627.83) Mass spectrum: [M+H]+ = 628 Example 7 2-(3-Carboxymethyloxy-phenyl)-1-dehydroabietyl-5-(3-aminophenyl)-benzimidazole chira~

1/1446-ff Boehringer Ingelheim International GmbH

Prepared analogously to Example 3.b by catalytic hydrogenation of 2-(3-carboxymethyloxy-phenyl)-1-dehydroabietyl-5-(3-nitrophenyl)-benzimidazole (Example 3) on Raney nickel in ethyl acetate.
Yield: 49 % of theory C4iHasN303 (627.83) Mass spectrum: [M-H]- = 626 Example 8 2-(3-carboxymethyloxy-phenyl)-1-dehydroabietyl-5-(4-dimethylaminomethyl-phenyl)-benzimidazole-hydrotrifluoroacetate a. 2-(3-tert-butoxycarbonylmethylox~phenyl)-1-dehydroabietyl-5-(4-dimethylaminomethyl-phenyll-benzimidazole 175 mg (0.25 mmol) 2-(3-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-(4-formylphenyl)-benzimidazole (prepared analogously to Example 3d) are dissolved in 5 ml THF and combined with 0.5 ml (1 mmol) dimethylamine (2 M in THF). The pH is adjusted to 4-5 with acetic acid and then 53 mg (0.25 mmol) sodium triacetoxyborohydride are added and stirred for 5 hours at ambient temperature. Then sodium hydrogen carbonate solution and ethyl acetate are added. The reaction solution is extracted with ethyl acetate. The combined organic phases are dried over magnesium sulphate and evaporated down. The residue is stirred with petroleum ether, suction filtered and dried.
Yield: 130 mg (0.18 mmol, 73 % of theory) C48H59N3~3 (726.02) Mass spectrum: [M+H]+ = 726 b. 2-(3-carboxymeth~y-phenyl)-1-dehydroabietyl-5-(4-dimethylaminomethyl-phenyl)-benzimidazole-hydrotrifluoroacetate 1/1446-ff Boehringer Ingelheim International GmbH

Prepared analogously to Example 3e from 2-(3-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-5-(4-dimethylaminomethyl-phenyl)-benzimidazole.
Yield: 74 % of theory C~HS1N303 x CZHF302 (783.94) Mass spectrum: [M+H]+ = 670 Example 9 2-(3-Carboxymethyloxy-phenyl)-1-dehydroabietyl-5-(3-dimethylaminomethyl-phenyl)-benzimidazole-hydrotrifluoroacetate Prepared analogously to Example 8 from 2-(3-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-5-(3-dimethylaminomethyl-phenyl)-benzimidazole.
Yield: 98 % of theory Melting point: 127°C
C~Hs1N303 x C2HF3O2 (783.94) Mass spectrum: M+ = 669 Example 10 2-(3-Carboxymethyloxy-phenyl)-1-dehydroabietyl-5-(3-morpholinomethyl-phenyl)-benzimidazole-hydrotrifluoroacetate Prepared analogously to Example 8 from 2-(3-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-5-(3-morpholinomethyl-phenyl)-benzimidazole.
Yield: 99 % of theory C46H53N3~4 x CZHF302 (825.98) Melting point: 133°C (decomp.) 1/1446-ff Boehringer Ingelheim International GmbH

Mass spectrum: [M+H]+ = 712 Example 11 2-(3-Carboxymethyloxy-phenyl)-5-(3-carboxymethyloxy-phenyl)-1-dehydroabietyl-benzimidazole Chiral a. 2-(3-tert-butoxycarbonylmethyloxy-phenyl)-5-(3-tert-butox c~ylmethyloxy-phenyl)-1-dehydroabietyl-benzimidazole 0.13 g (0.19 mmol) 2-(3-tent-butoxycarbonylmethyloxy-phenyl)-5-(3-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-benzimidazole (prepared analogously to Example 4) are dissolved in 2 ml DMF and combined with 0.026 g (0.19 mmol) potassium carbonate. The mixture is stirred for 1 hour at ambient temperature and 0.027 ml (0.19 mmol) tert-butyl chloroacetate are added. The mixture is stirred for 52 hours at ambient temperature and then the solvent is eliminated in vacuo. The residue is taken up in dichloromethane and washed twice with soda solution and twice with 10% citric acid. The organic phase is evaporated down and the residue is chromatographed on silica gel (petroleum ether/ethyl acetate =
5:1 ->
2:1).
Yield: 0.16 g (0.2 mmol, 99 % of theory) CS1H62N2~6 (799.07) Mass spectrum: M+ = 799 b. 2-(3-carboxymethyloxy-phenyl)-5-(3 -carboxymethyloxy-phenyl)-1-dehydroabiet~-benzimidazole Prepared analogously to Example 3e from 2-(3-tert-butoxycarbonylmethyloxy-phenyl)-5-(3-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-benzimidazole.
Yield: 89 % of theory C43H46N2~6 (686.86) Mass spectrum: [M+H]+ = 687 I/1446-ff Boehringer Ingelheim International GmbH

Example 12 5-(4-Acetylaminomethyl-phenyl)-2-(3-carboxymethyloxy-phenyl)-1-dehydroabietyl-benzimidazole on~r~i a. 5-(4-acetylaminomethyl-phenyl)-2-(3-tert-butox~carbonylmethylox~phenyly-1-dehydroabietyl-benzimidazole 250 mg (0.36 mmol) 5-(4-aminomethyl-phenyl)-2-(3-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-benzimidazole (prepared analogously to Example 3d) are dissolved in 10 ml dichloromethane and combined with 0.2 ml (1.5 mmol) triethylamine and 0.055 ml (0.77 mmol) acetylchloride. The mixture is stirred for 15 hours at ambient temperature. Then water is added. The reaction solution is extracted with dichloromethane. The combined organic phases are washed with saturated sodium chloride solution and dried over sodium sulphate. The residue obtained after elimination of the solvent is chromatographed on silica gel (dichloromethane/methanol/NH40H = 9:1:0.1 ).
Yield: 30 mg (0.04 mmol, 11 % of theory) C48H57N3~4 (740.01) Mass spectrum: [M+H]+ = 740 b. 5-(4-acetylaminomethyl-phenyl)-2-(3-carboxymethylox~-phenyl)-1-dehydroabietyl-benzimidazole Prepared analogously to Example 3e from 5-(4-acetylaminomethyl-phenyl)-2-(3-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-benzimidazole with trifluoroacetic acid.
Yield: 90 % of theory C~Ha9N30a (683.90) Mass spectrum: [M+H]+ = 684 1/1446-ff Boehringer Ingelheim International GmbH

The compounds of Examples 12.1 and 12.2 listed in Table IV are prepared analogously to Example 12:
Table IV

Exam R hysical data le m.p. 175C

12.1 3-acetylamino-phenyl (decomp.) (M+H)+ = 670 m.p. 166C

12.2 3-methylsulphonylamino-phenyl(decomp.) (M+H)+ = 706 Example 13 5-(3-Hydroxymethyl-phenyl)-2-(3-carboxymethyloxy-phenyl)-1-dehydroabietyl-benzimidazole Chiral 5.4 mg (0.143 mmol) sodium borohydride are added to a solution of 100 mg (0.143 mmol) 5-(3-formylphenyl)-2-(3-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-benzimidazole in 2 ml THF at ambient temperature. The mixture is stirred for 15 hours at ambient temperature. Then 5 ml trifluoroacetic acid are added.
After 4 hours' stirring the solvent is eliminated in vacuo. The residue is chromatographed through an RP column (acetonitrile/water = 1:9 -> 9:1 ).
Yield: 9 mg (10 % of theory) C42H46N2~4 (642.85) 1/1446-ff Boehringer Ingelheim International GmbH

Mass spectrum: [M+H]+ = 643 Example 14 5-[3-(2-Carboxyethylaminocarbonyl)-phenyl]-2-phenyl-1-dehydroabietyl-benzimidazole Chiral a. N-dehydroabietyl-2-nitro-4-phenylaniline 9.6 g (33.6 mmol) dehydroabietylamine and 7.2 g (33.1 mmol) 2-nitro-4-phenyl-fluorobenzene (Example I) are dissolved in 50 ml DMF. 7.1 g (51 mmol) potassium carbonate are added and the mixture is stirred for 15 hours at ambient temperature.
Then sodium hydrogen carbonate solution and common salt are added and the mixture is extracted with ethyl acetate. The combined organic phases are washed with water and dried over sodium sulphate. Then the solvent is eliminated in vacuo. The residue is stirred with petroleum ether and the residue is suction filtered. The product thus obtained is dried at 60°C.
Yield: 14.9 g (92 % of theory) C32H38N2~2 (482.67) Mass spectrum: (M+H)+ = 483 b. 5-f3-(2-carboxyethylaminocarbonyl~phen~l-2 phenyl-1-dehydroabietyl-benzimidazole 0.24 g (0.5 mmol) N-dehydroabietyl-2-nitro-4-phenylaniline are dissolved in 10 ml of ethyl acetate and combined with 50 mg Raney nickel. The mixture is hydrogenated for 5 hours at 50°C under 3.5 bar hydrogen pressure. Then the reaction solution is suction filtered to 0.5 ml 1 N hydrochloric acid and evaporated to dryness.
The phenylenediamine thus obtained is dissolved in 10 ml DMF/water (9:1) and combined with 0.11 g (0.5 mmol) 3-(2-carboxyethylaminocarbonyl)-benzaldehyde. The mixture is stirred for 15 hours at ambient temperature. Then the solvent is eliminated in vacuo.

1/1446-ff Boehringer Ingelheim International GmbH

The residue is chromatographed on silica gel (dichloromethane/methanol/NH40H =
4:1:0.25).
Yield: 0.17 g (52 % of theory) Rf value: 0.56 (silica gel, dichloromethane/methanol/NH40H = 4:1:0.25) C43H47N3~3 (653.87) Mass spectrum: (M+H)+ = 654 The compounds of Examples 14.1 to 14.96 listed in Table V are prepared analogously to Example 14 using the starting materials which may be obtained by the methods described in Examples I to XIX or by methods known from the literature. If the aldehyde component contains an ester, saponification is additionally carried out using one of the following general methods:
130 mmol of the ester are dissolved in 5 ml THF and stirred with 230 mmol 1 N
sodium hydroxide solution for 2 hours at ambient temperature. Then 230 mmol 1 N
hydrochloric acid are added. The solvent is eliminated in vacuo and the residue is taken up in dry acetone. Insoluble matter is filtered off and the solvent is again eliminated in vacuo.
390 mmol of the ester are dissolved in 5 ml dichloromethane and combined with 5 ml trifluoroacetic acid. The mixture is stirred for 1-2 hours at ambient temperature. Then the solvent is eliminated in vacuo. Water and a few drops of conc. ammonia are added. The precipitate is suction filtered.

1/1446-ff Boehringer Ingelheim International GmbH

Table V
ExampleRa Rb R hysical.data 14.1 3-carboxymethyloxy-phenylphenyl H (M+H)+ = 613 4-(3-carboxypropyloxy)-2- H

14.2 phenyl (M+H)+ = 671 methoxy-phenyl 4-(3-carboxypropyloxy)-2,6- H

14.3 phenyl (M+H)+ = 7p dimethoxy-phenyl 1 H m.p. 298-300 14.4 4-(2-carboxyethyl)-phenylphenyl C

(M+H)+ = 611 4-(2-carboxyethylcarbonylamino)- H

14.5 phenyl phenyl (M+H)+ = 654 14.6 4-(4-carboxypiperidino)-phenylphenyl H (M+H)+ = 666 4-(3-carboxypropyloxy)-3,5- H

14.7 phenyl (M+H)+ = 701 dimethoxy-phenyl 4-(3-carboxypropyloxy)-3- H

14.8 phenyl (M+H)+ = 671 methoxy-phenyl 4-(3-carboxypropyloxy)-3- H

14.9 phenyl (M+H)+ = 659 fluorophenyl 3-(1H tetrazol-5-ylmethylamino- H

14.10 phenyl (M+H)+ = 694 carbonylmethyloxy)-phenyl 3-(carboxymethylaminocarbonyl- H

14.11 phenyl (M+H)+ = 670 methyloxy)-phenyl 3 -(1H tetrazol-5-ylmethylamino- H

14.12 phenyl (M+H)+ = 664 c arbonyl)-phenyl H m.p.235C
14.13 -(carboxycarbonylamino)-phenylphenyl (M+H)+ = 626 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb R hysical data 4-(2-carboxyethylaminocarbonyl)- H m.p. 146-171 C

14.14 phenyl phenyl (M+H)+ = 654 3_(3_ H

m.p. 121-141 C

14.15 carboxypropylaminocarbonyl)-phenyl (M-H)- = 666 phenyl 14.16 3-(4-carboxybutyl)-phenylphenyl H (M+H)+ = 639 3-(1H tetrazol-5-ylmethylamino- H

14.17 3-fluorophenyl (M+H)+ = 696 carbonylmethyl)-phenyl 14.18 3-(2-carboxyethyloxy)-phenylphenyl H (M+H)+ = 627 3-(1H tetrazol-5-ylmethylamino- H

14.19 3-fluorophenyl (M+H)+ = 682 carbonyl)-phenyl 4-(2-carboxyethylaminocarbonyl)-3,4- H

14.20 (M+H)+ = 690 phenyl difluorophenyl 4-(2-carboxyethylaminocarbonyl)-3,5- H

14.21 (M+H)+ = 690 phenyl difluorophenyl 3-(2-carboxyethylaminocarbonyl)- H

14.22 4-isopropylphenyl (M+H)+ = 696 phenyl 3-(1H tetrazol-5-ylmethylamino- H

14.23 4-isopropylphenyl (M+H)+ = 706 carbonyl)-phenyl 4-dimethylamino-H

14.24 3-carboxymethyloxy-phenyl (M-H)- = 654 phenyl 3-acetylamino-H

14.25 4-(3-carboxypropyloxy)-phenyl (M+H)+ = 698 phenyl 3-acetylamino-H

14.26 3-(2-carboxyethyloxy)-phenyl (M+H)+ = 684 phenyl 4-(3-carboxypropyloxy)-2-3-aminocarbonyl-H

14.27 (M+H)+ = 714 methoxy-phenyl phenyl 3-aminocarbonyl-H

14.28 3-(2-carboxyethyloxy)-phenyl (M+H)+ = 670 phenyl 3-aminocarbonyl-H

14.29 4-(3-carboxypropyloxy)-phenyl (M+H)+ = 684 phenyl 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb R~ _ hysical data 3-(2-carboxyethylaminocarbonyl)- H

14.30 2-methylphenyl (M+H)+ = 668 phenyl 3-(2-carboxyethylaminocarbonyl)-3,4- H

14.31 (M+H)+ = 690 phenyl difluorophenyl 3-(1H tetrazol-5-ylmethylamino-3,4- H

14.32 (M+H)+ = 700 carbonyl)-phenyl difluorophenyl 3-(2-carboxyethylaminocarbonyl)-2,4- H

14.33 (M-H)-= 688 phenyl difluorophenyl 3-(1H tetrazol-S-ylmethylamino-2,4- H

14.34 (M+H)+ = 700 carbonyl)-phenyl difluorophenyl 14.35 3-[(E)-2-carboxyvinyl]-phenylphenyl H (M+H)+ = 609 14.36 3-(2-carboxyethyl)-phenylphenyl H (M+H)+ = 611 3-(N-carboxymethyl- H

14.37 phenyl (M+H)+ = 626 methylamino)-phenyl 14.38 4-(3-carboxypropyloxy)-phenylphenyl H (M+H)+ = 641 4-(3-carboxypropyloxy)-2-3-acetylamino-H

14.39 (M+H)+ = 728 methoxy-phenyl phenyl 4-(3-carboxypropyloxy)-2- H

14.40 2-methoxyphenyl (M+H)+ = 7p methoxy-phenyl 1 14.41 4-(3-carboxypropyloxy)-phenyl2-methoxyphenylH (M+H)+ = 671 14.42 3-(2-carboxyethyloxy)-phenyl3-acetylphenylH (M+H)+ = 669 14.43 3-(2-carboxyethyloxy)-phenyl2-methylphenylH (M+H)+ = 641 14.44 3-carboxymethyloxy-phenyl4-isopropylphenylH (M+H)+ = 655 14.45 3-(2-carboxyethyloxy)-phenyl4-isopropylphenylH (M+H)+ = 669 4-(2-carboxyethylaminocarbonyl)- H

14.46 4-isopropylphenyl (M+H)+ = 696 phenyl 3-(2-carboxyethylaminocarbonyl)- H

14.47 3-acetyphenyl (M+H)+ = 696 phenyl 3-(1H tetrazol-5-ylmethylamino- H

14.48 2-methylphenyl (M+H)+ = 678 c arbonyl)-phenyl 14.49 -(1H tetrazol-5-ylmethylamino-2-methylphenylH (M+H)+ = 692 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb R~ hysical data carbonylmethyl)-phenyl 3-(1H tetrazol-5-ylmethylamino- H

14.50 4-isopropylphenyl (M+H)+ = 720 carbonylmethyl)-phenyl 14.51 3-carboxymethyloxy-phenyl2-fluorophenylH (M+H)+ = 631 4-(3-carboxypropyloxy)-2- H

14.52 2-fluorophenyl (M+H)+ = 689 methoxy-phenyl 14.53 3-(2-carboxyethyloxy)-phenyl2-fluorophenylH (M+H)+ = 645 4-(3-carboxypropyloxy)-2- H

14.54 3-fluorophenyl (M+H)+ = 689 methoxy-phenyl 14.55 3-(2-carboxyethyloxy)-phenyl3-fluorophenylH (M+H)+ = 645 4-(3-carboxypropyloxy)-2- H

14.56 4-fluorophenyl (M+H)+ = 689 methoxy-phenyl 14.57 3-(2-carboxyethyloxy)-phenyl4-fluorophenylH (M+H)+ = 645 4-(3-carboxypropyloxy)-2-3,5- H

14.58 (M+H)+ = 707 methoxy-phenyl difluorophenyl 3,5- H

14.59 3-(2-carboxyethyloxy)-phenyl (M+H)+ = 663 difluorophenyl 4-(3-carboxypropyloxy)-2-3,4- H

14.60 (M+H)+ = 707 methoxy-phenyl difluorophenyl 3,4- H

14.61 3-(2-carboxyethyloxy)-phenyl (M+H)+ = 663 difluorophenyl 4-(3-carboxypropyloxy)-2- H

14.62 3-methylphenyl (M+H)+ = 685 methoxy-phenyl 14.63 3-(2-carboxyethyloxy)-phenyl3-methylphenylH (M+H)+ = 641 4-(2-carboxyethylaminocarbonyl)- H

14.64 4-fluorophenyl (M+H)+ = 672 phenyl 4-(2-carboxyethylaminocarbonyl)- H

14.65 3-methylphenyl (M+H)+ = 668 phenyl 3-(2-carboxyethylaminocarbonyl)- H

14.66 2-fluorophenyl (M+H)+ = 672 phenyl 14.67 3-(2-carboxyethylaminocarbonyl)-3-fluorophenylH (M+H)+ = 672 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb R~ hysical data phenyl 3-(2-carboxyethylaminocarbonyl)- H

14.68 4-fluorophenyl (M+H)+ = 672 phenyl 3-(2-carboxyethylaminocarbonyl)-3,5- H

14.69 (M+H)+ = 690 phenyl difluorophenyl 3-(2-carboxyethylaminocarbonyl)- H

14.70 3-methylphenyl (M+H)+ = 668 phenyl 4-(3-carboxypropyloxy)-2-chloro- H

14.71 2-fluorophenyl (M+H)+ = 695 phenyl 3-(1H tetrazol-5-ylmethylamino- H

14.72 4-fluorophenyl (M+H)+ = 682 carbonyl)-phenyl 3-(1H tetrazol-5-ylmethylamino-3,5- H

14.73 (M+H)+ = 700 carbonyl)-phenyl difluorophenyl 3-(1H tetrazol-5-ylmethylamino- H

14.74 3-methylphenyl (M+H)+ = 678 carbonyl)-phenyl 3-(1H tetrazol-5-ylmethylamino- H

14.75 2-fluorophenyl (M+H)+ = 696 carbonylmethyl)-phenyl 14.76 4-(3-carboxypropyloxy)-2- 4- m.p.145-159C

methoxy-phenyl H chloro-(M+H)+ = 707,705 phenyl 14.77 4-(1H tetrazol-5-ylmethylamino- H m.p. 165C

phenyl carbonylmethyl)-phenyl (M+H)+ = 678 14.78 3-(3-carboxypropyl)-phenylphenyl H (M+H)+ = 625 14.79 5-(3-carboxypropyloxy)-2- H (M-H)- = 669 phenyl methoxy-phenyl 14.80 3-(3-carboxypropyloxy)-2- H (M+H)+ = 671 phenyl methoxy-phenyl 14.81 3-(2-carboxyethyl- H (M+H)+ = 654 phenyl carbonylamino)-phenyl 14.82 4-(3-carboxypropyloxy)-2- H (M+H)+ = 713 4-isopropylphenyl methoxy-phenyl 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb R~ h sical data 14.83 4-(3-carboxypropyloxy)-2-3,4- H (M-H)- = 705 methoxy-phenyl difluorophenyl 14.84 4-(3-carboxypropyloxy)-2- H (M+H)+ = 685 3-methyl methoxy-phenyl 14.85 4-(3-carboxypropyloxy)-2-2,4- H (M+H)+ = 707 methoxy-phenyl difluorophenyl 14.86 4-(3-carboxypropyloxy)-2- H m.p.179C

4-fluorophenyl methoxy-phenyl (M+H)+ = 689 14.87 4-(3-carboxypropyloxy)-2- H m.p.182C

3-fluorophenyl methoxy-phenyl (M+H)+ = 689 14.88 3-(4-carboxypiperidino)-phenyl H m.p.166-178C

phenyl (M+H)+ = 666 14.89 3-(3-carboxypropyloxy)-phenyl H m.p.144-151C

phenyl (M+H)+ = 641 14.90 3-(4-carboxybut-1-inyl)-phenylphenyl H (M+H)+ = 635 14.91 3-(4-carboxypiperidino)-phenyl3-fluorophenylH (M+H)+ = 684 14.92 3-(4-carboxypiperidino)-phenyl3,5- H (M+H)+ = 702 difluorophenyl 14.93 3-(2-carboxy-2-hydroxyethyl- H (M+H)+ = 670 phenyl aminocarbonyl)-phenyl 14.94 4-(3-carboxypropyloxy)-2-3,5- H (M+H)+ = 707 methoxy-phenyl difluorophenyl 14.95 3-(2-carboxyethylcarbonylamino)- H (M+H)+ = 696 4-isopropylphenyl phenyl 14.96 3-(3-carboxypyrrolidin-1-yl)- H (M+H)+ = 670 3-fluorophenyl phenyl 1/1446-ff Boehringer Ingelheim International GmbH

Example 15 2-[4-(3-Carboxypropyloxy)-2-methoxy-phenyl)-1-dehydroabietyl-5-(2-methylphenyl)-benzimidazole onira~
Prepared analogously to Example 14b by catalytic reduction of N-dehydroabietyl-nitro-4-(2-methylphenyl)-aniline on Raney nickel in ethyl acetate and subsequent reaction with 4-(3-carboxypropyloxy)-2-methoxy-benzaldehyde in DMF.
Yield: 38 % of theory C45H52N2~4 (684.93) Mass spectrum: (M-H)- = 683 The compounds of Examples 15.1 to 15.151 listed in Tables VIa and VIb are prepared analogously to Example 15 using starting materials as described in Examples I
to XIX or obtainable by methods known from the literature:
Table VIa ExampleRa Rb physical data 3-(2-carboxyethylaminocarbonyl)-15.1 4-chlorophenyl (M+H)+ = 690, phenyl 3-(2-carboxyethylaminocarbonyl)-15.2 pyridin-4-yl (M+H)+ = 655 phenyl 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb physical data 4-(3-carboxypropyloxy)-2-methoxy-15.3 pyridin-3-yl (M+H)+ = 672 phenyl 4-(3-carboxypropyloxy)-2-methoxy-15.4 3-chlorophenyl (M+H)+ = 707, phenyl 4-(3-carboxypropyloxy)-2-methoxy-15.5 2-chlorophenyl (M-H)- = 705, phenyl 3-(1H tetrazol-5-ylmethylamino-15.6 tetrahydrofuran-3-yl(M+H)+ = 658 carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.7 tetrahydrofuran-3-yl(M+H)+ = 648 phenyl 4-(2-carboxyethylaminocarbonyl)-4-trifluoromethoxy-15.8 (M+H)+ = 738 phenyl phenyl 3-(1H tetrazol-5-ylmethylamino-15.9 methylsulphonylamino-(M+H)+ = 771 carbonylmethyl)-phenyl phenyl 4-(2-carboxyethylaminocarbonyl)-4-(4-chlorophenyl)-15.10 (M+H)+ = 766, phenyl phenyl 4-(2-carboxyethylaminocarbonyl)-15.11 3-chlorophenyl (M+H)+ = 690, phenyl 15.12 4-(3-carboxypropyloxy)-phenyl3-chlorophenyl (M+H)+ = 677, 3-(1H tetrazol-5-ylmethylamino-15.13 pyridin-4-yl (M+H)+ = 665 carbonyl)-phenyl 3-(1H tetrazol-5-ylmethylamino-15.14 4-chlorophenyl (M+H)+ = 700, carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.15 pyridin-2-yl (M+H)+ = 655 phenyl 4-(3-carboxypropyloxy)-2-methoxy-15.16 1H imidazol-2-yl (M-H)- = 659 phenyl 3-(2-carboxyethylaminocarbonyl)-15.17 pyridin-3-yl (M+H)+ = 655 phenyl 15.18 3-(1H tetrazol-5-ylmethylamino-pyridin-3-yl (M+H)+ = 665 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb physical data carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.19 3-chlorophenyl (M+H)+ = 690, phenyl 3-(1H tetrazol-5-ylmethylamino-15.20 3-chlorophenyl (M+H)+ = 700, carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.21 2-chlorophenyl (M+H)+ = 690, phenyl 3-(1H tetrazol-5-ylmethylamino-15.22 2-chlorophenyl (M+H)+ = 700, carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.23 4-methoxyphenyl (M+H)+ = 684 phenyl 3-(1H tetrazol-5-ylmethylamino-15.24 4-methoxyphenyl (M+H)+ = 694 carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-3-trifluoromethoxy-15.25 (M+H)+ = 738 phenyl phenyl 3-(1H tetrazol-5-ylmethylamino-3-trifluoromethoxy-15.26 (M-H)- = 746 carbonyl)-phenyl phenyl 3-(2-carboxyethylaminocarbonyl)-3-morpholinomethyl-15.27 (M+H)+ = 753 phenyl phenyl 3-(1H tetrazol-5-ylmethylamino-3-morpholinomethyl-15.28 (M+H)+ = 763 carbonyl)-phenyl phenyl 3-(2-carboxyethylaminocarbonyl)-15.29 methylsulphonylamino-(M+H)+ = 747 phenyl phenyl 3-(1H tetrazol-5-ylmethylamino-15.30 methylsulphonylamino-(M+H)+ = 757 carbonyl)-phenyl phenyl 3-(2-carboxyethylaminocarbonyl)-4-morpholinomethyl-15.31 (M+H)+ = 753 phenyl phenyl 3-( 1 H tetrazol-5-ylmethylamino-4-morpholinomethyl-15.32 (M+H)+ = 763 carbonyl)-phenyl phenyl 1/1446-ff Boehringer Ingelheim International GmbH
_77_ ExampleRa Rb physical data 3-(2-carboxyethylaminocarbonyl)-2-morpholinomethyl-15.33 (M+H)+ = 753 phenyl phenyl 3-(1H tetrazol-5-ylmethylamino-2-morpholinomethyl-15.34 (M+H)+ = 763 carbonyl)-phenyl phenyl 3-(2-carboxyethylaminocarbonyl)-15.35 thiophen-2-yl (M+H)+ = 660 phenyl 3-(1H tetrazol-5-ylmethylamino-15.36 thiophen-2-yl (M+H)+ = 670 carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.37 4-aminocarbonyl-phenyl(M+H)+ = 697 phenyl 3-(1H tetrazol-5-ylmethylamino-15.38 4-aminocarbonyl-phenyl(M+H)+ = 707 carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.39 thiazol-2-yl (M+H)+ = 661 phenyl 3-( 1 H tetrazol-5-ylmethylamino-15.40 thiazol-2-yl (M+H)+ = 671 carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.41 pyrazin-2-yl (M-H)' = 654 phenyl 3-(1H tetrazol-5-ylmethylamino-15.42 pyrazin-2-yl (M-H)' = 664 carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.43 pyrimidin-2-yl (M+H)+ = 656 phenyl 3-(1H tetrazol-5-ylmethylamino-15.44 pyrimidin-2-yl (M+H)+ = 666 carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.45 5-chlorothiophen-2-yl(M+H)+ = 696, phenyl 3-(1H tetrazol-5-ylmethylamino-15.46 5-chlorothiophen-2-yl(M+H)+ = 706, carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.47 isopropyl (M+H)+ = 620 phenyl 15.48 3-(1H tetrazol-5-ylmethylamino-isopropyl (M-H)' = 628 1/1446-ff Boehringer Ingelheim International GmbH
_78_ ExampleRa Rb physical data carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.49 tert-butyl (M+H)+ = 634 phenyl 3-(1H tetrazol-5-ylmethylamino-15.50 tert-butyl (M+H)+ = 644 carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.51 cyclohexyl (M+H)+ = 660 phenyl 3-(1H tetrazol-5-ylmethylamino-15.52 cyclohexyl (M-H)- = 668 carbonyl)-phenyl 3-(2-carboxyethylaminocarbonyl)-15.53 5-methylthiophen-2-yl(M-H)- = 672 phenyl 3-(1H tetrazol-5-ylmethylamino-15.54 5-methylthiophen-2-yl(M-H)- = 682 carbonyl)-phenyl 15.55 3-(2-carboxyethyloxy)-phenyl4-chlorophenyl (M+H)+ = 661 15.56 3-(2-carboxyethyloxy)-phenylpyridin-3-yl (M+H)+ = 628 15.57 3-carboxymethyloxy-phenyl 3-chlorophenyl (M+H)+ = 647 15.58 3-(2-carboxyethyloxy)-phenyl3-chlorophenyl (M+H)+ = 661 15.59 3-(2-carboxyethyloxy)-phenyl2-chlorophenyl (M+H)+ = 661 15.60 3-carboxymethyloxy-phenyl 1H imidazol-2-yl (M+H)+ = 603 15.61 3-(2-carboxyethyloxy)-phenyl1H imidazol-2-yl (M+H)+ = 617 15.62 3-carboxymethyloxy-phenyl pyridin-4-yl (M+H)+ = 614 15.63 3-(2-carboxyethyloxy)-phenylpyridin-4-yl (M+H)+ = 628 15.64 3-(2-carboxyethyloxy)-phenylpyridin-2-yl (M+H)+ = 628 4-(3-carboxypropyloxy)-2,6-15.65 2-chlorophenyl (M+H) = 735 dimethoxy-phenyl 3-(2-carboxyethylaminocarbonyl)-15.66 1H imidazol-2-yl (M+H)+= 644 phenyl 3-(1H tetrazol-5-ylmethylamino-15.67 1H imidazol-2-yl (M+H)+ = 654 carbonyl)-phenyl 3-(1H tetrazol-5-ylmethylamino-15.68 pyridin-2-yl (M+H) = 665 carbonyl)-phenyl 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb physical data 4 -(1H tetrazol-5-ylmethylamino-15.69 4 -chlorophenyl (M+H) = 728 c arbonylmethyloxy)-phenyl 3 -(1H tetrazol-5-ylmethylamino-15.70 4 -chlorophenyl (M+H) = 712 c arbonylmethyl)-phenyl 3 -(1H tetrazol-5-ylmethylamino-15.71 p yridin-3-yl (M+H) = 679 c arbonylmethyl)-phenyl 3 -(1H tetrazol-5-ylmethylamino-15.72 3 -chlorophenyl (M+H) = 712 c arbonylmethyl)-phenyl 15.73 3-(2-carboxyethyloxy)-phenyl-methoxyphenyl (M+H)+ = 657 15.74 3-carboxymethyloxy-phenylmethylsulphonylamino-(M+H)+ = 706 phenyl 15.75 3-(2-carboxyethyloxy)-phenylmethylsulphonylamino-(M+H)+ = 720 phenyl 4-(3-carboxypropyloxy)-2-methoxy-15.76 3-methoxyphenyl (M+H) = 701 phenyl 15.77 3-(2-carboxyethyloxy)-phenyl3-methoxyphenyl (M+H)+ = 657 4-(3-carboxypropyloxy)-2-methoxy-15.78 4-methoxyphenyl (M+H) = 701 phenyl 15.79 3-(2-carboxyethyloxy)-phenyl4-methoxyphenyl (M+H)+ = 657 3-trifluoromethoxy-15.80 3-carboxymethyloxy-phenyl (M+H) = 697 phenyl 4-(3-carboxypropyloxy)-2-methoxy-3-trifluoromethoxy-8 (M+H) = 755 15.

phenyl phenyl 3-trifluoromethoxy-15.82 3-(2-carboxyethyloxy)-phenyl (M+H) = 711 phenyl 3-(N-carboxymethyl-methylamino)-15.83 4-methoxyphenyl (M+H)+ = 656 phenyl 4-(2-carboxyethylaminocarbonyl)-3-trifluoromethoxy-(M+H
= 738 15.84 ) phenyl phenyl I/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb physical data 3-(2-carboxyethylaminocarbonyl)-15.85 2 -methoxyphenyl (M+H)+ = 684 phenyl 3-(2-carboxyethylaminocarbonyl)-l (M+H)+ = 747 i l h th l 15.86 ony no-y su p am me phenyl p henyl 3-(2-carboxyethylaminocarbonyl)-15.87 3-methoxyphenyl (M+H)+ = 684 phenyl 3-(1H tetrazol-5-ylmethylamino-15.88 2-methoxyphenyl (M+H) = 694 carbonyl)-phenyl 3-(1H tetrazol-5-ylmethylamino-15.89 methylsulphonylamino-(M+H) = 757 carbonyl)-phenyl phenyl 3-(1H tetrazol-5-ylmethylamino-15.90 3-methoxyphenyl (M+H) = 694 carbonyl)-phenyl 4-trifluoromethoxy-15.91 3-carboxymethyloxy-phenyl (M+H) = 697 phenyl 4-(3-carboxypropyloxy)-2-methoxy-4-trifluoromethoxy-(M+H) = 755 15.92 phenyl phenyl 4-trifluoromethoxy-15.93 3-(2-carboxyethyloxy)-phenyl (M+H) = 711 phenyl 2-trifluoromethoxy-15.94 3-(2-carboxyethyloxy)-phenyl (M+H) = 711 phenyl 4-(3-carboxypropyloxy)-2-methoxy-9 l (M+H)+ = 764 l i th l h 15. p ony no-me y su am phenyl phenyl 15.96 3-(2-carboxyethyloxy)-phenylmethylsulphonylamino-(M+H)+ = 720 phenyl 15.97 3-carboxymethyloxy-phenyl 2,4-difluorophenyl(M+H)+ = 649 4-(3-carboxypropyloxy)-2-methoxy-98 l (M+H) = 707 h difl . -1 uorop eny , phenyl 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb physical data 15.99 3-(2-carboxyethyloxy)-phenyl2-acetyphenyl (M+H)+ = 669 15.100 3-carboxymethyloxy-phenylmethylsulphonylamino-(M+H)+ = 706 phenyl 4-(3-carboxypropyloxy)-2-methoxy-15.1 methylsulphonylamino-(M+H)+ = 764 phenyl phenyl 15.102 3-(2-carboxyethyloxy)-phenylmethylsulphonylamino-(M+H)+ = 720 phenyl 3-(N-carboxymethyl-methylamino)-15.103 methylsulphonylamino-(M+H)+ = 719 phenyl phenyl 3-(N-carboxymethyl-methylamino)-15.104 methylsulphonylamino-(M+H)+ = 719 phenyl phenyl 4-(3-carboxypropyloxy)-2,6-15.1 methylsulphonylamino-(M+H)+ = 794 OS

dimethoxy-phenyl phenyl 3-(2-carboxyethylaminocarbonyl)-4-trifluoromethoxy-15.106 (M+H)+ = 73 phenyl phenyl 3-(2-carboxyethylaminocarbonyl)-2-trifluoromethoxy-15.107 (M+H)+ = 73 phenyl phenyl 3-(2-carboxyethylaminocarbonyl)-15.108 methylsulphonylamino-(M+H)+ = 747 phenyl phenyl 3-(2-carboxyethylaminocarbonyl)-15.109 2-acetyphenyl (M+H)+ = 696 phenyl 3-(1H tetrazol-5-ylmethylamino-4-trifluoromethoxy-15.110 (M+H)+ = 748 carbonyl)-phenyl phenyl 15.111 4-(3-carboxypropyloxy)-2-chloro-4-trifluoromethoxy-(M+H)+ = 759 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb physical data phenyl phenyl 3-(1H tetrazol-5-ylmethylamino-2-trifluoromethoxy-15.112 (M+H)+ = 748 carbonyl)-phenyl phenyl 3-(1H tetrazol-5-ylmethylamino-15.113 methylsulphonylamino-(M+H)+ = 757 carbonyl)-phenyl phenyl 3-( 1 H tetrazol-5-ylmethylamino-15.114 2-acetyphenyl (M+H)+ = 706 carbonyl)-phenyl 3-(1H tetrazol-5-ylmethylamino-15.115 methylsulphonylamino-(M+H)+ = 771 carbonylmethyl)-phenyl phenyl 15.1163-carboxymethyloxy-phenyl methoxycarbonyl (M+H)+ = 595 15.1173-carboxymethyloxy-phenyl methyl (M+H)+ = 551 4-(3-carboxypropyloxy)-2-methoxy- m.p. 256-262 C

15.118 4-acetylphenyl phenyl (M+H)+ = 699 4-(3-carboxypropyloxy)-2-methoxy-15.119 thiophen-2-yl (M-H)- = 675 phenyl 4-(3-carboxypropyloxy)-2-methoxy-15.120 4-chlorophenyl (M+H)+ = 707, phenyl 15.1213-carboxymethyloxy-phenyl H (M+H)+ = 537 15.1223-carboxymethyloxy-phenyl methylaminocarbonyl(M+H)+ = 594 3-(1H tetrazol-5-ylmethylamino-15.123 4-methoxyphenyl (M+H)+ = 708 carbonylmethyl)-phenyl 4-(3-carboxypropyloxy)-2-methoxy- m.p. 110-120C

15.124 2-phenylethyl phenyl (M+H)+ = 699 m.p. 165-190C
15.1253-(3-carboxypyrrolidin-1-yl)-phenylphenyl (M+H)+ = 652 4-(3-carboxypropyloxy)-2-methoxy-15.126 cyclopentyl (M+H)+ = 663 phenyl 4-(3-carboxypropyloxy)-2-methoxy-15.127 2-methylpropyl (M+H)+ = 651 phenyl 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb . physical data 4-(3-carboxypropyloxy)-2-methoxy-3-15.128 (M+H)+ = 755 phenyl trifluoromethoxyphenyl 4-(3-carboxypropyloxy)-2-methoxy-4-15.129 (M+H)+ = 755 phenyl trifluoromethoxyphenyl 4-(3-carboxypropyloxy)-2-methoxy-2-15.130 (M+H)+ = 755 phenyl trifluoromethoxyphenyl 4-(3-carboxypropyloxy)-2-methoxy-15.131 methylsulphonylamino-(M+H)+ = 764 phenyl phenyl 4-(3-carboxypropyloxy)-2-methoxy-15.132 methylsulphonylamino-(M+H)+ = 764 phenyl phenyl 4-(3-carboxypropyloxy)-2-methoxy-15.133 butyl (M+H)+ = 651 phenyl 4-(3-carboxypropyloxy)-2-methoxy-15.134 cyclohexyl (M+H)+ = 677 phenyl 4-(3-carboxypropyloxy)-2-methoxy-15.135 2-methoxyphenyl (M+H)+ = 701 phenyl 3-(3-carboxypropyloxy)-2-methoxy-15.136 3,5-difluorophenyl(M+H) = 707 phenyl 15.137 3-(4-carboxypiperidino)-phenyl4-chlorophenyl (M+H)+ = 702, 15.138 3-(4-carboxypiperidino)-phenyl2-chlorophenyl (M+H)+= 702, 3-(3-carboxypropyloxy)-2-methoxy-15.139 4-chlorophenyl (M+H)+ = 707, phenyl 3-(3-carboxypropyloxy)-2-methoxy-15.140 methylsulphonylamino-(M+H)+ = 764 phenyl phenyl 15.141 3-(4-carboxypiperidino)-phenyl (M+H)+ = 750 trifluoromethoxyphenyl 3-(2-carboxyethylcarbonylamino)-4-15.142 (M+H)+ = 738 phenyl trifluoromethoxyphenyl 1/1446-ff Boehringer Ingelheim International GmbH

ExampleRa Rb physical data 3-(2-carboxyethylcarbonylamino)-15.143 4-Clorphenyl (M+H)+ = 690, phenyl 3-(2-carboxyethylcarbonylamino)-15.144 methylsulphonylamino-(M+H)+ = 747 phenyl phenyl 15.145 3-(3-carboxypyrrolidin-1-yl)-phenyl4-isopropylphenyl (M+H)+=694 15.146 3-(3-carboxypyrrolidin-1-yl)-phenyl (M+H)+= 736 trifluoromethoxyphenyl 3-(3-carboxypropyloxy)-2-methoxy-3-15.147 (M+H)+ = 755 phenyl trifluoromethoxyphenyl 15.148 3-(3-carboxypyrrolidin-1-yl)-phenyl4-chlorophenyl (M+H)+=688, 15.149 3-(4-carboxypiperidino)-phenylmethylsulphonylamino-(M+H)+ = 759 phenyl Table VIb ExampleRa Rb physical data 15.150 4-(3-carboxypropyloxy)-2-methoxy-phenylmethyl (M+H)+ = 609 15.151 4-(3-carboxypropyloxy)-2-methoxy-phenylphenyl (M+H)+ = 671 1J1446-ff Boehringer Ingelheim International GmbH

Example 16 2-[3-(2-Carboxypropylaminocarbonyl)-phenyl]-1-dehydroabietyl-5-phenyl-benzimidazole cn~rai 6.6 ml 1 N sodium hydroxide solution are added to a solution of 0.3 g (0.43 mmol) 2-[3-(2-ethoxycarbonyl-propylaminocarbonyl)-phenyl]-1-dehydroabietyl-5-phenyl-benzimidazole (prepared analogously to Example 15) in 6.6 ml of ethanol. The mixture is stirred for 15 hours at ambient temperature. The solution is evaporated down and combined with 6.6 ml 1 N hydrochloric acid. The precipitate is suction filtered and washed with water.
Yield: 0.18 g (63 % of theory) C~H49N3O3 (667.90) Mass spectrum: (M+H)+ = 668 The following compound was prepared analogously to Example 16:
Example 16.1 3-[(2-Carboxy-2-fluorethylaminocarbonyl)-phenyl]-1-dehydroabietyl-5-phenyl-benzimidazole C43H46FN3~3 (671.86) Mass spectrum: (M+H)+ = 672 ~ 1/1446-ff Boehringer Ingelheim International GmbH

Example 17 2-(3-Carboxymethyloxy-4-nitrophenyl)-1-dehydroabietyl-5-phenyl-benzimidazole-hydrotrifluoroacetate Chira~
a. 2-(3-tert-butoxycarbon l~yloxy-4-nitrophenyl)-1-dehydroabietyl-Sphenyl-benzimidazole 0.16 g (1.17 mmol) potassium carbonate are added to a solution of 0.7 g (1.17 mmol) 2-(3-hydroxy-4-nitrophenyl)-1-dehydroabietyl-5-phenyl-benzimidazole (prepared analogously to Example 15) in 20 ml DMF. The mixture is stirred for 30 minutes at ambient temperature and then 0.17 ml ( 1.17 mmol) tert-butyl chloroacetate are added dropwise. After 3.5 hours another 0.5 ml (3.4 mmol) tert-butyl chloroacetate are added. After 3 days' stirring at ambient temperature the reaction solution is evaporated down, combined with 100 ml of water and extracted with ethyl acetate. The combined organic phases are washed with saturated saline solution, dried over sodium sulphate and concentrated by evaporation.
Yield: 140 mg (196 mmol, 17 % of theory) CasHsiNs~s (713.92) Mass spectrum: (M+H)+ = 714 b. 2-(3-carboxymethyloxy-4-nitropheny,-1-dehydroabietyl-5-phenyl-benzimidazole-hydrotrifluoroacetate Prepared analogously to Example 3e by reacting 2-(3-tent-butoxycarbonylmethyloxy-4-nitrophenyl)-1-dehydroabietyl-5-phenyl-benzimidazole with trifluoroacetic acid in dichloromethane.
Yield: 93 % of theory C41Ha3N3~5 x CzHF3O2 (771.84) Mass spectrum: (M+H)+ = 658 The following compound was prepared analogously to Example 17:

1/1446-ff Boehringer Ingelheim International GmbH
_87_ Example 17.1 2-(5-Carboxymethyloxy-2-methoxy-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole-hydrotrifluoroacetate C42H46N2~4 (642.85) Mass spectrum: (M+H)+ = 643 Example 18 2-(3-Carboxymethylamino-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole Chiral a. 2-(3-ethyloxycarbonylmethylamino-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole 0.16 g (0.29 mmol) 2-(3-aminophenyl)-1-dehydroabietyl-5-phenyl-benzimidazole (prepared analogously to Example 14) are dissolved in 2.5 ml DMF and at ambient temperature combined with 54 ~.1 (0.32 mmol) N-ethyl-diisopropylamine. After minutes 35 ~.l (0.32 mmol) ethyl bromoacetate are added. The mixture is stirred for 15 hours at ambient temperature and then for 5 hours at SO°C. Then 20 ml of water are added. It is extracted with ethyl acetate, the combined organic phases are washed with saturated saline solution, dried over sodium sulphate and evaporated to dryness. The residue is chromatographed on silica gel (ethyl acetate/petroleum ether =
2:3).
Yield: 80 mg (43 % of theory) C43H49N30z (639.89) Mass spectrum: (M+H)+ = 640 ~

' 1/1446-ff Boehringer Ingelheim International GmbH
_88_ b. 2-(3-carboxymethylamino-phenyl)-1-deh~droabietyl-S-phenyl-benzimidazole Prepared analogously to Example 17 by saponifying 2-(3-ethyloxycarbonylmethylamino-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole with lithium hydroxide in methanol/THF (1:3).
Yield: 27 % of theory melting point: 180°C
C41H4sN302 (611.84) Mass spectrum: (M-H)-= 610 The following compound was prepared analogously to Example 18:
Example 18.1 2-(2-Carboxyethylaminophenyl)-1-dehydroabietyl-5-phenyl-benzimidazole-hydrotrifluoroacetate C42H47N302 (625.86) Mass spectrum: (M+H)+ = 626 Example 19 2-(2-Amino-5-carboxymethyloxy-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole on~r~i 1/1446-ff Boehringer Ingelheim International GmbH

a. 2-(5-tert-butoxycarbonylmethyloxy-2-nitrophenyl)-1-dehydroabietyl-5-phenyl-benzimidazole Prepared analogously to Example 17a by reacting 2-(5-hydroxy-2-nitrophenyl)-1-dehydroabietyl-5-phenyl-benzimidazole with tert.butyl chloroacetate in DMF.
Yield: 80 % of theory C45HS1N3~5 (713.92) Mass spectrum: (M+H)+ = 714 b. 2-(2-amino-5-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-5 phenyl-benzimidazole Prepared analogously to Example 6 by catalytic hydrogenation of 2-(S-tert-butoxycarbonylmethyloxy-2-nitrophenyl)-1-dehydroabietyl-S-phenyl-benzimidazole on Raney nickel.
Yield: 52 % of theory C45H53N3~3 (683.94) Mass spectrum: (M+H)+ = 684 c. 2-(2-amino-5-carbox~yloxy-phenyl)-1-dehydroabietyl-5-phe~l-benzimidazole 125 mg (0.18 mmol) 2-(2-amino-5-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole are dissolved in 10 ml acetonitrile and combined successively with 110 mg (0.73 mmol) sodium iodide and 80 mg (0.73 mmol) trimethylsilane. The mixture is stirred for 5 hours at 40°C. Then the solvent is eliminated in vacuo. The residue is stirred twice with petroleum ether, suction filtered and in vacuo dried.
Yield: 100 mg (0.16 mol, 87 % of theory) melting point: >295°C (decomp.) C41H45N3~3 (627.83) Mass spectrum: (M+H)+ = 628 1/1446-ff Boehringer Ingelheim International GmbH

Example 20 2-(2-Acetylamino-5-carboxymethyloxy-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole a. 2-(2-acetylamino-5-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole 350 mg (0.51 mmol) 2-(2-acetylamino-5-carboxymethyloxy-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole (Example 19b) are dissolved in 10 ml dichloromethane and combined with 0.17 ml (0.95 mmol) N-ethyl-diisopropylamine and 57 ~l (0.6 mmol) acetic anhydride. The mixture is stirred for 3 hours at ambient temperature. Then saturated sodium hydrogen carbonate solution is added and the mixture is stirred for 15 minutes at ambient temperature . Then the reaction solution is extracted with dichloromethane. The combined organic phases are dried over sodium sulphate and evaporated to dryness. The residue is chromatographed on silica gel (ethyl acetate/petroleum ether = 1:1 ).
Yield: 150 mg (0.2 mmol, 40 % of theory) Ca~HssNsOa (725.98) Mass spectrum: (M+H)+ = 726 b. 2-(2-acetylamino-5-carbox~ylox~phenyl)-1-deh~droabietyl-5-phen~
benzimidazole Prepared analogously to Example 3e by reacting 2-(2-acetylamino-5-tert-butoxycarbonylmethyloxy-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole with trifluoroacetic acid in dichloromethane.
Yield: 87 % of theory melting point: 179°C
C43H47N304 (669.87) Mass spectrum: (M+H)+ = 670 1/1446-ff Boehringer Ingelheim International GmbH

Example 21 2-(5-Carboxymethyloxy-2-trifluoracetylamino-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole Chiro~
Prepared analogously to Example 20c by reacting 2-(5-tert-butoxycarbonylmethyloxy-2-trifluoracetylamino-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole with trifluoroacetic acid in dichloromethane.
Yield: 99 % of theory melting point: 168-172°C
C43H44F3N3~4 (723.84) Mass spectrum: (M+H)+ = 724 Example 22 2-(3-Carboxymethylcarbonylamino-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole on~r~i a. 2-(3-ethyloxycarbonylmethylcarbonylamino~henyl)-1-del~droabietyl-5-phenyl-benzimidazole Prepared analogously to Example la by reacting 2-(3-aminophenyl)-1-dehydroabietyl-5-phenyl-benzimidazole (prepared analogously to Example 14) with ethyl malonate chloride and triethylamine in dichloromethane.
Yield: 83 % of theory C44H49N303 (667.90) 1/1446-ff Boehringer Ingelheim International GmbH

Mass spectrum: (M+H)+ = 668 b. 2-(3-carboxymethylcarbonylamino-phenyl)-1-dehydroabiet~phenyl-benzimidazole Prepared analogously to Example 16 by saponifying 2-(3-ethyloxycarbonylmethylcarbonylamino-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole with sodium hydroxide solution in THF.
Yield: (86 % of theory) melting point: 210-215°C
C42H45N3~3 (639.85) Mass spectrum: (M+H)+ = 640 Example 23 2-[3-(1H tetrazol-5-ylmethylcarbonylamino)-phenyl]-1-dehydroabietyl-5-phenyl-benzimidazole cn~~ei 0.16 g (0.29 mmol) 2-(3-aminophenyl)-1-dehydroabietyl-5-phenyl-benzimidazole (prepared analogously to Example 14), 37 mg (0.29 mmol) 1H tetrazol-5-ylacetic acid and 0.19 ml (1.73 mmol) N-methylmorpholine are dissolved in 20 ml dichloromethane and at -10°C combined with 0.34 ml (0.58 mmol) propanephosphonic acid cycloanhydride solution (50 wt.% in ethyl acetate). The reaction solution is left to warm up to ambient temperature and stirred for 15 hours.
Then the solvent is eliminated in vacuo and the residue is taken up in ethyl acetate. It is washed with saturated sodium hydrogen carbonate solution, 1 N hydrochloric acid and saturated saline solution. Then it is evaporated to dryness. The residue is stirred with ether, suction filtered and dried in vacuo.
Yield: 0.11 g (57 % of theory) melting point: 200°C

1/1446-ff Boehringer Ingelheim International GmbH

Ca2H4sN70 (663.87) Mass spectrum: (M+H)+ = 664 Example 24 2-[4-(3-Methylaminocarbonyl-propyloxy)-2-methoxy-phenyl]-1-dehydroabietyl-5-phenyl-benzimidazole cn~m 0.3 g (0.45 mmol) 2-[4-(3-carboxypropyloxy)-2-methoxy-phenyl]-1-dehydroabietyl-5-phenyl-benzimidazole (Example 14.2) are dissolved in 10 ml DMF and combined with 0.18 g (0.55 mmol) TBTU, 0.22 ml (1.6 mmol) triethylamine and 30 mg (0.45 mmol) methylamine-hydrochloride. The mixture is stirred for 15 hours at ambient temperature. Then ethyl acetate is added and the mixture is washed with sodium hydroxide solution and saturated saline solution. The organic phase is dried over sodium sulphate and concentrated by evaporation. The residue is chromatographed on silica gel (dichloromethane/methanol = 90:10 -> 84:16).
Yield: 0.18 g (0.3 mmol, 58 % of theory) C4sH53N3~3 (683.94) Mass spectrum: (M+H)+ = 684 Example 25 2-(3-Aminocarbonylmethyloxy-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole cn~~ei Prepared analogously to Example 24 by reacting 2-(3-carboxymethyloxy-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole (Example 14.1) with 0.5 M ammonia solution in dioxane and TBTU in THF.

1/1446-ff Boehringer Ingelheim International GmbH

Yield: 31 % of theory C41H45N3~2 (611.84) Mass spectrum: (M+H)+ = 612 Example 26 2-[4-(3-Carboxypropyloxy)-2-methoxy-phenyl]-1-dehydroabietyl-6-fluoro-5-phenyl-benzimidazole Chiral a. 5-bromo-2-dehydroabietylamino-4-fluoroaniline Prepared analogously to Example lb by reacting 1-bromo-2,4-difluoro-5-nitrobenzene [prepared according to J.Amer.Chem.Soc. 78 (1956) 2593-2596] with dihydroabietylamine and potassium carbonate in DMF and subsequent catalytic hydrogenation on Raney nickel in ethyl acetate.
Yield: 64 % of theory C26H34BrFN2 (473.48) Mass spectrum: (M+H)+ = 475, 473 b. 5-bromo-1-dehydroabietyl-2-[4~3-ethoxycarbonyl~ropyloxy)-2-methoxy-phenYll-6-fluoro-benzimidazole Prepared analogously to Example 1 c from 5-bromo-2-dehydroabietylamino-4-fluoroaniline and 4-(3-ethoxycarbonylpropyloxy)-2-methoxy-benzaldehyde in DMF.
Yield: 64 % of theory CaoHaaBrFN204 (719.74) Mass spectrum: (M+H)+ = 721, 719 c. 2-f4-(3-ethoxycarboxypropyloxy)-2-methoxy~henyll-1-dehydroabietyl-6-fluoro-5-phenyl-benzimidazole Prepared analogously to Example 3d by reacting 5-bromo-1-dehydroabietyl-2-[4-(3-ethoxycarbonylpropyloxy)-2-methoxy-phenyl]-6-fluoro-benzimidazole with 1/1446-ff Boehringer Ingelheim International GmbH

benzeneboric acid, tetrakis-(triphenylphosphine)-palladium(0) and potassium carbonate in water/dioxane.
Yield: 17 % of theory C46Hs3FNz~4 (716.95) Mass spectrum: (M+H)+ = 717 d. 2-f 4-(3-carboxypropyloxy)-2-methoxy-phenyl -1-dehydroabietyl-6-fluoro-5-phenyl-benzimidazole Prepared analogously to Example 16 by saponifying 2-[4-(3-ethoxycarboxypropyloxy)-2-methoxy-phenyl]-1-dehydroabietyl-6-fluoro-5-phenyl-benzimidazole with sodium hydroxide solution in THF/methanol (5:2).
Yield: 94 % of theory C~H49FN20a (688.89) Mass spectrum: (M+H)+ = 689 Example 27 2-[4-(3-Carboxypropyloxy)-2-methoxy-phenyl)-1-dehydroabietyl-6-methoxy-5-phenyl-benzimidazole chira~
a. 1-bromo-2-dehydroabietylamino-2-methoxy-5-nitrobenzene 0.45 g (2.5 mmol) sodium methoxide solution (30 wt.% in methanol) are added dropwise within 5 minutes to a solution of 1.2 g (2.4 mmol) 1-bromo-2-dehydroabietylamino-2-fluoro-5-nitrobenzene (prepared analogously to Example 26a) in 30 ml of methanol. The mixture is stirred for 18 hours at ambient temperature and a further 0.45 g (2.5 mmol) sodium methoxide solution (30 wt.% in methanol) are added and the mixture is refluxed for 2.5 hours. Then the reaction solution is diluted with 600 ml of methanol at reflux temperature and heated for another 1.5 hours. The reaction solution is allowed to cool to ambient temperature, the solvent is eliminated 1/1446-ff Boehringer Ingelheim International GmbH

in vacuo and the residue is triturated several times with water and sharply removed by suction filtering.
Yield: 1.22 g (98% of theory) C27H3sBrN2O3 (S 15.50) Mass spectrum: (M+H)+ = 517, 515 b. 5-bromo-1-dehydroabietyl-2-j4-(3-ethoxycarbonylpropyloxy~-2-methoxy-phen~ll-6-methoxy-benzimidazole Prepared analogously to Example 12a and 12b by catalytic hydrogenation of 1-bromo-2-dehydroabietylamino-2-methoxy-5-nitrobenzene on Raney nickel in methanol and subsequent reaction with 4-(3-ethoxycarbonylpropyloxy)-2-methoxy-benzaldehyde in DMF.
Yield: 28 % of theory) C4iHsiBrN20s (731.78) Mass spectrum: (M+H)+ = 733, 731 c. 2-f4-(3-ethoxycarbonylpropyloxy)-2-methoxy-phen~ll-1-dehydroabietyl-6-methoxy-5-phenyl-benzimidazole Prepared analogously to Example 26c by reacting 5-bromo-1-dehydroabietyl-2-[4-(3-ethoxycarbonylpropyloxy)-2-methoxy-phenyl]-6-methoxy-benzimidazole with benzeneboric acid, tetrakis-(triphenylphosphine)-palladium(0) and potassium carbonate in water/dioxane.
Yield: 51 % of theory Ca7Hs6Nz~s (728.98) Mass spectrum: (M+H)+ = 729 d. 2-f4-(3-carboxypropyloxy)-2-methoxy_phenyll-1-dehydroabietyl-6-methoxy-5-phenyl-benzimidazole Prepared analogously to Example 26d by saponifying 2-[4-(3-ethoxycarbonylpropyloxy)-2-methoxy-phenyl]-1-dehydroabietyl-6-methoxy-5-phenyl-benzimidazole with sodium hydroxide solution in THF/methanol (2:1).
Yield: 95 % of theory CasHszN2~s (700.93) 1/1446-ff Boehringer Ingelheim International GmbH

Mass spectrum: (M+H)+ = 701 Example 28 2-(4-(3-Carboxypropyloxy)-2-methoxy-phenyl]-1-dehydroabietyl-5-(traps-2-phenylethenyl)-benzimidazole Chirel 181 mg (0.36 mmol) 3-dihydroabietylamino-3-nitrostilbene (Example IV.15) and 6.6 mg (0.017 mmol) 1,1-diethyl-4,4'-bipyridinium dibromide are dissolved in 2.5 ml dichloromethane and 0.3 ml of water and combined with a solution of 279 mg (1.6 mmol) sodium dithionite and 246 mg (1.8 mmol) potassium carbonate in 1.3 ml of water with vigorous stirring under a nitrogen atmosphere. The reaction mixture is stirred vigorously for 15 hours at 30°C. Then dichloromethane and water are added and the mixture is extracted with dichloromethane. The combined organic phases are dried over magnesium sulphate. The solvent is eliminated in vacuo. The crude product thus obtained is reacted analogously to Example 1 c with 4-(3-carboxypropyloxy)-2-methoxybenzaldehyde in DMF.
Yield: 99 mg (39% of theory) melting point: 59-72°C
C46Hs2Nz~4 (696.94) Mass spectrum: (M+H)+ = 697 The following compounds are obtained analogously to Example 28 using the starting materials described in Examples I to XIX:
Exam lp a 28.1 2-[4-(3-Carboxypropyloxy)-2-methoxy-phenyl]-1-dehydroabietyl-5-(furan-3-yl)-benzimidazole 1/1446-ff Boehringer Ingelheim International GmbH

Chinl C42H48N2~5 (660.86) Mass spectrum: (M+H)+ = 661 Rf value: 0.62 (silica gel, dichloromethane/methanol = 9:1 ) Example 28.2 2-[4-(3-Carboxypropyloxy)-2-methoxy-phenyl]-1-dehydroabietyl-5-(5-chlorothiophen-2-yl)-benzimidazole Chkel C42H47C1N2O4S (711.37) Mass spectrum: (M+H)+ = 713, 711 Rf value: 0.68 (silica gel, dichloromethane/methanol = 9:1) Example 29 2-[4-(3-Carboxypropyloxy)-2-ethoxy-phenyl]-1-dehydroabietyl-5-phenyl-benzimidazole ~hne~
a. 2-f 4-(3-ethoxycarbonylpropyloxy)-2-ethoxy~henxll-1-dehydroabietyl-5-phenyl-benzimidazole 150 mg (0.22 mmol) 2-[4-(3-ethoxycarbonyl-propyloxy)-2-hydroxy-phenyl]-1-dehydroabietyl-5-phenyl-benzimidazole (prepared analogously to Example 4) are dissolved in 2 ml DMF and combined with 21 ~1 (0.26 mmol)) ethyl iodide and 72 mg (0.52 mmol) potassium carbonate. The mixture is stirred for 15 hours at ambient 1/1446-ff Boehringer Ingelheim International GmbH

temperature. Then the solvent is eliminated in vacuo and the residue is taken up in dichloromethane/water. It is extracted with dichloromethane. The combined organic extracts are dried over magnesium sulphate. Then the residue is evaporated to dryness.
Yield: 70 mg (45% of theory) C47H56N204 (712.98) Mass spectrum: (M+H)+ = 713 b. 2-f4-(3-carboxypropyloxy)-2-ethoxy-phenyl-1-dehydroabiet~phenyl-benzimidazole Prepared analogously to Example 16 by saponifying 2-[4-(3-ethoxycarbonylpropyloxy)-2-ethoxy-phenyl]-1-dehydroabietyl-5-phenyl-benzimidazole with lithium hydroxide in THF/ethanol/water (8:8:1 ).
C45H52N2~4 (684.93) Mass spectrum: (M+H)+ = 685 Example 30 2-[4-(3-Carboxypropylamino)-2-methoxy-phenyl]-1-dehydroabietyl-5-phenyl-benzimidazole 270 mg (0.46 mmol) 2-(4-amino-2-methoxy-phenyl)-1-dehydroabietyl-5-phenyl-benzimidazole (prepared analogously to Example 4) are dissolved in 5 ml of dichloroethane under a nitrogen atmosphere and combined with 0.29 ml (0.46 mmol) of an aqueous 3-carboxypropionaldehyde solution and 412 mg (1.8 mmol) sodium triacetoxyborohydride. The mixture is stirred for 4 hours at ambient temperature and then the solvent is eliminated in vacuo. The residue is taken up in water/dichloromethane and extracted with dichloromethane. The combined extracts are dried over magnesium sulphate and evaporated to dryness. The residue is chromatographed on silica gel (dichloromethane/methanol = 100:0 -> 80:20).
Yield: 11 mg (4% of theory) 1/1446-ff Boehringer Ingelheim International GmbH

C~H51N3O3 (669.91) Mass spectrum: (M+H)+ = 670 Rf value: 0.41 (silica gel, dichloromethane/methanol =
9:1) Glucagon Binding Assay The binding of the compounds of formula I according to the invention to the glucagon receptor was determined in a displacement binding assay which is based on the displacement of radiolabelled glucagon from a membrane fraction containing the recombinant human glucagon receptor.
The cDNA coding for the human glucagon receptor was cloned into the expression vector pcDNA3.1 (Invitrogene). BHK-21 cells (Baby Hamster Kidney C-13 cells, ATCC) were transfected with this construct and a stable cell clone was selected by treatment with G-418 (Gibco) and isolated.
A membrane fraction containing the recombinant human glucagon receptor was prepared from this clone by the following steps: Cells growing to confluence were detached using ice-cooled PBS buffer (Gibco) with 0.05% EDTA and suspended.
After centrifugation the pellet was suspended in a buffer (IOmM tris/HCI, pH
7.2;
0.01 mM PMSF (phenylmethylsulphonylfluoride)) and incubated for 90 minutes at 4°C. After the lysate had been treated with a homogeniser (bounce) cell nuclei and other cell constituents were separated off by centrifuging at 500 g for 10 minutes. The supernatant was then centrifuged at 100.000 g for 35 minutes to pellet the membranes.
The precipitated membranes were suspended in incubation buffer (50 mM
Tris/HCI, pH 7.2; 100mM NaCI; 5 mM MgCl2; 1 mM EDTA; 0.2% BSA (bovine serum albumin)), aliquoted and stored at -80°C.
The displacement of glucagon was measured by incubating 20~g of the membrane fraction, 50.00 cpm of 125I-glucagon (Amersham Pharmacia) and a concentration of the test substance for 60 minutes at 20°C in a volume of 100,1 in incubation buffer in a microtitre plate (Optiplate, Packard Instruments). The bound radioligand was separated from the free ligand by filtration and washing using GCB filters (Packard) on a Multiscreen vacuum filtration system (Millipore). The measurement was done using a Topcount scintillation counter (Packard). The binding in the presence of 1 ~M
of unlabelled glucagon (Wherl GmbH) was defined as non-specific. The data was I/1446-ff Boehringer Ingelheim International GmbH

analysed so as to determine the percentage of bound activity in the presence of a test substance. The results were calculated as %CTL. The compounds listed in Examples 1 to 27 yielded values less than or equal to 92 % CTL at a test substance concentration of 10 p.M.
The glucagon receptor antagonists according to the invention may be administered by oral, transdermal, inhalative or parenteral route. The compounds according to the invention are present as active ingredients in conventional formulations, for example in compositions consisting essentially of an inert pharmaceutical carrier and an effective dose of the active substance, such as for example tablets, coated tablets, capsules, lozenges, powders, solutions, suspensions, emulsions, syrups, suppositories, transdermal systems etc.. An effective dose of the compounds according to the invention is between 1 and 100, preferably between 1 and 50, most preferably between 5-30 mg/dose for oral administration, and between 0.001 and 50, preferably between 0.1 and 10 mg/dose for intravenous or intramuscular administration. For inhalation, according to the invention, solutions containing 0.01 to 1.0, preferably 0.1 to 0.5 % active substance are suitable. For administration by inhalation the use of powders is preferred. It is also possible to use the compounds according to the invention as a solution for infusion, preferably in a physiological saline or nutrient saline solution.
The compounds according to the invention may be used on their own or in conjunction with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances. Suitable preparations include for example tablets, capsules, suppositories, solutions, elixirs, emulsions or dispersible powders. Suitable tablets may be obtained, for example, by mixing the active substances) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers.
Similarly 1/1446-ff Boehringer Ingelheim International GmbH

the tablet coating may consist of a number or layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanilline or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
Solutions for injection are prepared in the usual way, e.g. with the addition of preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, and transferred into injection vials or ampoules.
Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
A therapeutically effective daily dose is between 1 and 800 mg, preferably 10 -mg per adult.
The Examples which follow illustrate the present invention without restricting its scope:

1/1446-ff Boehringer Ingelheim International GmbH

Examples of pharmaceutical formulations A) Tablets per tablet active substance of formula I 100 mg lactose 140 mg corn starch 240 mg polyvinylpyrrolidone 15 mg magnesium stearate 5 mg 500 mg The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together.
The mixture is compressed to produce tablets of suitable shape and size.
B) Tablets per tablet active substance of formula IA 80 mg corn starch 190 mg lactose 55 mg microcrystalline cellulose 35 mg polyvinylpyrrolidone 15 mg sodium-carboxymethyl starch 23 mg magnesium stearate 2 m~

400 mg The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodium-carboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.

' CA 02512813 2005-07-07 1/1446-ff Boehringer Ingelheim International GmbH

C) Coated tablets per coated tablet Active substance of formula IA S mg Corn starch 41.5 mg Lactose 30 mg Polyvinylpyrrolidone 3 mg Magnesium stearate 0.5 ma 80 mg The active substance, corn starch, lactose and polyvinylpyrrolidone are thoroughly mixed and moistened with water. The moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45°C and the granules are then passed through the same screen. After the magnesium stearate has been mixed in, convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine . The tablet cores thus produced are coated in known manner with a covering consisting essentially of sugar and talc. The finished coated tablets are polished with wax.
D) Capsules per capsule Active substance of formula IA 50 mg Corn starch 268.5 mg Magnesium stearate 1.5 ma 320 mg The substance and corn starch are mixed and moistened with water. The moist mass is screened and dried. The dry granules are screened and mixed with magnesium stearate. The finished mixture is packed into size 1 hard gelatine capsules.
E) Ampoule solution active substance of formula IA 50 mg sodium chloride 50 mg water for inj. 5 ml The active substance is dissolved in water at its own pH or optionally at pH
5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free .. CA 02512813 2005-07-07 I/1446-ff Boehringer Ingelheim International GmbH

from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.
F) Suppositories Active substance 50 mg Solid fat 1650 m~
1700 mg The hard fat is melted. At 40°C the ground active substance is homogeneously dispersed therein. It is cooled to 38°C and poured into slightly chilled suppository moulds.

Claims (13)

Claims
1. Use of a substituted 2-phenylbenzimidazole of formula I

wherein R1 denotes optionally substituted C1-C6 alkyl, C6-C10 aryl or C3-C8 cycloalkyl, the substituents being selected from the group consisting of halogen, C6-C10 aryl, C3-C8 cycloalkyl groups and a group of formula wherein R11, R12 and R13 each independently of one another denote hydrogen or halogen or C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy;
R2 denotes hydrogen, Cl-C6 alkyl, C3-C7-cycloalkyl, C2-C6 alkenyl, C6-C10 aryl-C1-C6 alkyl, C6-C10 aryl-C2-C6 alkenyl, carboxy or cyano; or in the 4-, 5- or 6- position of the benzimidazole denotes optionally substituted C6-C10 aryl, to which a C6-C10-aryl or a 5- or 6-membered heteroaryl may be fused, or an optionally substituted, optionally benzo- or cyclohexano-fused 5-or 6-membered heteroaryl group, wherein the substituents are selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylsulphinyl, C1-C6 alkylsulphonyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkanoyl, C6-C10 aryl, C6-C10 haloaryl, C6-C10 aryloxy, C6-C10 aryl-C1-C6 alkyl, C6-C10 aryl-C1-C6 alkoxy, C3-C8 cycloalkyl, amino-C1-C6 alkyl, C1-C6 alkylamino-C1-C6 alkyl, di-(C1-C6 alkyl)-amino-C1-C6 alkyl, 5- to 7-membered cycloalkyleneimino-C1-C6 alkyl, morpholino-C1-C6 alkyl, piperazino-C1-C6 alkyl, C1-C6 alkoxy-C1-C6 alkyl, di-(C1-C6 alkoxy)-C1-C6 alkyl, cyano-C1-C6 alkyl, hydroxy-C1-C6 alkyl, dihydroxy-C1-C6 alkyl, amino, C1-C6 alkylamino, di-(C1-C6 alkyl)-amino, C1-C6 alkanoylamino, C1-C6 alkylsulphonylamino, aminocarbonyl, C1-C6 alkylaminocarbonyl, di-(C1-C6 alkyl)-aminocarbonyl, carboxy-C1-C6 alkyl, carboxy-C1-C6 alkoxy, carboxy, cyano, formyl, hydroxy, nitro;
or denotes a carboxamide group of formula-CO-NR21R22 in the 5- or 6- position of the benzimidazole, while R21 and R22 each independently of one another denote hydrogen, C1-C6 alkyl, C2-C8 alkenyl, C4-C12 alkadienyl, C1-C6 haloalkyl, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkylthio-C1-C6 alkyl, C6-C10 aryl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 cycloalkyl-C1-C6 alkyl, C3-C8 cycloalkyloxy-C1-C6 alkyl, C3-C8 cycloalkanoyl-C1-C6 alkyl, C5-C8 cycloalkenyl-C1-C6 alkyl, adamantyl-C1-C6 alkyl, amino-C1-C6 alkyl, C1-C6 alkylamino-C1-C6 alkyl, di-(C1-C6 alkyl)-amino-C1-C6 alkyl, C1-C6 alkoxycarbonylamino-C1-C6 alkyl, cyano-C1-C6 alkyl, hydroxy-C1-C6 alkyl; or one of the groups R21 and R22 denotes hydrogen or C1-C6 alkyl, and the other denotes C6-C10 aryl-C1-C6 alkyl, wherein C6-C10 aryl may carry a benzo-fused aromatic 6-membered ring or one or more substituents, while the substituents are selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6-haloalkoxy, C6-C10 aryl, thiadiazolyl, C6-C10 aryloxy, hydroxy-C6-C10 aryloxy, C1-C6 alkoxycarbonyl, C1-C6 alkoxycarbonyl-C1-C6 alkyl, aminocarbonyl, aminosulphonyl, carboxy, amino, hydroxy, cyano and wherein C1-C6 alkyl may carry a hydroxy group; or one of the groups R21 and R22 denotes hydrogen or C1-C6 alkyl, and the other denotes a group of formula -(CH2)n-X-Het wherein n denotes 0 or an integer from 1 to 6, X denotes CO or a single bond and if n is other than 0 may also denote O, S or NH, and Het denotes an optionally substituted 5- or 6-membered heterocyclic group which may be substituted by nitro or di-(C1-C6 alkoxy-C6-C10 aryl and wherein a CH2 group may be replaced by a carbonyl group, and -(CH2)n may be substituted by C1-C6-alkyl if n is other than 0;
or R21 and R22 in each case form, with the enclosed nitrogen atom, an optionally substituted, optionally benzo- or cyclohexano-fused 5- to 7-membered heterocyclic ring wherein one or two CH2 groups may be replaced by O, S or NR23, wherein R23 denotes hydrogen, C1-C6 alkyl, adamantyl-C1-C6 alkyl, C6-C10 aryl-C1-C6-alkyl, C6-C10 aryl, C1-C6 alkoxy-C1-C6 aryl, or di-(C1-C6 alkoxy)-C1-C6 aryl and the optionally benzo-condensed ring may carry one or two C1-C6 alkoxy groups, R3 denotes a group of formula A-(E)r-Y-(E)r-Z-wherein A denotes a tetrazolyl, amido, methylamido, amidino or hydroxyamidino group or a group of formula-COOR31, wherein R31 denotes hydrogen or C1-C6 alkyl; and E denotes an C1-C6 alkylenediyl or C2-C6 alkenylenediyl group optionally mono- or polysubstituted by halogen or hydroxy or a C2-C6 alkynylenediyl group; and Y denotes O, S, CO-NH, CO-N(CH3), NH-CO, N(CH3)-CO, NH, N(CH3) or a single bond; and Z denotes O, S, NH, N(CH3) or a single bond; and r denotes 0 or 1; or denotes a 4- to 7-membered cycloalkyleneimino or 4- to 7-membered cycloalkyleneimino-carbonyl group, which is substituted by the abovementioned group A;
R4 in each case independently of one another denotes halogen, cyano, nitro, C1-alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkanoyl, C6-C10 aryl, C6-C10 aryloxy, C6-C10 aryl-C1-C6 alkyl, C6-C10 aryl-C1-C6 alkoxy, C3-C8 cycloalkyl, amino-C1-C6 alkyl, C1-C6 alkylamino-C1-C6 alkyl, di-(C1-C6 alkyl)-amino-C1-C6 alkyl, amino, C1-C6 alkanoylamino or C1-C6 haloalkanoylamino or when m = 2 denotes a fused-on aromatic 6-membered ring ;
R5 denotes a hydrogen atom, halogen, hydroxy or C1-C6 alkoxy;
and m denotes 0 or is an integer from 1 to 4;
for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors.
2. A substituted 2-phenylbenzimidazole of formula IA
wherein R11, R12 and R13 each independently of one another denote hydrogen or halogen or C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1-C6 haloalkoxy;
R2 denotes optionally substituted C6-C10 aryl or an optionally substituted, optionally benzo- or cyclohexano-fused 5- or 6-membered heteroaryl group, wherein the substituents are selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkanoyl, C6-C10 aryl, C6-C10 aryloxy, C6-C10 aryl-C1-C6 alkyl, C6-C10 aryl-C1-C6 alkoxy, C3-C8 cycloalkyl, amino-C1-C6 alkyl, C1-C6 alkylamino-C1-C6 alkyl, di-(C1-C6 alkyl)-amino-C1-C6 alkyl, piperidyl-C1-C6 alkyl, morpholino-C1-C6 alkyl, C1-C6 alkoxy-C1-C6 alkyl, di-(C1-C6 alkoxy)-C1-C6 alkyl, cyano-C1-C6 alkyl, hydroxy-C1-C6 alkyl, dihydroxy-C1-C6 alkyl, amino, C1-C6 alkylamino, di-(C1-C6 alkyl)-amino, C1-C6 alkanoylamino, C1-C6 alkylsulphonamino, carboxamido, carbox-C1-C6 alkylamido, carboxyl-C1-C6 alkyl, carboxyl-C1-C6 alkoxy, carboxyl, cyano, formyl, hydroxy;
nitro, or denotes a carboxamide group of formula-CO-NR21R22, wherein R21 and R22 each independently of one another denote hydrogen, C1-C6 alkyl, C2-C8 alkenyl, C4-C12 alkadienyl, C1-C6 haloalkyl, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkylthio-C1-C6 alkyl, C6-C10 aryl, C6-C10 aryl-C1-C6 alkyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C3-C8 cycloalkyl-C1-C6 alkyl, C3-C8 cycloalkoxy-C1-C6 alkyl, C3-C8 cycloalkanoyl-C1-C6 alkyl, C5-C8 cycloalkenyl-C1-C6 alkyl, adamantyl-C1-C6 alkyl, amino-C1-C6 alkyl, C1-C6 alkylamino-C1-C6 alkyl, di-(C1-C6 alkyl)-amino-C1-C6 alkyl, C1-C6 alkoxycarbonylamino-C1-C6 alkyl, cyano-C1-C6 alkyl, hydroxy-C1-C6 alkyl; or one of the groups R21 and R22 denotes hydrogen or C1-C6 alkyl, and the other denotes a group of formula -(CH2)n-X-Het wherein n denotes 0 or an integer from 1 to 6, X denotes CO or a single bond and if N is other than 0 may also denote O, S or NH, and Het denotes an optionally substituted 5- or 6-membered heterocyclic group; or R21 and R22 in each case form, with the enclosed nitrogen atom, an optionally substituted, optionally benzo- or cyclohexano-fused 5- or 6-membered heterocyclic ring, wherein one or two CH2 groups may be replaced by O, S or NR23, wherein R23 denotes hydrogen, C1-C6 alkyl, adamantyl-C1-C6 alkyl, R3 denotes a group of formula A-(E)r-Y-wherein A denotes a tetrazolyl group or a group of formula-COOR31, wherein R31 denotes hydrogen or C1-C6 alkyl;
E denotes a C1-C6 alkylenediyl or C2-C6 alkenylenediyl group or a C2-C6 alkynylenediyl group; and Y denotes O, CO-NH, NH-CO, NH, N(CH3) or a single bond; and r denotes 0 or 1;
R4 in each case independently of one another represent halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkanoyl, C6-C10 aryl, C6-C10 aryloxy, C6-C10 aryl-C1-C6 alkyl, C6-C10 aryl-C1-C6 alkoxy, C3-C8 cycloalkyl, amino-C1-C6 alkyl, C1-C6 alkylamino-C1-C6 alkyl or di-(C1-C6 alkyl)-amino-C1-C6 alkyl;
R5 denotes a hydrogen atom or together with the group R2 forms a group of formula N=CH-N=CR51-, while R51 denotes a hydrogen atom or a group of formula-NR52R53, wherein R52 and R53 each independently of one another denote hydrogen, C1-C6 alkyl, C2-C8 alkenyl, C4-C12 alkadienyl, C1-C6 haloalkyl, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkylthio-C1-C6 alkyl, C6-C10 aryl, C6-C10 aryl-C1-C6 alkyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl or C3-C8 cycloalkyl-C1-C6 alkyl; and m denotes 0 or is an integer from 1 to 4.
3. A substituted 2-phenylbenzimidazole of formula IA according to claim 2, wherein R11, R12 and R13 each independently of one another denote hydrogen or C1-C6 alkyl;
R2 denotes hydrogen, C1-C6 alkyl, C3-C7-cycloalkyl, C2-C6-alkenyl, phenyl-C1-alkyl, phenyl-C2-C6 alkenyl, carboxy or cyano; or in the 4, 5 or 6 position of the benzimidazole denotes optionally substituted phenyl, naphthyl, quinolinyl, isoquinolinyl or a 5- or 6-membered heteroaryl group selected from the group consisting of imidazolyl, pyrazolyl, furanyl, tetrahydrofuranyl, thiophenyl, thiazolyl, pyridyl, pyrimidyl, pyrazinyl, wherein the substituents are selected from the group consisting of fluorine, chlorine, bromine, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylsulphinyl, C1-C6 alkylsulphonyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, C1-C6 alkanoyl, phenyl, halophenyl, phenoxy, phenyl-C1-C6 alkyl, phenyl-C1-C6 alkoxy, C5-C6 cycloalkyl, amino-C1-C6 alkyl, C1-C6 alkylamino-C1-C6 alkyl, di-(C1-C6 alkyl)-amino-C1-C6 alkyl, piperidyl-C1-C6 alkyl, morpholino-C1-C6 alkyl, C1-C6 alkoxy-C1-C6 alkyl, di-(C1-C6 alkoxy)-C1-C6 alkyl, cyano-C1-C6 alkyl, hydroxy-C1-C6 alkyl, dihydroxy-C1-C6 alkyl, amino, C1-C6 alkylamino, di-(C1-C6 alkyl)-amino, C1-C6 alkanoylamino, C1-C6 alkylsulphonylamino, aminocarbonyl,, C1-C6 alkylaminocarbonyl, di-(C1-C6 alkyl)-aminocarbonyl, carboxy-C1-C6 alkyl, carboxy-C1-C6 alkoxy, carboxy, cyano, formyl, hydroxy and nitro; or denotes a carboxamide group of formula -CO-NR21R22 in the 5- or 6- position of the benzimidazole, wherein R21 denotes hydrogen, C1-C6 alkyl, C2-C8 alkenyl, C4-C12 alkadienyl, C1-C6 haloalkyl, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkylthio-C1-C6 alkyl, phenyl, C5-C6 cycloalkyl, C5-C6 cycloalkenyl, C5-C8 cycloalkyl-C1-C6 alkyl, C3-C8 cycloalkoxy-C1-C6 alkyl, C3-C8 cycloalkanoyl-C1-C3 alkyl, C5-C8 cycloalkenyl-C1-C3 alkyl, adamantyl-C1-C2 alkyl, amino-C1-C6 alkyl, C1-C6 alkylamino-C1-C6 alkyl, di-(C1-C6 alkyl)-amino-C1-C6 alkyl, C1-C6 alkoxycarbonylamino-C1-C6 alkyl, cyano-C1-C6 alkyl, hydroxy-C1-C6 alkyl or denotes phenyl-C1-C6 alkyl, wherein phenyl may carry a fused-on benzene ring or one or more substituents, the substituents being selected from the group consisting of fluorine, chlorine, bromine, C1-C6 alkyl, C1-C6 alkoxy, C1-C6-haloalkoxy, phenyl, thiadiazolyl, phenyloxy, hydroxy-phenyloxy, C1-C6 alkoxycarbonyl, C1-C6 alkoxycarbonyl-C1-C6 alkyl, aminocarbonyl, aminosulphonyl, carboxy, amino, hydroxy, cyano and C1-C6 alkyl may carry a hydroxy group; and R22 denotes hydrogen or C1-C3 alkyl, or one of the groups R21 and R22 denotes hydrogen or C1-C3 alkyl, and the other denotes a group of formula -(CH2)n-X-Het wherein n denotes an integer from 1 to 4, X denotes CO, O, S, NH or a single bond, and Het denotes an optionally substituted 5- or 6-membered heterocyclic group selected from among imidazolyl, pyrrolidinyl, pyrrolidonyl, morpholino, furanyl, thienyl, pyridyl and pyrimidyl, while the above-mentioned heterocyclic group may be substituted by nitro or di-(C1-C6 alkoxy)-phenyl; or R21 and R22 in each case form, with the enclosed nitrogen atom, a tetrahydrobenzoazepino, morpholino, piperidyl, benzopiperidyl or cyclohexanopiperidyl group, or a piperazyl group optionally substituted by C1-C6 alkyl, adamantyl-C1-C2 alkyl, phenyl-C1-C2 alkyl, phenyl, C1-C6 alkoxyphenyl or di-(C1-C6 alkoxy)-phenyl, R3 denotes a group of formula A-(E)r-y-(E)r-Z-wherein A denotes a 1H-tetrazol-5-yl group or a group of formula-COOR31 wherein R31 denotes hydrogen or C1-C6 alkyl; and E denotes a C1-C4 alkylenediyl optionally mono- or polysubstituted by halogen or hydroxy or an ethenylenediyl group or a butynylenediyl group; and Y denotes O, S, CO-NH, CO-N(CH3), NH-CO, N(CH3)-CO, NH, N(CH3) or a single bond; and Z denotes O, S, NH, N(CH3) or a single bond; and r denotes 1; or denotes pyrrolidinyl, piperidinyl, pyrrolidinylcarbonyl or piperidinylcarbonyl, each of which is substituted by the abovementioned group A;
R4 in each case independently of one another represent fluorine, chlorine, bromine, cyano, nitro, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3-haloalkoxy, amino, C1-C3 alkanoylamino, C1-C3 haloalkanoylamino or, where m = 2, a fused-on benzene ring;
R5 denotes a hydrogen atom; and m is 0 or an integer from 1 to 2.
4. A substituted 2-phenylbenzimidazole of formula IA according to claim 2 or 3, wherein R11 and R12 denote methyl, and R13 denotes isopropyl.
5. A substituted 2-phenylbenzimidazole of formula IA according to one of claims 2 to 4, wherein R2 denotes hydrogen, C1-C6 alkyl, C3-C7-cycloalkyl, C2-C6 alkenyl, phenyl-C1-alkyl, phenyl-C2-C6 alkenyl, carboxy or cyano; or denotes optionally substituted phenyl, naphthyl, quinolinyl, isoquinolinyl, imidazolyl, furanyl, thiophenyl, thiazolyl, tetrahydrofuranyl, pyridyl, pyrimidinyl, pyrazinyl in the 4-, 5- or 6- position of the benzimidazole, the substituents being selected from the group consisting of fluorine, chlorine, bromine, C1-C3 alkyl, trifluoromethyl, C1-C3 alkoxy, C1-C3 alkylthio, C1-C6 alkylsulphinyl, C1-C6 alkylsulphonyl, trifluoromethoxy, difluoromethoxy, C1-C3 alkanoyl, phenyl, chlorophenyl, phenoxy, phenyl-C1-C2 alkyl, phenyl-C1-C2 alkoxy, cyclohexyl, amino-C1-C3 alkyl, C1-C3 alkylamino-C1-C3 alkyl, di-(C1-C3 alkyl)-amino-C1-C3 alkyl, piperidyl-C1-C3 alkyl, morpholino-C1-C3 alkyl, C1-C3 alkoxy-C1-C3 alkyl, di-(C1-C3 alkoxy)-C1-C3 alkyl, cyano-C1-C3 alkyl, hydroxy-C1-C3 alkyl, dihydroxy-C1-C3 alkyl, amino, C1-C3 alkylamino, di-(C1-C3 alkyl)-amino, C1-C3 alkanoylamino, C1-C3 alkylsulphonylamino, aminocarbonyl, C1-C6 alkylaminocarbonyl, carboxy-C1-C3 alkyl, carboxy-C1-C3 alkoxy, carboxy, cyano, formyl, hydroxy and nitro; or denotes a carboxamide group of formula-CO-NR21R22 in the 5- or 6- position of the benzimidazole , wherein R21 denotes hydrogen, C1-C3 alkyl, C2-C6 alkenyl, C6-C12 alkadienyl, 2,2,2-trifluoroethyl, C1-C3 alkoxy-C1-C3 alkyl, C1-C3 alkylthio-C1-C3 alkyl, phenyl, cyclohexyl, cyclohexenyl, cyclohexyl-C1-C3 alkyl, cyclohexyloxy-C1-C3 alkyl, cyclohexanoyl-C1-C3 alkyl, cyclohexenyl-C1-C3 alkyl, adamantyl-C1-C2 alkyl, amino-C1-C3 alkyl, C1-C3 alkylamino-C1-C3 alkyl, di-(C1-C3 alkyl)-amino-C1-C3 alkyl, C1-C3 alkoxycarbonylamino-C1-C3 alkyl, cyano-C1-C3 alkyl, hydroxy-C1-C3 alkyl; or denotes phenyl-C1-C6 alkyl, wherein phenyl may carry a fused-on benzene ring or one or more substituents, the substituents being selected from the group consisting of fluorine, chlorine, bromine, C1-C4 alkyl, C1-C3 alkoxy, trifluoromethoxy, phenyl, thiadiazolyl, phenyloxy, hydroxy-phenyloxy, C1-C3 alkoxycarbonyl, C1-C3 alkoxycarbonyl-C1-C6 alkyl, aminocarbonyl, aminosulphonyl, amino, hydroxy, cyano and C1-C3 alkyl may carry a hydroxy group; or denotes a group of formula -(CH2)n-X-Het wherein n denotes an integer from 1 to 4, X denotes CO, O, S, NH or a single bond, and Het denotes imidazolyl, pyrrolidinyl, pyrrolidonyl, morpholino, furanyl, thienyl and pyridyl, which may be substituted by nitro or dimethoxyphenyl; and R22 denotes hydrogen or methyl, or R21 and R22 in each case form, with the enclosed nitrogen atom, a tetrahydrobenzoazepino, morpholino, piperidyl, benzopiperidyl or cyclohexanopiperidyl group , or a piperazyl group optionally substituted by C1-C3 alkyl, adamantyl-C1-C2 alkyl, phenyl-C1-C2 alkyl, phenyl, methoxyphenyl or dimethoxyphenyl, R3 denotes a group of formula A-(E)r-Y-(E)r-Z-wherein A denotes a 1H-tetrazol-5-yl group or a group of formula-COOR31, wherein R31 denotes hydrogen or C1-C3 alkyl; and E denotes a C1-C4 alkylenediyl optionally mono- or polysubstituted by fluorine, chlorine, bromine or hydroxy or an ethenylenediyl group or a butynylenediyl group; and Y denotes O, S, CO-NH, CO-N(CH3), NH-CO, N(CH3)-CO, NH, N(CH3) or a single bond; and Z denotes O or a single bond; and r denotes 0 or 1; or denotes a 4- to 7-membered cycloalkyleneimino or 4- to 7-membered cycloalkyleneimino-carbonyl group which is substituted by the abovementioned group A;
R4 in each case independently of one another represent fluorine, chlorine, bromine, nitro, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3-haloalkoxy, amino, acetylamino or trifluoroacetylamino;
R5 denotes a hydrogen atom; and m is 0 or an integer from 1 to 2.
6. Compounds of formula IA according to one of claims 2 to 5, wherein R2 is in the 4-, 5- or 6- position of the benzimidazole structure and the 6-or 5-position of the benzimidazole structure is substituted by the substituent R5.
7. A substituted 2-phenylbenzimidazole of formula IA1 wherein R2, R3, R4 and m have the meanings given in claims 1 to 5.
8. A substituted 2-phenylbenzimidazole according to one of claims 2 to 7, wherein the group R3 is in the meta or para position in relation to the benzimidazole group.
9. A substituted 2-phenylbenzimidazole according to one of claims 2 to 8 as a pharmaceutical composition.
10. Pharmaceutical preparation containing at least substituted 2-phenylbenzimidazole according to one of claims 2 to 8 and a pharmacologically acceptable carrier.
11. Pharmaceutical preparation according to claim 10 containing at least one substituted 2-phenylbenzimidazole according to one of claims 2 to 7 as well as an active substance selected from among:
acarbose, beraprost, bexarotene, captopril, denileukin, diftitox, etanercept, farglitazar, fidarestat, glibenclamide, glibomuride, gliclazide, glimepiride, glipizide, glucagon, ilomastat, imidapril, insulin, lanreotide, linogliride, lisinopril, metformin, mexiletine, miglitol, minalrestat, mitiglinide, moxonidine, nafagrel, nateglinide, octreotide, orlistat, oxcarbazepine, pegvisomant, pioglitazone, ponalrestat, pramlintide, ramipril, repaglinide, rosiglitazone, sirolimus, sorbinil, tolrestat, troglitazone, voglibose, zenarestat and zopolrestat.
12. Use of a substituted 2-phenylbenzimidazole according to one of claims 2 to 8 or of a pharmaceutical preparation for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors.
13. Use of a substituted 2-phenylbenzimidazole according to claim 12 for the preparation of a medicament for the treatment or prevention of diabetes mellitus.
CA002512813A 2003-01-09 2003-12-23 Use of substituted 2-phenylbenzimidazoles as phamaceutical compositions Abandoned CA2512813A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10300398.3 2003-01-09
DE10300398A DE10300398A1 (en) 2003-01-09 2003-01-09 Use of substituted 2-phenylbenzimidazoles as a drug
PCT/EP2003/014760 WO2004062663A1 (en) 2003-01-09 2003-12-23 Use of substituted 2-phenylbenzimidazoles as medicaments

Publications (1)

Publication Number Publication Date
CA2512813A1 true CA2512813A1 (en) 2004-07-29

Family

ID=32519722

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002512813A Abandoned CA2512813A1 (en) 2003-01-09 2003-12-23 Use of substituted 2-phenylbenzimidazoles as phamaceutical compositions

Country Status (6)

Country Link
EP (1) EP1585517A1 (en)
JP (1) JP2006515857A (en)
AU (1) AU2003292263A1 (en)
CA (1) CA2512813A1 (en)
DE (1) DE10300398A1 (en)
WO (1) WO2004062663A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006227435A1 (en) 2005-03-21 2006-09-28 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
JP2009001495A (en) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd 2-aryl-benzimidazole-5-carboxamide derivative
US7855193B2 (en) 2005-11-23 2010-12-21 Epix Pharmaceuticals, Inc. S1P receptor modulating compounds and use thereof
US7919519B2 (en) 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
EP1961745A1 (en) * 2005-12-12 2008-08-27 Ono Pharmaceutical Co., Ltd. Bicyclic heterocyclic compound
EP2010524A2 (en) 2006-03-21 2009-01-07 Epix Delaware, Inc. S1p receptor modulating compounds
EP2001472A2 (en) 2006-03-23 2008-12-17 Merck and Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7935713B2 (en) 2006-05-16 2011-05-03 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2121648A2 (en) * 2007-03-21 2009-11-25 EPIX Pharmaceuticals, Inc. S1p receptor modulating compounds and use thereof
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
JP2010540438A (en) 2007-09-20 2010-12-24 アムジエン・インコーポレーテツド 1- (4-Benzylbenzamido) -benzyl) azetidine-3-carboxylic acid derivatives and related compounds as S1P receptor modulators for treating immune disorders
EA021424B1 (en) 2008-12-19 2015-06-30 Сертрис Фармасьютикалз, Инк. Thiazolopyridine sirtuin modulating compounds
EP2655331A1 (en) 2010-12-23 2013-10-30 Pfizer Inc Glucagon receptor modulators
PT2673260T (en) 2011-02-08 2016-10-24 Pfizer Glucagon receptor modulator
CN103732578B (en) 2011-07-22 2015-08-12 辉瑞大药厂 Quinolinyl glucagon receptor conditioning agent
WO2015066252A1 (en) 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000143635A (en) * 1998-06-10 2000-05-26 Takeda Chem Ind Ltd Arterialization inhibitor
US7781596B1 (en) * 1998-11-03 2010-08-24 Abbott Laboratories Substituted 2-phenylbenzimidazoles, the production thereof and their use
CA2363274A1 (en) * 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c

Also Published As

Publication number Publication date
WO2004062663A1 (en) 2004-07-29
EP1585517A1 (en) 2005-10-19
AU2003292263A1 (en) 2004-08-10
JP2006515857A (en) 2006-06-08
DE10300398A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
CA2512813A1 (en) Use of substituted 2-phenylbenzimidazoles as phamaceutical compositions
AU2017219132B2 (en) Purine diones as WNT pathway modulators
RU2707870C2 (en) N-((het)arylmethyl)-heteroaryl-carboxamide compounds as plasma kallikrein inhibitors
TW495498B (en) Amide derivative and a pharmaceutical composition containing the same as a Ca2+ release activated Ca2+ channel inhibitor
SK1812002A3 (en) 3(5)-Amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
AU2008234017B2 (en) Imidazolidinone derivatives
WO2004020393A1 (en) Dibenzylamine compound and medicinal use thereof
CA2645434A1 (en) Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
WO2005079791A1 (en) Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
JP2008513508A (en) Compounds used for inflammation and immunity related applications
CN102464658A (en) Oxazolidinone derivative and preparation method and application thereof
TW200900397A (en) Tricyclic compounds as matrix metalloproteinase inhibitors
JP2011518138A (en) Novel arylsulfonylglycine derivatives, their preparation and their use as pharmaceuticals
WO2012170554A1 (en) N-biphenylmethylindole modulators of pparg
JP2012188352A (en) 3-(4-substituted alkyl-phenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt of the same
WO2001085723A1 (en) Gastrin and cholecystokinin receptor ligands (ii)
US7151114B2 (en) Use of substituted 2-phenylbenzimidazoles as medicaments
TWI748491B (en) 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
PL203161B1 (en) Oxadiazole derivatives having anticancer effects
EP2431362A1 (en) 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof
EA037264B1 (en) Heterocyclic sulfonamide derivative and medicament containing same
WO2011015646A2 (en) Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
Class et al. Patent application title: Purine Diones As Wnt Pathway Modulators
TW202345847A (en) Multicyclic compounds
TW202340166A (en) Multicyclic compounds

Legal Events

Date Code Title Description
FZDE Dead